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Abbreviations: 
6-OHDA: 6-hydroxydopamine 
AAVs: Adeno-Associated Viruses 
AD: Alzheimer’s disease 
ALS: Amyotrophic Lateral Sclerosis 
CAGE: Cap Analysis of Gene Expression 
Cygb: cytoglobin  
cDNA: complementary DNA 
CMA: chaperone-mediated autophagy 
CNS: Central Nervous System 
CPu: striatum (caudatoputamen) 
CTX: Cerebral cortex 
DA: dopaminergic 
eGFP: enhanced Green Fluorescent Protein 
FACS: Fluorescent Activated Cell Sorting 
GFP: Green Fluorescent Protein 
Hb: hemoglobin 
Hb-mut: mutant hemoglobin 
HD: Huntington’s disease 
iMN9D: MN9D-Nurr1Tet-On dopaminergic neuroblastoma cells 
LBs: Lewy bodies 
LCM: Laser Capture Microdissection 
LNs: Lewy neurites 
MB: Midbrain 
mDA: mesencephalic dopaminergic 
MPP+: 1-methyl-4-phenylpyridinium 
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
Ngb: neuroglobin 
NO: Nitric Oxide 
PCR: Polymerase Chain Reaction 
PD: Parkinson’s disease 
ROS: Reactive Oxygen Species 
RR: retrorubral 
SN: Substantia Nigra 
SNpc: Substantia Nigra pars compacta 
TH: Tyrosine Hydroxilase 
UPS: Ubiquitin-proteasome system 
VTA: Ventral Tegmental Area 
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Abstract 
 
 
 
Parkinson’s disease (PD) is the second most common neurodegenerative disease after 
Alzheimer’s disease (AD). One of the most evident pathological hallmarks in PD is 
the selective loss of mesencephalic dopaminergic (mDA) neurons with the consequent 
decrease of dopamine in the brain. mDA neurons present two main groups of 
projecting cells: the A9 neurons of the Substantia Nigra (SN) and the A10 cells of the 
Ventral Tegmental Area (VTA). A9 neurons control the nigrostriatal pathway and are 
involved in regulation of voluntary movements and postural reflexes. Their selective 
degeneration leads to PD and the loss of DA synapses in the striatum is believed to be 
primary cause for the disruption of the ability to control movements. Until now, the 
causes of the degeneration of A9 neurons in PD are still unknown and a lot of efforts 
have been done to determine the molecular differences between the DA cell 
subpopulations that could explain the selective susceptibility of A9 neurons (Chung et 
al., 2005; Greene et al., 2005). 
By a combination of different gene expression platforms coupled to Laser Capture 
Microdissection (LCM) hemoglobin α, adult chain 1 (Hba-a1) and β, adult chain 1 
(Hbb-b1) transcripts have been previously identified as expressed. Furthermore, Hb 
protein in DA cells is present in the large majority of A9 cells, whereas only in 5% of 
A10 neurons. Importantly, this pattern of expression is conserved in mammals 
(Biagioli et al., 2009). 
In this study, we aim to better understand the function of Hb in DA neurons. In 
particular, we assess the role of Hb in PD. To this purpose, we have taken advantage 
of MN9D-Nurr1Tet-On dopaminergic neuroblastoma cell lines (iMN9D) stably 
transfected with α and β chains of Hb (Biagioli et al., 2009) and their differentiated 
cultures as an in vitro model system to evaluate the effects of PD-mimicking insults, 
like 1-methyl-4-phenylpyridinium (MPP+) and rotenone. In this study, we 
demonstrate that: 1) the impact of Hb overexpression depends on differentiation state 
of iMN9D cells upon MPP+ treatment. Hb overexpression is protective in 
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undifferentiated cells, wheares it is toxic in differentiated cells; 2) Hb overexpression 
increases susceptibility to cell death upon rotenone in both undifferentiated and 
differentiated iMN9D cells; 3) Hb protection/toxicity doesn’t depend on oxygen 
binding; 4) α2β2 structure of Hb is not altered upon neurotoxic stimuli; 5) Hb-induced 
toxicity is concomitant with an increases of globin chains in the nucleus; 6) Hb 
overexpression is associated with an impairment of autophagy upon PD-like stimuli. 
Furthermore, we have studied the overexpression of Hb in an in vivo mouse model of 
PD. In details, we stereotaxically injected in SNpc AAV9-mediated overexpression of 
α and β globin in a MPTP regime. Preliminary data demonstrated that upon stimulus 
Hb overexpression influences DA neurons, even if there is not statistical difference. 
Further investigations must be done. 
Our findings support a model in which Hb expression may contribute to A9-specific 
vulnerability in PD pathogenesis. 
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Introduction 
 
 
 
Parkinson’s disease 
 
 
History 
PD was first described by James Parkinson in 1817 in his monograph “Essay on the 
Shaking Palsy” as characterized by “Involuntary tremolous motion, with lessened 
muscular power, in parts not in action and even when supported; with a propensity to 
bend the trunk forewords and to pass from a walking to a running pace: the senses 
and the intellect being injured”. PD was named by Jean Martin Charcot in 1862 and 
its clinical description was refined. 
In 1912 Friedrich Lewy observed microscopic particles in affected brains later named 
“Lewy Bodies” (LBs). In 1997, α-synuclein was found to be the main component of 
LBs. 
In 1919 Konstantin Tretiakoff reported that the SN is the main cerebral part affected 
in PD and finally in 1958, Arvid Carlsson (Nobel Prize in 2000) discovered that 
patients showed a massive loss of the neurotransmitter dopamine in the brain and its 
role in PD. 
 
 
Epidemiology 
PD is the second most common age-related neurodegenerative disease (six million 
patients worldwide) after AD. The prevalence of PD is about 0.3% of the whole 
population in industrialized countries. It is more common in the elderly and 
prevalence rises from 1% in those over 60 years of age to 4% of the population over 
80 (de Lau and Breteler, 2006). The mean age of onset is around 60 years, although 
5–10% of cases, classified as young onset, begin between the ages of 20 and 50 and 
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are probably hereditary. Some studies have proposed that it is more common in men 
than women, but others failed to detect any sex differences (de Lau and Breteler, 
2006). 
The incidence of PD is between 8 and 18 per 100,000 person/year. The precise mode 
of death is difficult to identify in most cases but pneumonia is the most certificated 
cause. 
 
 
Clinical features 
PD is a progressive neurodegenerative disorder and the motor symptoms result from 
the death of dopamine-generating cells in the SN. Clinically, any disease that includes 
striatal DA deficiency or direct striatal damage may lead to “parkinsonism” and PD is 
the most common cause of this syndrome. In 95% of cases PD is sporadic and 
idiopathic but in 5% the disease is genetically inherited (Fitzgerald and Plun-Favreau, 
2008). 
Early, in the course of the disease, the most obvious symptoms involve alteration of 
the ability to control movements and are characterized by tremor at rest, rigidity, 
slowness (bradykinesia) or absence of voluntary movement, postural instability and 
freezing. Later, cognitive and behavioral problems may arise, with dementia 
commonly occurring in the advanced stages of the disease; patients become passive or 
withdrawn with lacking of initiative. Depression is common. 
Although PD is classically diagnosed by onset of motor manifestation, pre-motor 
symptoms have been observed; these include olfactory dysfunction, sleep 
abnormalities, cardiac sympathetic denervation, constipation and pain (O’Sullivan et 
al., 2008). 
Clinically, the disease is heterogeneous however two major subtypes exist: a “tremor 
predominant form” that is often observed in younger people and a type known as 
“postural imbalance and gait disorder” (PIGD) often observed in older people (>70 
years old), characterized by akinesia, rigidity and gait of balance impairment. In 
general, the first type leads to a slow decline of motor functions whereas the latter 
worsens more rapidly (Selikhova et al., 2009). 
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Therapy 
PD is still incurable but therapeutic treatments improve quality of life of patients. L-
dopa in combination with a peripheral dopa-decarboxylase inhibitor (benserazide or 
carbidopa) is the most effective therapy and allows the replace, at least in part, of the 
dopamine lost during degeneration of SNpc cells. Although prediction of therapeutic 
response in an individual is not possible, motor symptoms initially improve by 20-
70%. Speech, swallowing and postural instability can also improve but these 
symptoms are generally less responsive and escape more readily from long-term 
control. The non-ergoline dopamine agonists (pramipexole, ropinirole, rotigotine and 
piribedil) are efficacious and in contrast to L-dopa, when used as monotherapy, do not 
provoke dyskinesias. They are a popular first-line treatment in patients under 55 years 
of age but L-dopa is usually necessary in 3 years from diagnosis. Unfortunately, 
dopamine agonists cause some side effects as gastrointestinal and psychiatric effects 
and sleep attack. 
The monoamine oxidase B (MAO-B) inhibitors (selegiline and rasagiline) are well 
tolerated but they are less efficacious than dopamine agonists. They seem to delay 
disease progression. The combination of L-dopa and MAO-B inhibitor could help to 
eliminate early wearing-off effects (that represents the period of time between the end 
of the effect of one dose of medication, and the beginning of the next one) and the 
partial substitution of L-dopa with a dopamine agonist could also reduce dyskinesias 
(Lees et al., 2009). 
Although the treatments for PD have improved the life expectancy and control of 
bradykinesia, no neuroprotective treatment can arrest the disease process and 
dopaminergic therapy is far from solving the motor impairments. 
Some studies have proposed fetal mDA cell implantation to achieve physiological 
dopamine release (Paul et al., 2006). Stem cell, especially human embryonic stem 
cells, that can differentiate in vitro, provide a potentially unlimited supply of DA 
neurons. However it has to be considered the potential risk of tumor formation 
(Laguna Goya et al., 2008). 
Glial-cell-line-derived neurotrophic factor has potent neurotrophic effect in DA 
neurons in animal models. Unfortunately, a controlled trial with monthly 
administration of these factors gave negative result at six months (Gill et al., 2003; 
Lang et al., 2006). 
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In conclusion, further research on the PD neurodegeneration process is needed to 
discover disease biomarkers and develop therapeutic interventions. 
 
 
Neuropathological features of PD 
The most evident pathological hallmarks of PD are the loss of the nigrostriatal DA 
neurons and the presence of intraneuronal proteinacious cytoplasmatic inclusions 
termed LBs (figure1). 
 
 
 
Figure 1. Neuropathology of Parkinson’s disease. 
(A) Schematic representation of the normal nigrostriatal pathway. (B) Schematic representation of the 
diseased nigrostriatal pathway. There is a marked loss of DA neurons that project to putament (dashed 
line) and more modest lose of those that projects to the caudate (red line). The photograph 
demonstrates depigmentation of SNpc due to the loss of DA neurons (adapted from Dauer and 
Przedborski, 2003). 
 
 
Loss of DA neurons and depletion of dopamine in striatum 
The characteristic motor symptoms of PD are due to the alteration of motor system in 
central nervous system (CNS) in particular to the gradual, selective and progressive 
loss of nigrostriatal DA neurons. 
Voluntary movements originate at motor cortex level: signals are sent through the 
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encephalic trunk (mesencephalon, pons and medulla) to the brain stem and spinal 
cord. These signalling pathways are controlled by different sub-cortical structures 
(thalamus, putamen and subthalamic nuclei) that modulate movements thanks to a 
complex network of excitatory and inhibitory signals (figure 2). These nuclei are, in 
turn, innervated and modulated by ventral midbrain DA neurons, subdivided into 
three main groups: A8 (retrorubral field; RRF), A9 (substantia nigra pars compacta; 
SNpc) and A10 (ventral tegmental area; VTA). The sensorimotor striatum involved in 
control of movement (putamen) is mainly innervated by A9 DA cells whereas the 
limbic ventral striatum and the thalamus are preferentially targeted by A10 and dorsal 
SNc neurons. 
 
 
Figure 2. Schematic illustration of the basal ganglia-thalamocortical “motor” circuit and its 
neurotrasmitters. 
Blue arrows represent excitatory transmission and black arrows inhibitory transmission, red symbols 
represent the pathway disregulations that happen in PD. (GPe, GPi globus pallidus external and internal 
segment, STN subthalamic nucleus, PPN pedunculopontine nucleus). 
 
The cell bodies of A9 nigrostriatal neurons are in SNpc and they project primary to 
putamen. The loss of these neurons, which normally contain conspicuous amount of 
neuromelanin (Marsden, 1983), produces the classic neuropathological finding of 
SNpc depigmentation. The pattern of SNpc cell loss parallels with the decrease of 
expression level of the DA transporter (DAT) mRNA (Uhl et al., 1994) and it is 
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consistent with the observation that depletion of DA innervations is most pronounced 
in the dorsolateral putamen (Bernheimer et al., 1973). 
At the onset of the symptoms, putamen is depleted about 80% and 60% of SNpc DA 
neurons have already been lost. The mesolimbic DA neurons, the cell bodies of which 
reside adjacent to the SNpc in the VTA is much less affected in PD (Uhl et al., 1985). 
The loss of striatal DA pathway causes an unbalance between excitatory and 
inhibitory transmission in the basal ganglia thalamocortical “motor” circuit (figure 2). 
On one hand, decreased striatal dopamine stimulation causes the direct reduction of 
the inhibition of the GPi/SNr; on the other hand, decreased dopamine activity causes 
increased inhibition of the globus pallidus external segment (GPe), resulting in 
blocking the inhibition of the subtalamic nucleus (STN). Augmented STN output 
increases GPi/SNr inhibitory output to the thalamus that can not regulate the activity 
of the motor cortex any longer. The pattern of progressive cell loss displays a 
complex topographical and regional organization because the degeneration starts from 
the most lateral part of SNc and spreads to the most medialis region in different stages 
of the disease. The loss of the nigral DA neurons and terminals are responsible for the 
movement disorders associated with PD, however additional neuronal populations are 
affected in the disease such as medulla oblongata, pontine, tegmentum, olfactory bulb 
and anterior olfactory nucleus (Braak et al., 2004). 
 
Lewy bodies 
Distinct intraneuronal lesions accompany the nerve-cell loss: the LBs and the Lewy 
neurites (LNs). LBs and LNs are present in PD patients’ brains in some of the 
surviving DA neurons and in other regions like dorsal motor nucleus of the vagus, 
locus ceruleus, thalamus, amygdala, olfactory nuclei, pediculopontine nucleus, and 
cerebral cortex. In late stages of PD, when patients manifest all motor and cognitive 
clinical symptoms, inclusion bodies decorate the entire neocortex comprising the 
sensory association area (Braak et al., 2004). 
LBs are round cytoplasmatic eosinophilic inclusions, 5–25 µm in diameter (figure 3). 
The ultrastructure shows they are composed of a dense core of filamentous and 
granular material, surrounded by radially orientated filaments of 10–20 nm in 
diameter. LBs are composed by the accumulation of cytoplasmic aggregates 
containing a variety of proteins, like α-synuclein, the major component, parkin and 
UCHL1 (genes whose mutations have been correlated with PD) and many others like 
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Hsp-70, ubiquitin and components of the proteasome (Spillantini and Goedert, 2000). 
LNs are abnormal neurites that contain the same proteins and abnormal filaments 
found in Lewy bodies. 
 
 
Figure 3. Immunohistochemical staining of Lewy Bodies found in DA neurons of PD patients in SNpc. 
Unsoluble fibrous component of aggregates are detected with anti-αsynuclein antibody and anti-
ubiquitin (adapted from Dauer and Przedborski, 2003). 
 
The mechanism causing the abnormal accumulation of proteins in Lewy bodies and 
Lewy neurites is not yet known and their toxic or protective role in neurodegenerative 
process is still matter of debate because till now there is no clear correlation between 
inclusion formation and neuronal cell death. According to the hypothesis that LBs are 
toxic, cytoplasmic protein aggregates may interfere with intracellular trafficking or 
sequestrate proteins important for cell survival. On the other hand, LBs are present in 
surviving cells that seem to be healthier than neighboring cells by morphological and 
biochemical analysis (Tompkins and Hill, 1997). Moreover, LBs have been found 
also in people without evident neuronal loss or clinical signs of PD, so they could be a 
protective structure in which proteins accumulate after the pathological failure of 
protein degradation. 
 
Iron accumulation 
In the brain, iron has different roles ranging from facilitation of cellular aerobic 
metabolism to synthesis and signal transduction of neurotransmitters. Through a 
critical component of cytochromes, enzymes and binding proteins, free iron can be 
cytotoxic by catalyzing the production of hydroxyl radical from hydrogen peroxide. 
Iron has been suggested to be responsible for nigrostriatal dopamine neuron 
degeneration in PD owing to its ability to produce toxic ROS and cause lipid 
peroxidation (Sian-Hülsmann et al., 2011). 
Iron deposits in degenerating neurons of the SN and in LBs can have deleterious 
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effects on the extrapyramidal system and on psychomotor function. The presence of 
the pigment, neuromelanin, in the SN in PD also might result in iron accumulation, 
because neuromelanin can function like ferritin and store iron (figure 4). 
 
 
Figure 4. Iron distribution is abnormal in PD midbrain. 
Transverse section of normal midbrain (a) and PD midbrain (b). 
 
Iron may interact and interfere with the normal dopaminergic functions including α-
synuclein, dopamine and TH. Moreover, it has been demonstrated that iron deficiency 
diet produces several expression changes in dopamine-related genes in the ventral 
midbrain in mice. These included dopamine receptor 2 (Drd2), Alas2, which encodes 
an erythroid enzyme that catalyzes heme biosynthesis, Ahsp, which gived rise to an 
erythroid protein that stabilizes α hemoglobin, and β hemoglobin (Hbb-b1) (Jellen et 
al., 2013). 
All these mechanisms suggest that disturbances in iron homeostasis and metabolism 
in PD occur at several levels, such as iron uptake, storage, intracellular metabolism, 
release, and post-transcriptional control. A disturbance in iron homeostasis can 
provide a favorable condition in which free iron, via generation of ROS, causes 
permanent tissue damage. 
 
 
Aetiology 
The cause of sporadic PD is unknown and the role of environmental toxins and 
genetic factors are not yet well understood. 
 
Environmental factors 
The environmental toxin hypothesis was largely supported in the 20th century 
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especially because of the discovery that some toxins can mimic the pathological 
features of PD. Examples are the post-encephalitic PD syndromes (as described by 
Oliver Sacks in his book “Awakenings”) and the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyrydine (MPTP)-induced parkinsonism (Langston and Ballard, 1983). 
Moreover, the exposure to some herbicides (i.e. paraquat) and pesticides (i.e. 
rotenone) have been correlated to elevated risk of PD (Tanner et al., 2011). 
Another possibility is that an endogenous toxin derived from distortion in the normal 
metabolism may be responsible for PD neurodegeneration. One source of endogenous 
toxins may be the normal metabolism of DA which generates reactive oxygen species 
(ROS) (Cohen, 1984). Consistent with this hypothesis is the fact that patients with 
specific polimorfisms in the gene codifying the xenobiotic detoxifying enzyme 
cytochrome P450 may be at greater risk of young onset-PD (Sandy et al., 1996). 
 
Genetic factors 
In the 5% of the cases, PD is a genetic disorder and 13 loci and 9 genes have been 
associated to both autosomal and recessive forms of disease. There is a growing list of 
mutations linked to PD and they account 2-3% of the late-onset cases and 50% of 
early-onset forms (Farrer, 2006). The most part of these mutations have been 
identified in genes encoding proteins that accumulate in LBs and LNs. The mutated 
genes associated with familial PD are SNCA, PARKIN, UCHL1, DJ-1 and LRRK2.  
 
 
Table 1. Genes associated to L-dopa-responsive parkinsonism (adapted from Lees et al., 2009). 
 
The study of these mutations may help to define the molecular pathways involved in 
neurodegeneration in PD. Genetic studies have shown that several mutation in seven 
genes are linked with L-dopa-responsive parkinsonism (Table 1). 
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SNCA (PARK1 and PARK4) gene encodes for α-synuclein. Missense mutations, 
gene duplications and triplication are observed in PD (Polymeropoulos et al., 1997; 
Ross et al., 2008; Singleton et al., 2003). α-synuclein is a natively unfolded protein 
because of the lack of secondary or tertiary structure and it accumulates in pre-
synaptic nerve terminals associated with membranes of synaptic vesicles. It has 
natively a great propensity to aggregate both in vitro and in vivo, especially in the 
presence of oxidative stress and of several herbicide and pesticide. 
The mutant forms Ala30Pro and Ala52Thr form protofibrils, an intermediate in the 
process of aggregation. Pesticides (such as rotenone, dieldrin and paraquat), metal 
ions (copper, iron) and other factors accelerate its fibrillation. The causes and 
consequences of α-synuclein aggregation is not yet fully understood but mutations 
and overexpression of this protein seem to be especially toxic to DA neurons. 
Furthermore, dopamine-synuclein toxicity may inhibit chaperone-mediated autophagy 
(Xilouri et al., 2009). The in vitro expression of α-synuclein in DA neurons also 
results in inclusion formation and triggers pronounced (~50%) neuronal loss. 
Finally, transgenic mice expressing the wild-type human gene for α-synuclein 
develop several of the clinic-pathological features of PD like accumulation of LBs in 
neurons of the neocortex, hippocampus and SN and loss of DA terminals in the basal 
ganglia (Masliah et al., 2000).  
 
PARKIN (PARK2) mutations are the second most common genetic cause of disease. 
Parkin encodes an E3 ubiquitin ligase that controls key step in the cycle of ubiquitin-
mediated hydrolysis of damaged or misfolded proteins that are degraded via the 
proteosome. This form of PD is characterized by the absence of Lewy bodies and 
since LBs found in PD patient are immunoreactive for some of parkin substrates, it 
has been proposed a role of this protein in LB formation (Dawson, 2006). 
 
Mutations in LRRK2 (PARK8), encoding the leucine-rich repeat kinase2 (also named 
dardarin), represent the highest risk of development of familiar PD and the disease 
penetrance markedly increases with age (Healy et al., 2008; Paisán-Ruíz et al., 2004). 
It is a large protein and contains both Rab-GTPase and kinase activity and also other 
domains involved in multi-protein scaffold interactions (Smith et al., 2005). 
It has numerous roles in the secretory pathway and may contribute to adult 
neurogenesis, remodelling of cytoskeletal architecture and membrane and 
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dopaminergic signalling. Among the six pathogenic forms of LRRK2 found in PD 
patients, the most common mutation is Gly2019Ser with a worldwide frequency of 
1% in sporadic and 4% in genetic form (Healy et al., 2008). 
Transgenic mice that express the mutated form of LRRK2 (R1441G) recapitulate 
most of the PD motor symptoms that are reverted by the administration of Levodopa 
(Li et al., 2009). 
Loss-of-function mutations in four genes cause recessive early-onset parkinsonism 
(age of onset <40 years). 
 
UCH-L1 (Ubiquitin C-terminal hydrolase L1) (PARK5) is mainly expressed in the 
brain and catalyzes the hydrolysis of ubiquitin C-terminal ends. In particular UCH-L1 
regulates ubiquitin-mediated proteolysis, preparing the monomers of ubiquitin that 
must be added to the substrates. Mutated forms of the gene have been identified in an 
autosomal dominant form of PD. The mutations cause a decrease of the enzymatic 
activity of the protein (Das et al., 2006). Deletions and missense mutations (I93M) 
have been identified (Setsuie et al., 2007). A polymorphism (S18Y) appears to reduce 
the risk of developing PD (Carmine Belin et al., 2007). 
It is important to note that UCH-L1 KO mice show signs of neurodegeneration but 
not in the nigrostriatal dopaminergic pathway (Chen et al., 2010). 
 
PINK1 (PTEN induced-kinase 1) (PARK6) is a mitochondrial serine/threonine 
protein kinase, functionally linked to parkin because their concomitant expression 
induces mitochondrial fission and survival of striatal neurons (Lutz et al., 2009). 
Parkin is recruited to dysfunctional mitochondria to promote their autophagic 
degradation and rescues degeneration in PINK1-null flies (Narendra et al., 2009). 
Moreover, PINK1 protects cells against apoptosis induced by exposure to proteosome 
inhibitors (Valente et al., 2004). 
 
The function of DJ-1 (PARK7) is not yet fully understood. It was cloned as interactor 
of GAPDH playing a role in mRNA regulation by stabilizing mRNA species after 
transcription (Hod et al., 1999). It maintains neuronal viability by modulating gene 
expression under cellular stress condition (Mitsumoto et al., 2001). 
The L166P mutant promotes localization of the normally cytoplasmatic DJ-1 protein 
to mitochondria (Bonifati et al., 2003) implying that the loss of normal function of 
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DJ-1 is sufficient to induce PD. 
DJ-1 functions as a cytoplasmic redox-sensitive molecular chaperone in vitro and in 
vivo, inhibiting the aggregation of α-synuclein in neuronal cell lines at an early step of 
the aggregation process; in fact, its loss increases the accumulation of insoluble α-
synuclein. It has been hypothesized that DJ-1 may promote the degradation of 
misfolded proteins, either through the proteasome or through chaperone-mediated 
autophagy (Shendelman et al., 2004).  
 
ATP132A (PARK9) mutation has been linked to juvenile and rare forms of PD often 
with atypical symptoms and no LBs or loss of DA neurons. This gene encodes for a 
large lysosomal P-type ATPase and mutations lead to a truncated protein that is 
retained in the endoplasmic reticulum instead of inserted in lysosomal membranes and 
degraded by proteasome. Its mutations seem to lead to a failure of autophagy 
execution and aggregation of α-synuclein (Ramirez et al., 2006; Di Fonzo et al., 
2007). 
 
 
Pathogenesis 
The studies of toxic PD models, the functions of PD-related genes and the analysis of 
post-mortem brains of PD patients suggest two major interconnected hypothesis 
regarding the pathogenesis of the disease: misfolding and aggregation of proteins and 
mitochondrial dysfunctions and the consequent oxidative stress (figure 5). 
 
Mitochondrial dysfunction and oxidative stress 
The possibility that an oxydative phosphorylation defect plays a role in the 
pathogenesis of PD was supported by the discovery that MPTP blocks the 
mitochondrial electron transport chain by inhibiting complex I (Nicklas et al., 1987). 
Other studies identified abnormalities in complex I activity in PD (Greenamyre et al., 
2001) and in vitro experiments showed that complex I defects may induce oxidative 
stress and energy impairment. 
In the cell, molecular oxygen is consumed by mitochondrial respiration and powerful 
oxydants are produced as bioproducts including hydrogen peroxide, and superoxide 
radicals. Inhibition of complex I increases the ROS superoxide which may form 
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peroxynitrite. These molecules may cause cellular damage by reacting with DNA, 
proteins and lipids. The electron transport chain may be a target leading to 
mitochondrial damage and further ROS production (Cohen, 2000). In turn, ROS 
increase the amount of misfolded proteins. 
 
Figure 5. Mechanisms of neurodegeneration in Parkinson’s disease. 
A growing body of evidence suggests that the accumulation of misfolded proteins is likely to be a key 
event in PD neurodegeneration. Pathogenic mutations may directly induce abnormal protein 
conformations (as believed to be the case with α-synuclein) or damage the ability of the cellular 
machinery to detect and degrade misfolded proteins (Parkin, UCH-L1); the role of DJ-1 remains to be 
identified. Oxidative damage, linked to mitochondrial dysfunction and abnormal dopamine 
metabolism, may also promote misfolded protein conformations. It remains unclear whether misfolded 
proteins directly cause toxicity or damage cells via the formation of protein aggregates (Lewy body). 
Controversy exists regarding whether Lewy bodies promote toxicity or protect a cell from harmful 
effects of misfolded proteins by sequestering them in an insoluble compartment away from cellular 
elements. Oxidative stress, energy crisis (i.e., ATP depletion) and the activation of the programmed 
cell death machinery are also believed to be factors that trigger the death of DA neurons in Parkinson’s 
disease (adapted from Dauer and Przedborski, 2003). 
 
DA neurons may be important ROS generators because metabolism of DA produces 
hydrogen peroxide and superoxide radicals and auto-oxidation of DA produces 
DAquinone (Graham, 1978), which reacts with cysteines damaging proteins. 
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Mitochondrial-related energy failure may disrupt vesicular storage of DA, causing the 
free cytosolic concentration of DA to rise and allowing harmful DA-mediated 
reactions to damage cellular macromolecules. Accordingly, DA may be fundamental 
in rendering DA neurons particularly susceptible to oxidative attack. 
 
Misfolding and aggregation of proteins 
The abnormal deposition of proteins is observed in brain of patients affected by 
several age-related neurodegenerative disease, including PD. 
Alteration of protein folding, ubiquitin-proteasome system (UPS) and autophagy are 
considered among the main molecular events inducing aggregate formation. 
Aggregated or soluble misfolded proteins could be toxic through a variety of 
mechanisms: such as forming cells’ damage, interfering with intracellular trafficking, 
sequestering proteins important for cell survival. Cytoplasmic inclusions may not 
result simply from precipitated misfolded proteins but rather from an active process 
meant to sequester soluble misfolded proteins (Kopito, 2000). Thus, inclusion 
formation may be a defensive measure to remove toxic soluble misfolded proteins 
(Warrick et al., 1999; Cummings et al., 1999, 2001; Auluck et al., 2002). This is 
supported by the fact that chaperons as Hsp-70 protect against neurodegeneration 
mediated by α-synuclein toxicity (Muchowski, 2002). 
The presence of dysfunctional protein metabolism in PD may be due to oxidative 
stress caused by ROS. The tissues content of abnormally oxidized proteins (which 
may misfold) increases with age and neurons may be particularly susceptible since 
they are post mitotic cells. In fact, LBs contain oxidatively modified α-synuclein, 
which in vitro has a great propensity to aggregation (Giasson et al., 2002). 
Moreover, some herbicides and pesticides induce misfolding and aggregation of α-
synuclein (Uversky et al., 2001; Lee et al., 2002; Manning-Bog et al., 2002). 
 
Ubiquitin-proteasome system 
Cells normally respond to misfolded proteins through chaperons but if not properly 
refolded they are targeted to proteasomal degradation by poly-ubiquitination. 
Ubiquitination of a substrate requires a cascade of enzymes: ubiquitin-activating 
enzyme (E1), ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) 
that are responsible for highly specific target recognition in this system through 
physical interactions with the substrate. 
 23	  
 
Figure 6. Schematic representation of the ubiquitin proteasome system. 
 
Proteasome is a multi-subunit protein complex composed by a 20S core complex 
where proteins are degraded, a 19S regulatory complex that removes the ubiquitin and 
unfolds the protein for translocation into the 20S chamber and the so called 11S 
complex (or REG or PA28) that is thought to activate the 20S. 
With age, the cells decline in their ability to manage misfolded proteins and also the 
ability to induce chaperons and proteosomal function is impaired (Sherman and 
Goldberg, 2001). Proteosomal dysfunction and consequent accumulation of misfolded 
proteins inhibit an already compromised proteosome. When misfolded proteins are 
not correctly degraded and UPS is misregulated, toxic aggregates form. It is 
interesting to note that LBs are immunoreactive against chaperone proteins (i.e. 
Hsp70), ubiquitin, and components of the 20S of the proteasome system. 
 
 
 24	  
Autophagy 
Autophagy is another mechanism through which proteins can be degraded. Most 
long-lived proteins, cytoplasmic constituents, including organelles, are sequestered 
into double-membraned autophagosomes, which subsequently fuse with lysosomes 
where their contents are degraded thanks to proteolytic enzymes. There are three 
different types of autophagy: macroautophagy, microautophagy and chaperone-
mediated autophagy (CMA) (Mizushima et al., 2008) (figure 7). 
 
 
Figure 7. Different types of autophagy: macroautophagy, the microautophagy and mediated chaperone-
mediated autophagy (CMA) (adapted from Mizushima et al., 2008)). 
 
CMA involves direct translocation of unfolded substrate proteins across the lysosome 
membrane through the action of a cytosolic and lysosomal chaperone Hsp70 and the 
integral membrane receptor LAMP-2A (lysosome-associated membrane protein type 
2A). CMA involves the degradation of cytoplasmic proteins that contain a consensus 
sequence KFERQ for lysosome association. Interestingly, many proteins involved in 
neurodegenerative diseases contain this sequence, as α-synuclein in PD and the 
amyloid precursor protein (APP) in AD (Massey et al., 2004). 
Microautophagy refers to the sequestration of cytosolic components directly by 
lysosomes through invaginations in their limiting membrane. 
Macroautophagy (also called autophagy) requires the formation of a double 
membrane structure called the phagosome, whose origin is unknown. The phagosome 
sequester portions of cytoplasm containing proteins prone to aggregation or damaged 
organelles. Subsequently the phagosome becames autophagosome and merges with 
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the lysosome to form an autolysosome, where contents will be degraded due to 
hydrolases. 
 
 
Figure 8. Autophagy induction and autophagosome biogenesis. 
Autophagosome formation can be initiated via mTOR inhibition or AMPK activation. This results in 
the phosphorylation of ULK1 at sites that activate it and catalyze phosphorylation of other components 
of the Atg1–ULK complex, composed of ULK1, ULK2, Atg13, FIP200 and Atg101. ULK1 also 
phosphorylates AMBRA, a component of the PI3K CIII complex I (Vps34, Vps15, Atg14, and beclin-
1), enabling it to relocate from the cytoskeleton to the isolation membrane. Phosphatidylinositol 3-
phosphate (PI3P), generated by Vps34 activity, specifically binds the PI3P effectors WD repeat domain 
phosphoinositide-interacting 1 (WIPI1) and WIPI2 and catalyzes the first of two types of 
ubiquitination-like reactions that regulate isolation membrane elongation. In this first reaction, Atg5 
and Atg12 are conjugated to each other in the presence of Atg7 and Atg10. Attachment of the fully 
formed complex containing Atg5, Atg12 and Atg16L on the isolation membrane induces the second 
complex to covalently conjugate phosphatidylethanolamine to LC3, which facilitates closure of the 
isolation membrane184. Atg9 (the Atg9–Atg2–Atg18 complex), another factor essential for this event, 
cycles between endosomes, the Golgi and the phagophore, possibly carrying lipid components for 
membrane expansion. Atg4 removes LC3-II from the outer surface of newly formed autophagosomes, 
and LC3 on the inner surface is eventually degraded when the autophagosome fuses with lysosomes. 
The steps known to be affected in Parkinson’s diseases are indicated in red. PE, 
phosphatidylethanolamine. Modified from (Nixon, 2013). 
 
Autophagy is orchestrated by a family of proteins called Atg (Autophagy related 
gene), which are negatively regulated by mTOR (mammalian Target Of Rapamycin).  
One of the key molecular components involved in autophagy is Atg8/LC3 
(microtubule associated protein 1 Light Chain 3). The conversion of soluble LC3I to 
lipid bound LC3II is associated with the formation of autophagosomes (Komatsu et 
al., 2005, 2006). 
Interestingly, accumulation of autophagic vacuoles has been seen in DA neurons of 
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histopathological sections of PD patients post-mortem brains (Nedelsky et al., 2008). 
Moreover, recent evidence demonstrated protection effects of autophagy-induced 
drug (rapamycin) on cellular and animal models of PD (Tzeng et al., 2010; Liu et al., 
2011). 
It is still to clarify whether autophagy is a cause or a protective factor of neuron death. 
It has been suggested that the increased number of autophagic vacuoles is responsible 
for neuronal cell death. However, a more evident model suggests that autophagy is 
induced to protect neurons by enhancing degradation of abnormal proteins that might 
trigger injury or apoptosis in the early stages of cell death (Butler et al., 2006; 
Bandyopadhyay et al., 2007). 
 
 
Animal model of PD 
Various animal models have provided as tools to better understand PD etiology, 
pathology, and molecular mechanisms. For the past several decades, animal models of 
PD have come in a variety of forms. Typically, they can be divided into those using 
environmental or synthetic neurotoxins or those utilizing the in vivo expression of 
PD-related mutations. 
 
Toxin-based models 
The neurotoxins used to induce dopaminergic neurodegeneration are divided in 
reversible compounds, as reserpine, and irreversible compounds, as 6-
hydroxydopamine (6-OHDA), MPTP, paraquat and rotenone. A common feature of 
all toxin-induced models is their ability to produce oxidative stress and to cause cell 
death in DA neuronal populations that reflect what is seen in PD (Betarbet et al., 
2002; Dauer and Przedborski, 2003). Oxidative stress results from increased 
production of extremely reactive free radicals, including reactive oxidative species 
and peroxynitrite. ROS may be formed during a number of cellular processes, 
including mitochondrial oxidative respiration and metabolism.  
 
MPTP 
In 1982, MPTP was accidentally discovered in a synthesis process gone awry and 
young drug addicts developed an idiopathic parkinsonian syndrome after intravenous 
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injection of MPPP. After investigating the etiology of their condition, it was found 
that MPPP was contaminated with MPTP and this was the neurotoxic molecule 
responsible for the parkinsonian effect (Langston et al., 1983). Today it represents the 
most important and most frequently used parkinsonian toxin applied in animal 
models. It has been demonstrated that MPTP is indeed able to mimic oxidative stress, 
ROS, energy failure, and inflammation, which have been reported as hallmarks of PD 
(Langston et al., 1983). Unfortunately, lacking in this list is one of the characteristics 
of PD, LB formation (Forno et al., 1993; Halliday et al., 2009). 
 
Figure 9. Schematic representation of MPP+ intracellular pathways. 
Inside DA neurons, MPP+ can follow one of three routes: (1) concentration into mitochondria through 
an active process (toxic); (2) interaction with cytosolic enzymes (toxic); (3) sequestration into synaptic 
vesicles via the vesicular monoamine transporters (VMAT; protective). Within the mitochondria, 
MPP+ blocks complex I (X), which interrupts the transfer of electrons from complex I to ubiquinone 
(Q). This perturbation enhances the production of reactive oxygen species (not shown) and decreases 
the synthesis of ATP (adapted from Dauer and Przedborski, 2003). 
 
MPTP is highly lipophilic and after systemic administration rapidly crosses the blood-
brain barrier. Once in the brain, MPTP enters astrocytes and is metabolized into 
MPP+, its active metabolite, by monoamine oxidase B (MAO B). Once released from 
the astrocytes into the extracellular space via the OCT-3 transporter (Cui et al., 2009), 
MPP+ is taken up into neurons by the dopamine transporter (DAT) and can be stored 
in vesicles via uptake by the vesicular monoamine transporter (VMAT2) (Javitch et 
al., 1985). Once inside the cell, MPP+ is able to inhibit complex I of the 
mitochondrial electron transport chain, resulting in the release of ROS as well as 
reduced ATP production. Additionally, MPP+ stored in vesicles is thought to expel 
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DA out into the intercellular space where it can be metabolized into a number of 
compounds, including toxic metabolites, such as superoxide radical (5-cysteinyl-DA) 
and hydroxyl radical (6-OHDA) attack (Burke et al., 2008; Panneton et al., 2010). 
MPTP can be administered by a variety of regimens, but the most common and 
reproducible form is still systemic injection (subcutaneous, intravenous) (Przedborski 
et al., 2001). 
 
 
Table 2. Summary of mitochondrial dysfunction by environmental toxins to PD model (adapted from 
Blesa et al., 2012). 
 
6-Hydroxydopamine 
6-OHDA was first isolated in the 1950s (Senoh and Witkop, 1959). Today the use of 
6-OHDA remains widespread for both in vitro and in vivo investigations. Although 
the structure of 6-OHDA is similar to that of dopamine, the presence of an additional 
hydroxyl group makes it toxic to DA neurons. 
This model does not mimic all of the clinical features of PD. Dopamine depletion, 
nigral dopamine cell loss, and neurobehavioral deficits have been successfully 
achieved using this model, but it does not seem to affect other brain regions, such as 
olfactory structures, lower brain stem areas, or locus coeruleus. Although 6-OHDA 
does not produce or induce proteinaceous aggregates or Lewy-like inclusions like 
those seen in PD, it has been reported that 6-OHDA does interact with α-synuclein 
(Blandini et al., 2008). 
This compound does not cross the blood-brain barrier, which necessitates its direct 
injection into the SNpc or into striatum (Perese et al., 1989; Przedborski et al., 1995). 
 
Rotenone 
Rotenone is both an herbicide and an insecticide (Hisata et al., 2001). It is the most 
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potent member of the rotenoid family of neurotoxins found naturally in tropical 
plants. 
Rotenone is highly lipophilic and freely crosses the bloodbrain barrier. Chronic 
exposure to low doses of rotenone results in inhibition of the mitochondrial electron 
transport chain in rodents. 
In animals, rotenone has been administered by different ways. Oral administration 
appears to cause little neurotoxicity (Inden et al., 2011). Chronic systemic 
administration using osmotic pumps has been the most common delivery regimen 
(Betarbet et al., 2000). Intraperitoneal injections have been reported to elicit 
behavioral and neurochemical deficits, although mortality is very high (Alam et al., 
2004). Intravenous administration is able to cause damage to nigrostriatal DA neurons 
that is accompanied by α-synuclein aggregation, Lewy-like body formation, oxidative 
stress, and gastrointestinal problems (Cannon et al., 2009). However, a subsequent 
study has found that rotenone is not specific to the DA system and has deleterious 
effects on other neuronal populations, as serotorinergic, noradrenergic and cholinergic 
neurons (Höglinger et al., 2003). Furthermore, there are no documented cases of 
rotenone-induced PD in humans. Thus, it is not clear that this model offers any 
advantage over other toxic models, such as that of 6-OHDA or MPTP. 
 
Gene-based models 
The underlying principle for studying genetic mutations of a disease is the belief that 
the clinical similarities between the inherited and sporadic forms of the disease share 
a common mechanism that can lead to the identification of molecular and biochemical 
pathways involved in the disease pathogenesis. 
Mutations to the α-synuclein gene were the earliest evidence for genetic link to PD. 
Two mutations in the α-synuclein gene (A53T, A30P) cause a dominantly inherited 
form of PD (Krüger et al., 1998) and have been used to create transgenic mice in an 
effort to recapitulate the pathophysiology of PD. Studies done using α-synuclein 
transgenic mice have yielded considerable progress, showing that A53T mutations in 
mice can result in a severe motor phenotype which can eventually lead to paralysis 
and death (Giasson et al., 2002). Additionally, mutations to the α-synuclein gene in 
mice produce inclusions that resemble LBs (Masliah et al., 2000). However this 
phenotype is restricted to the A53T mutation and not found in A30P transgenic mice. 
Furthermore, it has been shown that knocking out α-synuclein does not affect DA 
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neuron development or maintenance (Abeliovich et al., 2000; Thomas et al., 2011). 
Some of the α-synuclein transgenic mice have olfactory impairments and colonic 
dysfunction, and it seems that there are other nonmotor abnormalities (Wang et al., 
2008). However, since the function of α-synuclein has yet to be figured out, the actual 
role of α-synuclein in PD still remains elusive. 
Mutations to parkin, DJ1 and PINK1 cause autosomal recessive forms of PD. Knock-
out rodent models of these genes do not demonstrate any nigrostriatal degeneration 
and intranuclear inclusions (only PINK1 knockout mice display reduced DA release 
in the striatum) (Moore and Dawson, 2008). However, recently it has been shown that 
knocking out parkin in mice at adult age causes neurodegeneration in the SNc (Shin et 
al., 2011). 
Overall, this genetic mouse models are able to recapitulate specific aspects of PD, 
although none produce the neuronal degeneration associated with PD; therefore these 
themselves may be defective and may require additional modulations or modifications 
(Peng et al., 2010). 
 
 
The selective vulnerability of SNpc cells 
mDA neurons and their projections 
The largest assembly of DA neurons is found in the ventral midbrain. A distinction is 
usually made between nigral (A9) and non-nigral (A8 and A10) DA neurons, 
although there is no clear definable boundary between them and these groups can be 
seen as a continuous cell system (Björklund and Lindvall, 1984, from Handbook of 
Chemical Neuroanatomy). Nigral neurons are confined to the pars compacta and pars 
lateralis of the SN. Few A9 cells are scattered ventrally in the pars reticulata. The A10 
cell group is largely confined to the VTA and is positioned medially to the SN proper 
(figure 10). A8 cell group is located in the retrorubral field, caudally to the SN proper 
and it can be considered as a caudal extension of the A9 cell group as they too project 
to the striatum. 
The DA cells of the A10 group are implicated in the control of emotional balance, 
reward-associated and addictive behaviour, attention and memory. The A9 cells play 
an essential role in the control of postural reflexes and initiation of voluntary 
movement. Finally, the A8 dopamine neurons are thought to influence orofacial 
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movements. 
 
 
Figure 10. Rappresentation of ventral midbrain (VMB). 
TH-immunocytochemistry in the midbrain dopaminergic areas, showing the Substantia Nigra (SN), the 
Ventral Tegmental Area (VTA), interfascicular nucleus (IF), the rostral linear nucleus (RLi). The 
ventral tegmental area is divided into the medial (VTAM) and lateral (VTAL) parts by a dotted line 
between the lateral edge of the mamillary peduncle (mp) and the medial edge of medial lemniscus. 
 
It has become evident that mDA neurons are not a simple system but they are 
organized in a complex circuit that comprises subpopulations of neurons exhibiting 
differences in their morphology, but also in several molecular markers and patterns of 
forebrain projections. Although the projections of the three DA pathways 
(nigrostriatal, mesolimbic and mesocortical) are both anatomically and functionally 
distinct and confined to their projection targets with a very limited degree of 
collateralization, their cells of origin are more intermixed than originally thought. 
More specifically, A9 cells project to the sensorimotor striatum through the 
“nigrostriatal” pathway, in the strict sense of the term. Lateral VTA (A10) and RR 
(A8) project to the limbic part of the striatum, which includes the nucleus accumbens 
rostrally and the central nucleus of the amygdala and adjacent parts of the caudal 
striatum. It follows that the term mesostriatal DA pathway may be more appropriate 
to describe all components of the midbrain DA system projecting to the striatum. 
Therefore, often the three DA projections arising from mDA are described with the 
terms mesostriatal and mesocorticolimbic pathways. 
 
Cellular diversity in SN DA cells 
One key question is why only specific subsets of dopamine neurons die in PD. 
Neurons in the ventral and lateral SN are much more sensitive to neurodegeneration 
than neurons in the VTA (figure 11). This differential vulnerability is a key 
characteristic of the disease and it is well recapitulated in PD animal models like 
rodents or primates (Dawson and Dawson, 2002). 
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Figure 11. DA neurons of mouse midbrain. 
From the left different groups of DA neurons: A9 lateralis (A9L) and medialis (A9M) neurons forming 
Substantia Nigra (SN) and A10 neurons, forming Ventral Tegmental Area (VTA). The progressive 
neurodegeneration observed in PD affects first A9L and then spreads to A9M. Notably, A10 neurons 
are almost spared even in severe cases of the disease. 
 
A9 and A10 cells have many common features. They present long and thin axons and 
these have little or no myelination (Braak et al., 2004). They have a high-energy 
demand, feature that renders these neurons particularly dependent on proper 
mitochondrial dynamics. However, Liang and collegues found that the cytoplasmic 
area occupied by mitochondria in the DA neurons in the SN is lower than in 
neighbouring nondopaminergic neurons or in dopaminergic neurons of VTA (resistant 
in PD), suggesting the possibility that the vulnerable neurons may be more susceptible 
to subtle changes in mitochondrial maintenance (Liang et al., 2007).  
Other factors that may selectively affect SNpc neurons include their less capacity for 
calcium buffering (Esteves et al., 2010) and in their expression of specific 
transcription factors that regulate cell fate and survival (Alavian et al., 2008). 
However, these characteristics are not sufficient to explain the different susceptibility 
of SNpc neurons to neurodegeneration. 
 
Transcriptional anatomy of DA neurons 
In the last decade, a lot of efforts have been done in order to determine the critical 
molecular differences between A9 and A10 neurons. In particular, the advantage to 
use new tools and techniques like LCM (that permits the isolatation of A9 and A10 
cells) and high-throughput gene expression methods, such as Affymetrix array 
analysis, CAGE and nanoCAGE technologies coupled to next generation sequencing, 
has represented a new approach to analyze differences between A9 and A10, 
obtaining gene expression profiles of the two DA neuronal populations. 
In comparison to A10 neurons, A9 cells show higher expression of genes related to 
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metabolism and genes encoding mitochondrial proteins as well as genes involved in 
protein, lipid and vesicle-mediated transport. Interestingly, the level of metabolic 
transcripts correlates directly with susceptibility to complex I toxins (Greene et al., 
2005). Several genes related to small GTPase-mediated signaling and synaptic vesicle 
recycling, including RAB and RAS proteins, are elevated in A9 cells. Transcripts 
related to neuropeptide signalling and neurotrophic factors like BDNF, NGF or VGF 
were also markedly different between A9 and A10 cells. Several genes related to 
hormone activity and axon guidance are elevated in A10 neurons (Chung et al., 2005; 
Greene et al., 2005). 
 
Hemoglobin in DA neurons 
As mentioned above, gene expression profiles of A9 and A10 DA neurons has been 
performed to evaluate differences between the two subpopulations. In the laboratory 
of professor Gustincich, combination of different gene expression platforms unveiled 
transcripts of α hemoglobin, adult chain 1 (Hba-a1), and β hemoglobin, adult chain 1 
(Hbb-b1) in A9 neurons. Interestingly, Hb immunoreactivity decorated the large 
majority of A9 cells, whereas it stained only 5% of A10 neurons. Hb is expressed in 
almost all oligodendrocytes and cortical and hippocampal astrocytes. This pattern of 
expression was conserved in mammals and in human post-mortem brain. 
In addition, by gene expression analysis of mouse DA cell stably transfected with α 
and β chains of Hb, changes in genes involved in oxygen homeostasis as well as in 
mitochondrial oxidative phosphorylation were observed. Other variations involved 
genes in oxidative stress, iron metabolism as well as in Nitric Oxide (NO) synthesis. 
Genes that encode for subunits of mitochondrial complex I-V were upregulated with a 
marked induction of complex I transcripts. Furthermore, the mitochondrial proton 
carrier Uncoupling Protein 2 (Ucp2), was also strongly up-regulated. Genes well 
known as detoxifying agents from cellular free radicals as SOD2, Prdx5, Gpx4, Trn2 
and Txnrd2 were also up-regulated as well as neuronal nitric oxide synthase 1 (Nos1). 
Among genes involved in iron metabolism, an up-regulation of ferritin heavy chain 
(Fth1) was observed while transferrin receptor (Tfrc) transcript was decreased. 
These results open a new scenario for hemoglobin role in brain physiology and in PD 
pathogenesis. 
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Hemoglobin 
 
 
Globin family 
Globin family members are characterized by the coordination of heme group and by 
the consequent binding with oxygen that is the essential ligand for their function. 
 
 
Figure12. Human globins family characteristics: tissue distribution, biochemical and phylogenetics 
aspects (adapted from Hankeln et al., 2005). 
 
Globins have been identified in different organisms like in plants (leghemoglobin) 
where single-chain globins are involved with electron tranfer, oxygen storage and 
scavenging, in yeast (flavohemoglobin) or in bacteria where they seem to be primarily 
NO dioxygenases for detoxifying NO (Hardison, 1998). 
Beside their role of transport and storage of oxygen, other functions have been 
identified like enzymatic and detoxifying functions (Minning et al., 1999). 
Four main components of the family have been discovered and characterized in 
mammals up to now: hemoglobin, myoglobin, cytoglobin and neuroglobin (figure 12) 
(Hankeln et al., 2005). 
All these proteins share a similar tertiary structure even though their primary 
sequences have less than 50% of homology. The residues responsible for heme 
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binding are conserved. 
 
Myoglobin 
Myoglobin is a monomeric protein strongly resembling one single hemoglobin chain. 
It coordinates an heme group and its oxygen binding site has an higher affinity for the 
ligand in comparison to the other globins. It is mainly expressed by the striated 
muscules and cardiac tissue and its classical function is to store oxygen and to release 
it instantaneously under high request of energy by muscular tissue, in particular it 
facilitates oxygen diffusion to mitochondria. It also helps maintaining nitric oxide 
homeostasis (acting as a NO dioxygenase and nitrite reductase), and scavenge 
reactive oxygen species (Garry et al., 2003). Although it has been studied since 40’s, a 
detailed understanding of its function has still not been achieved; interestingly, 
knockout mice for myoglobin have almost normal physiology (Gödecke et al., 1999). 
 
Cytoglobin 
Cytoglobin (Cygb) is one of the newly discovered oxygen-binding members of the 
globin family (Burmester et al., 2002). It’s monomeric and very similar to myoglobin 
in the tertiary structure. Mammalian Cygb is longer than most globins and covers 190 
amino acids instead of the typical 140–150 aminoacids. This is due to two 20 amino 
acid extensions at both the N- and the C- terminal. Its affinity for oxygen is similar to 
myoglobin and it can bind CO and NO like hemoglobin but with a weaker affinity. 
It is prevalently cytoplasmic and is ubiquitously expressed, in particular in eyes, liver, 
heart, skeletal muscle and neurons, where its subcellular localization is both 
cytoplasmic and nuclear (Schmidt et al., 2004). 
Its function is still unknown and many hypotheses have been made on a possible 
implication in oxygen sensing or storage and in ROS scavenging. Up to now several 
studies show that it is over-expressed under hypoxic conditions (Singh et al., 2009), 
Cygb is correlated with cell respiration and proliferation in fibroblasts via NO 
dioxygenation (Halligan et al., 2009) and with collagen synthesis. It also seems to be 
a tumor suppressor, in fact it has been demonstrated that its down-regulation is a key 
event in a familial cancer syndrome of the upper aerodigestive tract (Shivapurkar et 
al., 2008). 
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Neuroglobin 
Neuroglobin (Ngb) was first observed in vertebrate brain (Burmester and Hankeln, 
2004), now it is known how it is widely expressed in vertebral central and peripheral 
nervous system as well as in retina, endocrine tissues and gastrointestinal tract (Reuss 
et al., 2002; Schmidt et al., 2004). Recently, Ngb has also been detected in human 
glioblastoma cell lines and in quiescent and reactive astrocytes (Brunori and Vallone, 
2006; DellaValle et al., 2010; Emara et al., 2010). Like myoglobin and cytoglobin, it 
is monomeric but unlike cytoglobin, it is exclusively cytoplasmic. 
Ngb binds several ligands such as O2, CO and NO (Brunori and Vallone, 2006). 
Besides small ligands, Ngb has been reported to interact with several proteins, 
modulating their functions (Yu et al., 2012a). 
Previous studies demonstrated that expression of Ngb increases in response to oxygen 
deprivation and that it is neuroprotective against hypoxic/ischemic brain injuries (Sun 
et al., 2001, 2003; Liu et al., 2009). It’s important to note that metabolically most 
active oxygen-consuming cell types express Ngb, including neurons that are 
particularly sensitive to hypoxic/ischemic insults. In this contex it has been observed 
that increased levels of Ngb protect neurons from neurodegerative disorders, as AD, 
modulating the activation of the apoptotic cascade (Yu et al., 2012b). Recently it has 
been identified an endogenous modulators that up-regulates Ngb levels. In details, 
Ngb is part of the 17β-estradiol signalling mechanism that is activated to exert 
protective effects against H2O2-induced neurotoxicity (De Marinis et al., 2010). Ngb 
can also act as a guanine nucleotide dissociation inhibitor (GDI) regulating signal 
transduction (Wakasugi et al., 2003). 
 
 
Hemoglobin 
The oxygen-carrying protein hemoglobin was discovered by Friedrich Ludwig 
Hünefeld in 1840. In 1851, Otto Funke published a series of articles in which he 
described growing hemoglobin crystals by successively diluting red blood cells with a 
solvent such as pure water, alcohol, or ether, followed by slow evaporation of the 
solvent from the resulting protein solution. Hemoglobin’s reversible oxygenation was 
described a few years later by Felix Hoppe-Seyler. In 1962 Perutz won Nobel Prize 
for Chemistry for his studies of the structures of hemoglobin and globular proteins. 
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Hemoglobin structure 
Hemoglobin is a hetero-tetrameric protein composed of two couples of identical 
subunits. Human hemoglobin coding genes are distinguished in two groups: alpha (α) 
and zeta (ζ) chains belong to the first group, on the chromosome 16, beta (β), epsilon 
(ε), gamma (γ) and delta (δ) chains belong to the second, on the chromosome 11. 
During development, different couples of genes are expressed, forming at least five 
different hemoglobin tetramers: in temporal order, the first is composed by two ζ and 
two ε chains and it’s called Gower Hb (ζ2ε2), the second is called Portland Hb (ζ2γ2), 
the third is the fetal Hb, HbF (α2γ2). During adult life both β and δ chains are 
expressed, forming adult Hb, HbA (α2β2) and HbA2 (α2δ2). In adulthood, HbA 
accounts for approximately 97% of the protein molecules, HbA2 for about 2% and 
HbF for only 1% (Collins and Weissman, 1984). 
HbA is composed by two α chains of 141 aminoacids and two β chains of 146 
aminoacids, held together by non-covalent interactions. Each chain is folded around a 
heme group that coordinates an iron atom, responsible for the binding with oxygen. 
The primary and secondary structures of the two chains do not share a high similarity, 
but the tertiary one is much conserved. Each polypeptide chain is made up of eight or 
nine α-helical segments and an equal number of non-helical ones placed at the corners 
between them and at the ends of the chain. The helices are named A-H, starting from 
the amino acid terminal (figure 13).  
 
 
Figure 13. Terameric structure of adult hemoglobin. 
 
The most conserved aminoacids are the proximal histidines (87th residue in α chain 
and 92nd in the β chain), involved in the binding with heme, and the distal histidines 
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(58th residue in α chain and 63rd in β chain), involved in the interaction between the 
four chains. 
The heme consists of an organic part, porphyrin, and an iron atom. Porphyrin is made 
up of four pyrrole groups that are linked by methane bridges to form a tetrapyrrole 
ring. The porphyrin found in hemoglobin is protoporphyrin IX, which contains four 
methyl, two vinyl, and two propionate side chains. The iron atom (Fe2+) in 
deoxyhemoglobin is pentacoordinated: four of its ligands are nitrogens residues in the 
centre of the protoporphyrin ring, the fifth is the nitrogen atom of the proximal His. In 
the oxyhemoglobin the iron atom is exacoordinated because it also binds an oxygen 
atom. The second oxygen atom is linked to the distal His through a hydrogen bond. 
The hydrophobic environment in which the heme group is located prevent the iron 
atom from oxidation; if hemoglobin comes in contact with air, the iron atom become 
oxidized (Fe3+), forming the so called methemoglobin in which the oxygen binding 
site is occupied from H2O and becomes inactive (Spiro et al., 1990). 
 
 
Hemoglobin genes 
In human 
The α-like globin genes are located in chromosome 16 near the telomere. The β-like 
genes (chromosome 11) are in a region that contains multiple DNA sequences that act 
as strong tissue and developmental stage-specific enhancers of transcription. 
The α globin gene cluster is composed by only 3 coding genes (ζ, α1, α2) and at least 
4 pseudogenes whereas, in β globin gene cluster, there are 5 coding genes (ε, Gγ, Aγ, 
δ, β) and only one pseudogene (Schechter, 2008) (figure 14). 
The expression of the different genes is controlled by multiple cis-acting elements 
like promoters, enhancers, silencer, insulators, MARs/SAR/s and LCR, because of 
their fine regulation from embryonic to adult life. The β globin cluster is the most 
regulated one because it has to control the perfect switch between 5 genes during 
development: in particular its proximity to a group of 5 LCRs contribute significantly 
to regulation of the sequential 5’-to-3’ expression of the globin genes during 
development, as well as their very high level of expression, with matched 
contributions from the α locus, in normal erythrocyte. Interestingly, sequencing of the 
globin gene clusters has revealed an enormous number of additional DNA motifs, 
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which appear to be binding sites for many other proteins and may contribute to 
enhancing or silencing transcription. 
 
 
Figure 14. The genomic structure of α and β globin clusters. 
The functional α-like and β-like genes are respectively in dark blue and light green. Pseudogenes are in 
light blue. The important control elements, HS-40 and the LCR, are also shown at their approximate 
locations. The various hemoglobin species formed from these genes, with their prime developmental 
stages, are shown in the lower part of the figure (Schechter, 2008). 
 
The molecular mechanisms of the β globin LCR have been only partially elucidated: 
they are major regulators of globin gene expression, both as a strong general enhancer 
of transcription and as a specific mediator of developmental control. They are 
supposed to “open” the chromatin allowing the transcription initiation complex and 
other trans-acting factors to bind at the appropriate gene. 
The most studied transcription regulatory protein with a strong erythroid specificity is 
GATA-1 but many others like FOG-1, TAL-1, EKLF, Gfi-1b and BCL11A, have a 
role in fine control of individual globin genes or their sequential expression (Mahajan 
et al., 2007). 
 
In mouse 
Murin α and β clusters have some differences compared to human’s: α cluster is on 
chromosome 11 and is composed by 3 coding genes (Hba-x, Hba-a1 and Hba-a2) that 
encode for X embryonic chain and α adult chains and 2 pseudogenes. There are also 
two added genes (Hbq1 and Hbq2) encoding for adult θ globins that in homo sapiens 
are evolved in a pseudogene (Storz et al., 2008). β cluster is on chromosome 7 and is 
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composed by 4 coding genes (Hbb-y, Hbb-bh1, Hbb-b1 and Hbb-b2) that encode for 
Y, Z embryonic chains and βminor, βmajor adult chains and 3 pseudogenes. 
In mouse embryo three different types of tetramers are expressed: X2Y2, α2Y2 and 
α2Z2; the switch to adult hemoglobin occurs between 14th and 15th gestation day. 
 
 
Hemoglobin function 
Oxygen 
In mammals, the most studied function of hemoglobin is to transport oxygen from the 
lungs to tissues and the most abundant sites of expression are the red blood cells. The 
binding with oxygen for α and β subunits does not happen contemporary: when the 
first oxygen molecule binds to the iron atom of one chain, it “pulls” the proximal His 
and induces a conformational change that propagates to all the chain structure. This 
change induces, in turn, conformational rearrangements of the other chains and the 
consequent increase of their affinity for oxygen. In this way the binding of the other 
three oxygen molecules is much faster. The vice versa, the release of oxygen, follows 
the same mechanism. 
The cooperative binding of hemoglobin by its ligand oxygen dramatically increases 
its physiological oxygen-carrying capacity: in the lungs the partial pressure of oxygen 
(pO2) is relatively high (100 torr) and hemoglobin becomes nearly saturated with 
oxygen (98% of the oxygen-binding sites are occupied); in the tissues pO2 is much 
lower (20 torr) and hemoglobin saturation level drops to 32%. The cooperative 
binding of oxygen by hemoglobin enables it to deliver about two times as much 
oxygen as it would if sites were independent. 
However, the cooperative binding only partially explains the behaviour of 
hemoglobin in efficiently transporting oxygen: other allosteric effectors like CO2, pH 
and 2,3-bisphosphoglycerate (2,3-BPG) regulate hemoglobin structural changes and 
function. CO2 stabilizes deoxyhemoglobin by reacting with the terminal amino groups 
to form carbamate groups, so the presence of CO2 in tissues decreases hemoglobin 
affinity for oxygen, facilitating its release. On the other hand, in lungs, the high 
concentration of oxygen stabilizes the oxyhemoglobin, inducing the release of CO2. 
Moreover, a portion of CO2 reacts with H2O becoming HCO3- with the release of a 
H+, responsible of the Bohr effect. In fact the oxygen affinity of hemoglobin 
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decreases as pH decreases. As hemoglobin moves into a region of low pH, for 
example from lungs to tissues, its tendency to release oxygen increases due to 
conformational changes in the four chains. 
Another allosteric effector is 2,3-diphosphoglycerate (2,3-DPG). This highly anionic 
compound is present in red blood cells and gives to hemoglobin the capacity to act as 
an extremely efficient oxygen transporter. Single molecules of DPG bind to 
deoxyhemoglobin and stabilize it, reducing the oxygen affinity and increasing the 
capacity to release oxygen. DPG binding to hemoglobin has other crucial 
physiological consequences in the passage of oxygen from maternal to fetal red blood 
cells. Fetal hemoglobin tetramers include two α chains and two γ chains in which 
there is the substitution of a serine residue for His143 of the β chain of the DPG-
binding site. This change reduces the affinity of DPG for fetal hemoglobin, thereby 
increasing the oxygenbinding affinity of fetal hemoglobin relative to that of maternal 
(adult) hemoglobin. This difference in oxygen affinity allows oxygen to be effectively 
transferred from maternal to fetal red blood cells. 
 
Nitric oxide 
Nitric oxide is present in all the tissues of the organism and its concentration increases 
in ischemic conditions. It is a ubiquitously produced cell signalling molecule, acting 
via soluble guanylyl cyclase production of cyclic GMP and through other 
mechanisms. It is especially important in mammals in the regulation of vascular tone, 
cell interactions, and neural function. 
Under basal conditions, in blood vessels, NO are produced by endothelial NO 
synthase enzymes to activate soluble guanylyl cyclase (sGC) to produce cyclic GMP 
and regulate vascular tone. 
In neurons it is synthesised by NO synthase (NOS type1) and acts as a 
neuromodulator in different processes like memory, neuronal plasticity or 
nociception. It is also a toxic molecule at high concentration and in presence of ROS: 
it reacts in particular with anion superoxide (O2•-) to form peroxinitrite (ONOO-), a 
highly reactive molecule that oxidise cellular molecules and inhibits Glutamate 
transporter (Trotti et al., 1996). 
The presence of nitrosilated molecules in post-mortem human brains of PD, SLA and 
Alzheimer patients lead to the hypothesis of a role of NO in neurodegenerative 
diseases (Good et al., 1996;Beal et al., 1997). 
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NO can bind hemoglobin in different ways: it can react with iron atom of 
deoxyhemoglobin to form nitrosyl(heme)hemoglobin (NO-hemoglobin) and it can 
also bind the cystein in position 93 of the β chain to form S-nitrosylhemoglobin 
(SNO-hemoglobin) (figure 15). The first reaction had generally been assumed to be 
irreversible, however, there is now evidence that NO-hemoglobin in the circulating 
red blood cell may release NO molecules, potentially allowing a mechanism for 
hemoglobin-based, endocrine-like transport of NO from one tissue to another within 
the body. 
 
 
Figure 15. A representation of nitric oxide (NO)/hemoglobin reactions in the arterial microcirculation 
(adapted from Schechter, 2008). 
 
SNO-hemoglobin seems to be able to dissociate and to release NO at low oxygen 
concentration. This could be a mechanism for homeostatic control of blood flow to 
tissues, because NO promotes vascular dilatation and increases blood flow and 
oxygen delivery, but this hypothesis is still controversial (Singel and Stamler, 2005). 
NO reacts also with oxyhemoglobin to produce methemoglobin, with ferric iron 
(Fe3+) and nitrate ions. Recent work suggests that most of the methemoglobin 
circulating in red blood cells is derived from this oxidation process which is normally 
reversed by the erythrocytic methemoglobin reductase system. 
More recently, an alternative hypothesis to account for the transport of NO by 
erythrocytes has been proposed. It has been suggested that nitrite ions within 
erythrocytes could be reduced to NO by deoxyhemoglobin in regions of relative 
hypoxia (Dejam et al., 2004). 
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It is important to consider that the interactions of NO, produced by endothelial cells 
under physiological condition, with red cells is limited by several barriers. Whereas, 
in case of hemolysis, cell-free oxyhemoglobin acts as an efficient scavenger of NO, 
causing vasoconstriction and perhaps pathological organ conditions. 
 
 
Atypical localization of hemoglobin 
In the last years it has becoming clear that hemoglobin expression is not restricted to 
erythrocytes and his precursors. For this reasons other potential functions have been 
postulated. 
In 1999, Liu et al. described the expression of βmin chain of hemoglobin in murine 
macrophages (Liu et al., 1999): they showed that both an immortalized macrophagic 
cell line and primary macrophages expressed βmin chain of hemoglobin after treatment 
with IFN-γ and LPS, inducers of inflammatory response. The role of this induction is 
still unknown but it suggests alternative functions for globins in mammalian cells and 
challenges the prevailing view that the expression of α and β globin genes is always 
balanced and coordinated. The functional properties of the single chains compared to 
those of the tetramer, are very different: α chain monomer is very unstable and doesn’t 
aggregate in tetramers; on the contrary β chain can form tetramers (known as HbH), 
isolated from the blood of α-thalassemic or HbH disease patients (Tongsong et al., 
2009) with a high affinity for oxygen. β4 tetramer biochemical properties can be 
affected by pH and by BPG like hemoglobin. However, its physiological role, if any, 
is still under investigation. 
In 2006, Newton et al. demonstrated the expression of both α and β chains in alveolar 
epithelial cells and Clara cells, the primary producers of pulmonary surfactant, 
implicating then in the physiology and pathology of the lung (Newton et al., 2006). 
Moreover, in 2008 Nishi et al. observed an up-regulation of hemoglobin in the 
hypoxic kidney, in particular in rat glomerular mesangial cells. With the support of in 
vitro studies, they hypothesized a protective role of this protein against oxidative 
stress induced by hydrogen peroxide and superoxide anion (Nishi et al., 2008). 
Other sites of globin subunits mRNAs expression have been reported included the 
pituitary of neonatal rats after exposure to estrogen and human cardiac ventricular 
tissue after ischemia-reperfusion (Leffers et al., 2006). 
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Moreover, α and β chains of hemoglobin were found in human hepatocytes cells and 
oxidative stress upregulated its expression (Liu et al., 2011b). 
Futhermore, hemoglobin was found in thyroid cancer cells, breast cancer and cervical 
carcinoma cells (Onda et al., 2005; Capulli et al., 2012; Li et al., 2013). In these cases 
hemoglobin awards to the tumours a more aggressive phenotype. 
Finally, in the laboratory of professor Gustincich, it has been demonstrated the 
presence of hemoglobin in mammalia DA neurons as well as in a subpopulation of 
hippocampus and cortex astrocytes and in almost all oligodendrocytes. Similarly, 
Richter and colleagues showed the existence of Hb in mammalia brain neurons 
(Richter et al., 2009). 
 
 
Hemoglobin disorders  
Hemoglobin disorders consist of two different groups, the structural hemoglobin 
variants and the thalassemias. 
 
Hemoglobinopathy 
Hemoglobinopathies are diseases related to mutations in globin chain, which alter the 
structure of hemoglobin or lead to a drastic decrease in the production of a type of 
chain. The structural hemoglobin variants typically are based on the point mutations 
in the α or β globin chain that result in a single-amino acid substitution in the 
corresponding globin chain. There are more than hundreds genetic variants of 
hemoglobin. The most common Hb variants worldwide are HbS, HbE, HbC, and 
HbD. All of these Hb variants have single amino acid substitutions in the Hb β chain. 
In details, HbS has a valine for glutamic acid substitution at position 6 of the β chain. 
HbC is a different variant mutation (lysine substituted for glutamic acid) at the same 
site as HbS mutation on the β chain. HbE contains a substitution of lysine for 
glutamic acid at position 26 of the β chain, and HbD Punjab (also called HbD Los 
Angeles) contains a substitution of glutamine for glutamic acid at position 121 of the 
β-globin chain. The presence of any of these four variants does affect the ionic charge 
of the Hb molecule (Little and Roberts, 2009). These hereditary blood disorders are 
named as Sickle-cell anemia (SCA) and causes abnormal, rigid, sickle shape red 
blood cells. Sickling decreases the cells' flexibility and results in a risk of various 
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complications. In particular, homozygosity for HbS (SCA) causes a serious disease 
with vascular obstruction and consequent tissue infarction. Those with HbC disease 
(also called HbCC disease) may have a normal hemoglobin concentration or be 
mildly or moderately anemic. Subjects with HbSC disease (also called sickle-
hemoglobin C disease) can be affected mildly or moderately with chronic hemolytic 
anemia. Subjects with homozygous E disease (also called HbEE disease) are usually 
completely asymptomatic, and those with HbD Punjab disease may have mild 
hemolysis and sometimes a mild hemolytic anemia. Heterozygous individuals for any 
of these Hb variants are usually asymptomatic and have normal red cell survival.  
 
Thalassemia 
Thalassemias are due to a large number of mutations that cause abnormal globin gene 
expression and result in total absence or quantitative reduction of globin chain 
synthesis (Steinberg and Brugnara, 2003). 
They are divided according to which globin chain is produced in reduced amounts: α 
thalassemia, in which α globin chain is reduced or absent, and β thalassemia, in which 
β globin chain is reduced or absent. 
The two main problems of thalassemias are decreased hemoglobin synthesis and an 
imbalance between the α and β globin chains. In the absence of the complementary 
globin chains, the excess unbound globin protein aggregates and precipitates, 
damaging cell membranes and leading to premature destruction (Schrier, 2002). 
When this occurs in immature erythroid precursors it results in ineffective 
erythropoiesis, wheares in mature blood cells it results in hemolysis. Both result in 
anemia. Other factors may involve iron overload and oxidative stresses (Shinar and 
Rachmilewitz, 1993; Weatherall and Clegg, 2001). 
The thalassemias are widespread in areas that in the past were malarial 
(Mediterranean, Middle East, India) because of the thalassemia trait that confers 
protection against malaria. The parasite that causes malaria in fact colonize 
erythrocytes and its survival is linked to the "health" of the erythrocytes themselves. 
 
Hemoglobin and its implication in other diseases 
Over the last years there has been increasing evidence of the direct involvement of 
hemoglobin and its derivatives in many diseases, such as cancer and 
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neurodegererative diseases. 
Recently it has been demonstrated that increased expression of a set of genes involved 
in oxygen metabolism, including β hemoglobin, confer a more aggressive metastatic 
phenotype in breast cancer cells (Capulli et al., 2012). Moreover, the expression of 
hemoglobin, in cervical carcinoma cells, may have important implications in the 
pathology of solid tumors because of the functions inherent to the structure of the Hb 
molecule, including gas exchange, and protection against oxidative and nitrosative 
stress (Li et al., 2013). 
It has been demonstrated the involvement of Hb in neurodegeneration. Interestingly, 
the levels of Hb are positively correlated with age in rats and negatively correlated to 
their learning and memory performances (Blalock et al., 2003). 
Concerning AD, Hb and Hb-derived peptides have been isolated from human 
cerebrospinal fluid and brain tissues of AD patients (Slemmon et al., 1994; 
Raymackers et al., 2000; Schonberger et al., 2001). In particular, it has been shown 
that Hb is present in neurons, glial cells and amyloid plaques of post-mortem AD 
brains (Wu et al., 2004). Furthermore, Hb induces the formation of structure 
composed of amyloid-beta in a transgenic mouse model of AD, suggesting its 
involvement in the AD pathogenesis (Chuang et al., 2012).  
Iron deposition occurs in the SN with normal aging but its accumulation is markedly 
higher in PD post-mortem brains (Kaur and Andersen, 2004; Bartzokis et al., 2007). 
Since Hb is the major source of iron in the brain, it has been proposed that toxic levels 
of brain iron may cause neurodegeneration by promoting oxidative stress through a 
Hb-induced iron homeostasis dysregulation (Kaur and Andersen, 2004). Furthermore, 
the presence of Hb formations (nitrosyl-Hb) in the SN could explain brain iron 
dysregulation, reduction of nigral glutathione levels and increase of dopaminergic 
nitric oxide (Cammack et al., 1998; Chinta et al., 2007; Shergill et al., 1996). 
Moreover, brain iron may aggregate with α-synuclein. Indeed in humans it has been 
found α-synuclein in red blood cells (Barbour et al., 2008). By metal binding and α-
synuclein interaction, Hb may have an important role in formation of Lewy bodies, 
which are the major hallmark of PD pathogenesis (Wolozin and Golts, 2002). Lastly, 
epidemiologic studies demonstrated that Hb, that remains high in elderly men, is 
associated with an increase risk of PD (Abbott et al., 2012). 
In this thesis we aim to elucidate the role of hemoglobin in PD.
 47	  
 
 
Materials and methods 
 
 
 
Constructs  
We used pBudCE4.1 vector (Invitrogen), designed for the independent expression of 
two genes from a single plasmid, in order to express α and β chains of mouse 
hemoglobin, as described previosly (Biagioli et al., 2009). Briefly, a fragment 
composed by β globin-MYC-IRES-eGFP was cloned into the MCS1 (SalI/XbaI) 
whether 2xFLAG-α globin was placed into MCS2 (KpnI/XhoI). We called this vector 
pBudCE4.1-β globin-MYC-IRES-eGFP, 2xFLAG-α globin. A control vector 
containing only IRES-eGFP in CMV-MCS (SalI/XhoI) was also created. We called 
this vector pBudCE4.1-IRES-eGFP. 
From pBudCE4.1-β globin-MYC-IRES-eGFP, 2xFLAG-α globin we generated a 
mutated Hb (Hb-mut). In particular we mutated the proximal hystidine of α and β 
chains into a glycine (respectively His87Gly and His92Gly). We used QuickChange 
Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer’s 
instructions. We designed the indicated primers: 
 
Primers Sequence Tm 
α globin 
H87G 
FW           
REV 
GCTCTGAGCGACCTGGGTGCCCACAAGCTGCGTG 
CACGCAGCTTGTGGGCACCCAGGTCGCTCAGAGC 
83,5 °C 
β globin 
H92G 
FW 
REV 
CAGCCTCAGTGAGCTCGGCTGTGACAAGCTGCATG 
CATGCAGCTTGTCACAGCCGAGCTCACTGAGGCTG 
81,1 °C 
 
We used pcDNA3-2xFLAG-α globin and pcDNA3.1--β globin-MYC, already present 
in the laboratory of professor Gustincich. 
We used pAAV-MCS (Agilent Technologies), designed for the production of AAVs, 
in order to express α and β chains of mouse Hb. Briefly, from pcDNA3-2xFLAG-α 
globin, the fragment composed by 2xFLAG-α globin was cloned into the MCS 
(HindIII/XhoI) of pAAV-MCS. We called this vector pAAV-2xFLAG-α globin. 
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Meanwhile from pcDNA3.1--β globin-MYC we generated another construct, in 
particular the fragment corresponding to β globin-MYC was placed in the MCS 
(EcoRI/HindIII) of pAAV-MCS. We called this vector pAAV-β globin-MYC. 
 
 
Generation and purification of recombinant Adeno-Associated Viruses 
We decided to use Adeno-Associated Viruses (AAVs) serotypes 9 for our 
experiments because of its high-expression level and its brain tropism (Zincarelli et 
al., 2008). 
As previously described, the fragments corresponding to 2xFLAG-α globin and β 
globin-MYC were cloned into the pAAV-MCS vector (Agilent Technologies), which 
was used to produce recombinant AAV vectors. In addition we use the vector alone as 
control. Recombinant AAV vectors were prepared, as described previously (Eulalio et 
al., 2012). Briefly, AAV vectors of serotype 9 were generated in HEK 293T cells, 
using a triple-plasmid co-transfection for packaging. Viral stocks were obtained by 
CsCl2	  gradient centrifugation. Titration of AAV viral particles was performed by real-
time PCR quantification of the number of viral genomes. The viral preparations had 
the following titres: AAV9-α globin 5×1013 viral genome particles/ml, AAV9-β 
globin 6,7×1013 viral genome particles/ml and AAV9-control 2,2×1013 viral genome 
particles/ml. AAV9-α globin and AAV9-β globin were diluted in PBS 1X at the 
concentration of 2,2×1013 viral genome particles/ml before use in order to have the 
same ratio of infection of AAV9-control. 
In addition, we used also an AAV9-GFP (3×1012 viral genome particles/ml). 
 
 
Cell cultures 
HEK 293T cells were grown in Gibco® DMEM (Life Technlogies) supplemented 
with 10% fetal bovine serum (Sigma–Aldrich), 100 µg/ml penicillin (Sigma–Aldrich), 
and 100 µg/ml streptomycin (Sigma–Aldrich) at 37 °C in a humidified CO2 incubator. 
MN9D-Nurr1Tet-On (iMN9D) cell line (Hermanson et al., 2003) was obtained from Dr. 
Perlmann (Ludwig Institute for Cancer Research, Stockholm, Sweden). Cells were 
maintained in culture using DMEM/F12 medium (Life Technlogies) supplemented 
with 10% fetal bovine serum (Sigma–Aldrich), 100 µg/ml penicillin (Sigma–Aldrich), 
100 µg/ml streptomycin (Sigma–Aldrich) and neomycin selection (Life Technlogies) 
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(250 mM) at 37 °C in a humidified CO2 incubator. Nurr1 expression in iMN9D cell 
lines was induced by addition of 3 µg/ml doxycycline (Sigma–Aldrich) to the culture 
medium every 48 hours. Cells were grown as above except that the 10% fetal bovine 
serum was changed to 5% (Hermanson et al., 2003). The same condition were used 
for iMN9D cell line stably transfected with pBUD-IRES-GFP (that we called control 
cells) or with pBUD-β globin-MYC IRES-GFP, 2xFLAG-α globin (that we called Hb 
cells) or with pBUD-β globin mutated-MYC IRES-GFP, 2xFLAG-α globin mutated 
(that we called Hb-mut cells) with the exemption of zeocyn (Life Technologies) 
selection (150 µg/ml).  
 
 
Cell transfections 
Cells were transfected with Lipofectamine 2000 (Life Technologies) according to the 
manufacturer’s instructions. 
 
 
Cell infections 
Cells were detached, counted and plated. After 24 hours doxycycline were added to 
the colture medium in order to induce differentiation. Doxycycline was added every 
48 hours. After 96 hours cells were treated with 50 mU/ml of Neuroaminidase in 
serum-free medium for 3 hours at 37 °C and then washed with sereum-free medium. 
Cells were infected with AAV9s (108 MOI) in serum-free medium for 3 hours at 37 
°C and then washed with sereum-free medium. 3 days after infection cells were 
recovered. 
 
 
Cell treatments 
For treatments, the following reagents were used: MPP+ (Sigma–Aldrich) and 
Rotenone (Sigma–Aldrich) for 16 hours at different concentrations. 
 
 
FACS sorting 
iMN9D cell line was transfected with pBUD-β globin mut-IRES-GFP, 2xFLAG-α 
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globin mut. After 24 hours from transfection, cells were collected. 7-Amino-
actinomycin D (7-AAD) (Beckman-Coulter) was added to the cell suspension before 
sorting: it is excluded by viable cells but can penetrate membranes of dying or dead 
cells and it intercalates into double-stranded nucleic acids. A high-speed cell sorter 
(MoFlo) was used to sort a population of cells expressing GFP. Sorting parameters 
used are described previously (Biagioli et al., 2009). Briefly, we first excluded from 
the analysis cell doublets and debris on the basis of their Pulse Width vs. Forward 
Scatter (PW/FSC) dot plot. Physical parameters such as FSC and Side Scatter (SSC) 
were then used to remove a part of dead cells and debris. 7-AAD exclusion was also 
employed in order to exclude cells with loss in the membrane integrity and, finally, a 
subpopulation of cells with increased GFP emission was identified and sorted. After 
sorting, cells were re-plated and 48 hours later, zeocyn (300µg/ml) was added for 
selection. After 3 weeks polyclonal cell populations expressing mutated tagged α and 
β chains of mouse Hb was obtained. 
 
 
Animals 
All animal experiments were performed in accordance with European guidelines for 
animal care and following SISSA Ethical Committee permissions (DM 2/2012-B, 
January 9th 2012). Mice were housed and bred in SISSA animal facility, with 12   
hours dark/light cycles and controlled temperature and humidity. Food and water 
were provided ad libitum. 
 
 
Stereotaxic surgery 
The stereotaxic procedure followed were according to (Cetin et al., 2006). Adult (8–
12  weeks old) male C57BL/6 mice weighing 25g ± 3g were used for experiments. 
Mice were pre-anaesthetised with Tramadolo i.p. (30 mg/kg body weight, 
intraperitoneally) and anaesthetised with a mixture of Xylazina (15 mg/kg body 
weight) and Zoletil (15 mg/kg body weight) i.p.. A stereotaxic injection of 2 µl of 
viral vector suspension (AAV9-GFP or AAV9-control or a mixture of AAV9-
2xFLAG-α globin and AAV9-β globin-MYC) was delivered to the left SNpc. The 
coordinates were: anterior/posterior (A/P) -3.2 mm from bregma, medio/lateral (M/L) 
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-1,2 mm from bregma and (D/V) dorso/ventral -4,5 mm from the dura (Cao et al., 
2010; St Martin et al., 2007). The coordinates used were accorded with the Franklin 
and Paxinos Mouse Atlas. The injection rate was 0,2 µl/30 seconds using a 10 µl 
syringe with 26 gauge needle (SGE). 
 
 
MPTP treatment 
MPTP (Sigma-Aldrich) was handled according to the published safety 
recommendations (Przedborski et al., 2001). Mice were injected i.p. with 35,1 mg/kg 
of MPTP hydrochloride (corresponding to 30 mg/kg free base MPTP) daily for five 
consecutive days (Jackson-Lewis and Przedborski, 2007). 
 
 
Tissue collection and processing 
At the indicated number of weeks after injection of AAVs into SN and MPTP 
treatment (see Results), animals were sacrified. Animals were anesthetized with an 
overdose of a mixture of Xylazina and Zoletil. Following induction of deep 
anesthesia, animals were intensively perfused transcardially with PBS 1X. For 
biochemical analysis, ventral midbrain, striatum and cortex were dissected and 
immediately put in liquid nitrogen, stored at -80°C and subsequently processed. For 
immunohistochemistry analysis, after the intensively transcardially perfusion with 
PBS 1X, animals were perfused with 4% paraformaldehyde diluted in PBS 1X. Brains 
were immediately dissected with the Mouse Brain Matrix instrument and separated 
into two pieces, the anterior part containing CPu and the posterior one containing SN. 
Brains were post-fixed in 4% paraformaldehyde for 1h at room temperature. The 
regions containing CPu and SN were cut in 40 µm free floating slides with a 
vibratome (Vibratome Series 1000 Sectioning System). Five consecutive series were 
collected, in order to represent the whole area of interest.  
 
 
Western blot 
Proteins derivated from adherent and floating cells were collected, washed intensely 
with PBS 1X and lysed in SDS sample buffer 2X or in Nonidet P-40 (NP-40) lysis 
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buffer (150 mM NaCl, 50 mM Tris-Cl pH 7.5 and 0.5% NP-40) with the addition of 
protease inhibitor mixture (Roche). Proteins derivated from tissue were obtained 
using TRIzol reagent (Life Technologies) following the manufacturer’s instructions. 
In SDS-PAGE proteins were separated in 10–17% SDS polyacrylamide gel as 
needed. Native PAGE was performed on gradient polyacrylamide gel electrophoresis 
(10–12–17% of acrylamide). Standard proteins were loaded using Native Mark 
Unstained Protein Standard (Sigma-Aldrich). The proteins supplied in the kit have a 
molecular mass range of 14.2–545 kDa. After the separation on gel, proteins were 
transferred to nitrocellulose membrane (Schleicher & Schuell). Membrane was 
blocked with 5% nonfat milk in TBST solution (TBS + 0.1% Tween20), then 
incubated with primary antibodies overnight at 4 °C or at room temperature for 2 h. 
The following antibodies were used: anti-Hb 1:1000 (Cappel), anti-FLAG 1:2000 
(Sigma–Aldrich), anti-MYC 1:2000 (Cell Signaling), anti-cleaved Caspase-3 1:1000 
(Cell Signaling), anti-GFP 1:1000 (Life Technologies), anti-LC3b 1:1000 (Cell 
Signaling), anti-TH 1:1000 (Sigma–Aldrich), anti-UBF 1:1000 (SantaCruz) and anti-
βactin 1:10000 (Sigma–Aldrich). For development, secondary antibodies conjugated 
with horseradish peroxidase (Dako) were used in combination with ECL reagent (GE 
Healthcare). 
 
 
FACS analysis 
For FACS analysis, both adherent and floating cells were collected and fixed in ice-
cold 70% ethanol. After rehydration, cells were resuspended in PBS + 0.1% NP40 + 
200 µg/ml o 2 µg/mL RNaseA and treated with 40 o 10 µg/mL propidium iodide and 
analyzed on a flow cytometer (FacsCalibur; BD). At least 104 green fluorescent 
protein (GFP)-positive cells were analyzed in each acquisition. FACS data were 
processed using FlowJo software, and cell cycle profiles were determined using the 
Watson pragmatic model (Tree Star). 
 
 
WST-1 analysis 
Cell viability was assayed using WST-1 reagent (Roche), according to the 
manufacturer’s protocol. In details absorbance was measured on a microplate ELISA 
reader (Thermo Scientific) at a 450 nm and 620 nm detection wavelength. Normalized 
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WST was calculated as follows: WST(%) = [(A450nm – A620nm of treated sample – 
A450nm – A620nm of blank)/( A450nm – A620nm of untreated sample – A450nm – A620nm of 
blank)] × 100. Blank represents wells containing culture medium only (Lunardi et al., 
2010). 
 
 
Cellular fractionation 
Nucleo-cytoplasmic separation was performed using Nucleo-Cytoplasmic separation 
kit (Norgen) according to the manufacturer’s instruction. The effectiveness of cellular 
separation were controlled with cytoplasmatic and nuclear markers, respectivately TH 
and UBF. 
 
 
RNA isolation and reverse transcription 
Total RNA was extracted from cells and mouse tissue samples (cortex, striatum and 
substantia nigra) using the TRIzol reagent (Life Technologies) following the 
manufacturer’s instructions. All tissues were homogenized using a glass-Teflon® 
(Thomas Scientific). A fraction of the total RNA samples were subjected to DNase I 
treatment (Ambion) at 37°C for 1 hour and the sample was then purified on RNAeasy 
mini kit columns (Qiagen). The final quality of RNA sample was tested on agarose 
gel. Single-strand cDNA was obtained from 1 µg of purified RNA using the iSCRIPT 
cDNA synthesis kit (Bio-Rad) according to the manufacturer’s instructions. 
 
 
PCR 
To amplify transcripts the polymerase chain reaction mix was prepared by adding 1µl 
of first strand reaction to a mix containing 0,5µl of Ex Taq DNA polymerase, 10X 
buffer, dNTPs mix 2,5mM each (all reagents from Takara), 10µM of each 
olignucleotide primer and water to a final volume of 50µl. All products were analyzed 
on agarose gel. 
The oligonucleotide primer pairs designed to amplify the transcripts are listed below: 
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Primers Sequence Expected product size 
FLAG-α globin FW 
REV 
GCGCAAGCTTATGGACTACAAGGA 
ATATCTCGAGTTAACGGTACTTGG 
500 bp 
Β globin-MYC FW 
REV 
GCGCATGGTGCACCTGACtGAtGC 
ATATTTACAGGTCCTCCTCGCTGA 
500 bp 
TH FW 
REV 
CCGTCTCAGAGCAGGATACC 
CGAATACCACAGCCTCCAATG 
200 bp 
 
 
Immunocytochemistry and immunohistochemistry 
For immunocytochemistry experiments, cells were fixed in 4% paraformaldehyde for 
10 minutes, then washed with PBS 1X, treated with 0.1M glycine for 4 minutes in 
PBS 1X and permeabilized with 0.1% Triton X-100 in PBS 1X for another 4 minutes. 
After washing with PBS 1X and blocking with 0.2% BSA, 1% NGS, 0.1% Triton X-
100 in PBS 1X, cells were incubated with the indicated antibodies diluted in blocking 
solution for 90 minutes at room temperature. After washes in PBS 1X, cells were 
incubated with labeled secondary antibodies for 60 minutes. For nuclear staining, 
cells were incubated with 1µg/ml DAPI for 5 minutes. Cells were washed and 
mounted with Vectashield mounting medium (Vector). The following antibodies were 
used: anti-Hb 1:1000 (Cappel), anti-FLAG 1:1000 (Sigma–Aldrich) and anti-MYC 
1:2000 (Cell Signaling). For detection, Alexa Fluor -488, -594 or -405 (Life 
Technologies) antibodies were used. 
For immunohistochemistry, slides were treated with 1% SDS in PBS 1X for 1 
minutes at RT and blocked with 10% NGS, 1% BSA, 1% Fish gelatin in PBS 1X 
(filtered) for 1h at RT, the primary and secondary antibodies were diluted in 1% BSA, 
0.1% Fish gelatin, 0.3% triton X-100 in PBS 1X. Incubation with primary antibodies 
was performed for 16h at RT; incubation with secondary antibodies was performed 
for 2h at RT. Nuclei were labeled with DAPI. Slides were mounted with mounting 
medium for fluorescence Vectashield (Vector Lab.). The following antibodies were 
used: anti-GFP (Life Technologies), anti-Hb 1:1000 (Cappel), anti-FLAG 1:100 
(Sigma–Aldrich), anti-MYC 1:100 (Cell Signaling) and anti-TH 1:1000 (Sigma–
Aldrich). For detection, Alexa Fluor -488, -594 or -405 (Invitrogen) antibodies were 
used. 
All images were collected using a confocal microscope (LEICA TCS SP2 and Nikon). 
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Lysotracker 
Cell were stained without fixation with 50nM Lysotracker Red (Molecular Probes) in 
growth medium for 1 hour. Stained cells were immediately fixed with 4% 
paraformaldeide and follow a standard immunofluorescence protocol (Wu et al., 
2009). Lysotracker stainining were visualized with confocal microscope (Nikon). 
Using Volocity 3D Image Analysis Software (PelkinElmer), Lysotracker Red foci per 
cell were counted. Autophagy activity was defined as follows: high: >10 Lysotracker 
Red foci/cell; medium: 6–10 Lysotracker Red foci/cell; low: <6 Lysotracker Red 
foci/cell. The values were represented as percentage of the total. 
 
 
Quantification of DA neurons in the SNpc 
One out of five series of 40 µm freefloating slides was stained for anti-TH antibody. 
SNpc was outlined under a low magnification objective (10X) following landmarks 
from the Franklin and Paxinos Mouse Atlas and the analysis was performed under the 
40X objective of a Leica DM6000 microscope. Cells were counted throughout the 
whole SNpc area and through the entire section thickness. TH+ cells were counted 
manually. All counts were performed blind to the experimental status of the animals. 
The orientation for each brain was determined by marking one side of each brain by 
performing an incision through one side of the brain. The TH+ cells values were 
expresses relative to the controlateral side of control-injected mice treated with saline. 
 
 
Determination of striatal DA density 
DA innervation in the striatum was estimated via optical density determination of 
fluorescent immunostaining using Leica DM6000 microscope. Briefly, striatal 
sections were immunostained with anti-TH antibody. Scans of three different section 
were acquired corresponding to a frontal, media and caudal area of striatum. Using 
Volocity 3D Image Analysis Software (PelkinElmer), the region of interest on the 
section was outlined and the mean of fluorescence value for the region determined (St 
Martin et al., 2007). A background value, corresponding to corpus callosum, was 
subtracted from the fluorescence values (Diaz-Ruiz et al., 2009). The optical density 
values were expresses as a percentage relative to the controlateral side of control-
injected mice treated with saline. 
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Statistical analysis 
All data were obtained by at least three independent experiments. Data represent the 
mean ± S.D., each group was compared individually with reference control group 
using Student’s t test (Microsoft Excel software). Significance to reference samples 
were indicated. Regarding statistical analysis of in vivo experiments, data represent 
the mean ± SEM, each group was compared individually with reference control group 
using ANOVA. Statistical significance was assessed using one-way ANOVA. 
Significance was set at p<0.05. 
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Results 
 
 
 
Preliminary data in the laboratory of Professor Gustincich 
Hemoglobin is a well-known blood-associated protein, where it transports oxygen 
throughout the body. In the last few years, expression of Hb has been found in 
atypical sites, including the brain. α and β chains of Hb have been detected in the 
majority of A9 DA neurons (Biagioli et al., 2009), the site of neurodegeneration in 
PD. Therefore, we asked whether Hb could have a role in PD. 
To address this hypothesis, we took advantage of the iMN9D that, under the control 
of doxocycline, are inducible for the pro-dopaminergic transcription factor Nurr1 
(Hermanson et al., 2003). As Hb acts as heterotetramer of two different subunits, we 
took advantage of pBUDCE4.1 vector to overexpress tagged α and β chains of mouse 
Hb in iMN9D cells, as previously described (Biagioli et al., 2009). Briefly, by the use 
of an Internal Ribosomal Entry Site (IRES) driving the expression of eGFP, two 
stable polyclonal cell lines were obtained by FACS and zeocyn selection: iMN9D 
cells expressing tagged α and β chains of mouse Hb together with eGFP (Hb cells) 
and iMN9D cells expressing eGFP only (control cells). 
 
 
The impact of Hb overexpression depends on the differentiation state of iMN9D 
cells upon MPP+ treatment 
In order to investigate the function of Hb and its involvement in PD, we analyzed Hb 
overexpresssion upon typical PD-mimicking insults. We studied cell death induced by 
the administration of MPP+, the active ion of the Parkinson-inducing neurotoxin 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyride. MPP+ is reported to induce damage in cells 
(Chee et al., 2005) resulting in the activation of caspases cascade. Therefore, we 
analyzed the expression of cleaved Caspase 3 in undifferentiated and differentiated 
Hb and control cells. Moreover, we tested cell viability through FACS and WST-1 
(for technical details see material and methods). We must note that we used different 
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techniques to measure viability/mortality that are based on different features of 
viable/death cells. Clevead Caspase 3 expression and FACS monitor cell mortality, 
while WST-1 analyzes the metabolic activity of viable cells. 
 
Figure 16. In undifferentiated cells overexpression of Hb is protective upon MPP+. 
Undifferentiated Hb cells (Hb) and control cells (control) were treated with MPP+ (at the indicated 
concentrations) for 16 hours. A. Western blot analysis of cleaved Caspase 3 expression. α and β globin 
were detected with anti-FLAG and anti-MYC antibodies respectively. βactin was used as loading 
control. (n=5) B. FACS analysis. Percentage of subG1 cells is expressed as fold increased relative to 
controls, arbitrary set as 1. (n=3) C. WST-1 analysis. In graph are represented the percentage of viable 
cells. (n=4) Value are mean ± SD. Data were evaluated statistically by Student’s t-test. Statistical 
analysis is indicated as: * = p value ≤ 0.05, * *= p value ≤ 0.01, *** = p value ≤ 0.001, NS=non-
significance. 
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80% confluence, MPP+ was added and cells were collected 16 hours later for analysis. 
We decided to use MPP+ at concentrations of 0.1 mM, 1 mM, 2.5 mM or 5 mM for 16 
hours. 
As shown in figure 16A, upon MPP+ treatment Hb cells showed lower levels of 
cleaved Caspase 3 expression than controls. Untreated cells didn’t express cleaved 
Caspase 3, as expected. In addition we observed a dose-dependent cleavage of 
Caspase 3 in response to increased concentration of MPP+, in according to literature 
data (Nicotra and Parvez, 2002). We also performed FACS analysis in order to 
discriminate subG1 cells, which represent death cells. The amount of death cells was 
higher in control cells than Hb cells upon 0.2 mM MPP+, confirming previous data 
(figure 16B). Upon 1mM MPP+ we didn’t observe any difference. In addition, we 
evaluated viable cells through WST-1 assay (figure 16C). Upon MPP+ treatment we 
observed about 50% decrease of viability. Furthermore, Hb cells were more viable of 
about 10% in comparison to control cells upon 0.1 mM MPP+. Upon 1mM MPP+ 
there was no difference. In conclusion, these data suggest that overexpression of Hb 
protects undifferentiated iMN9D cells from MPP+ treatment.  
We then analyzed differentiated Hb and control cells. In differentiated condition, cells 
were detached, counted and plated. 24 hours later, doxycycline was added to the 
colture medium to induce dopaminergic differentiation. The drug was added 56 hours 
later (cells at approximately 80% confluence) and after 16 hours cells were collected 
(72 hours after differentiation induction). We used MPP+ at the concentrations of 0.1 
mM, 0.2 mM, 0.5 mM or 1 mM for 16 hours. 
Surprisingly, in differentiated conditions, expression of cleaved Caspase 3 was higher 
in Hb cells than controls (figure 17A). We noticed a dose-dependent cleavage of 
Caspase 3. In addition, FACS analysis demonstrated that in Hb cells cell death was 
clearly more evident in comparison to control cells upon 1mM MPP+ (figure 17B). 
Upon 0.2 MPP+ there wasn’t statistical difference even if the trend was maintained 
(p=0.11). Moreover, the analysis of viable cells through WST-1 assay showed that in 
general there was a 30-40% decrease of viability. Furthermore, Hb cells presented 
about 20% less viability in comparison to control cells upon MPP+ treatments (figure 
17C). All these results suggest a toxic role of Hb after MPP+ treatment in 
differentiated conditions. 
In conclusion, upon MPP+ the impact of the overexpression of Hb depends on iMN9D 
cells’ differentiation state. 
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Figure 17. In differentiated cells overexpression of Hb is toxic upon MPP+. 
Differentiated Hb cells (Hb) and control cells (control) were treated with MPP+ (at the indicated 
concentrations) for 16 hours. A. Western blot analysis of cleaved Caspase 3 expression. α and β globin 
were detected with anti-FLAG and anti-MYC antibodies respectively. βactin was used as loading 
control. (n=10) B. FACS analysis. Percentage of subG1 cells is expressed as fold increased relative to 
controls, arbitrary set as 1. (n=3) C. WST-1 analysis. In graph are represented the percentage of viable 
cells. (n=4) Value are mean ± SD. Data were evaluated statistically by Student’s t-test. Statistical 
analysis is indicated as: * = p value ≤ 0.05, * *= p value ≤ 0.01, *** = p value ≤ 0.001, NS=non-
significance. 
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use 1 mM MPP+ based on previous data. As shown in figure 18B, after 48 hours of 
dopaminergic differentiation the effect of Hb overexpression switched from protective 
to toxic upon MPP+ treatment. Untreated cells didn’t express cleaved Caspase 3, as 
expected (figure 18A). We hypothesize that there may be some different gene 
expressions that influence the healthy state of iMN9D cells upon Hb overexpression. 
 
Figure 18. Hb protection/toxicity depends on differentiated state of iMN9D cells. 
Differentiation time course of Hb cells (Hb) and control cells (control) untreated (A) or treated with 
1mM MPP+ for 16 hours (B). A, B. Western blot analysis of cleaved Caspase 3 expression. α and β 
globin were detected with anti-FLAG and anti-MYC antibodies respectively. βactin was used as 
loading control. (n=4) 
 
 
Hb overexpression is toxic upon rotenone treatment on both undifferentiated 
and differentiated iMN9D cells 
We then decided to analyze the effects of Hb upon another PD-mimicking drug, that 
is rotenone. Rotenone, together with MPP+, is one of the common drugs used to 
induce neuronal cell death (Panov et al., 2005). The experimental procedure was 
described above with the unique difference that we used rotenone instead of MPP+. 
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Figure 19. In undifferentiated cells overexpression of Hb is toxic upon Rotenone. 
Undifferentiated Hb cells (Hb) and control cells (control) were treated with Rotenone (at the indicated 
concentrations) for 16 hours. A. Western blot analysis of cleaved Caspase 3 expression. α and β globin 
were detected with anti-FLAG and anti-MYC antibodies respectively. βactin was used as loading 
control. (n=6) B. FACS analysis. Percentage of subG1 cells is expressed as fold increased relative to 
controls, arbitrary set as 1. (n=3) C. WST-1 analysis. In graph are represented the percentage of viable 
cells. (n=4) Value are mean ± SD. Data were evaluated statistically by Student’s t-test. Statistical 
analysis is indicated as: * = p value ≤ 0.05, * *= p value ≤ 0.01, *** = p value ≤ 0.001, NS=non-
significance. 
 
As shown in figure 19A, in undifferentiated cells there was a higher expression of 
cleaved Caspase 3 in Hb cells in comparison to controls upon rotenone treatments. 
Cleaved Caspase 3 expression was rotenone dose-dependent. The percentage of 
subG1 cells measured with FACS demonstrated a higher cell death count in Hb cells 
upon drug treatment (figure 19B). Furthermore, WST-1 experiment proved about 
50% of mortality. Interestingly, lower viability was evident in Hb cells (figure 19C). 
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There was no statistical difference between Hb and control cells upon 100 µM 
rotenone, although the trend was maintained (p=0.08). All these data suggest that Hb 
overexpression is toxic upon Rotenone treatment in undifferentiated condition. 
 
Figure 20. In differentiated cells overexpression of Hb is toxic upon rotenone. 
Differentiated Hb cells (Hb) and control cells (control) were treated with Rotenone (at the indicated 
concentrations) for 16 hours. A. Western blot analysis of cleaved Caspase 3 expression. α and β globin 
were detected with anti-FLAG and anti-MYC antibodies respectively. βactin was used as loading 
control. (n=8) B. FACS analysis. Percentage of subG1 cells is expressed as fold increased relative to 
controls, arbitrary set as 1. (n=4) C. WST-1 analysis. In graph are represented the percentage of viable 
cells. (n=3) Value are mean ± SD. Data were evaluated statistically by Student’s t-test. Statistical 
analysis is indicated as: * = p value ≤ 0.05, * *= p value ≤ 0.01, *** = p value ≤ 0.001, NS=non-
significance.  
 
We then analyzed differentiated Hb and control cells. There was a higher expression 
of cleaved Caspase 3 in Hb cells in comparison to control cells upon Rotenone 
treatment (figure 20A). The expression of cleaved Caspase 3 was again dose-
A
control Hb
17 kDa
42 kDa ??????
Cleaved Caspase 3
Rotenone      DMSO?????????????????????????????DMSO????????????????????????????
34 kDa
34 kDa ???????????????
??????????????
B
C
????????????????????????????????????????????????????????
*
**
*
**
??
??
??
??
??
???
??
???
??
??
??
?
??
??
??
??
??
???
control
Hb
control
Hb
7
6
?
4
3
2
1
?
?
???
??
??
???
??
??
????????????????????????????????????????????????????????
 64	  
dependent. Furthermore, FACS analysis showed higher death ratio in Hb cells than 
control cells upon stimuli (figure 20B). Moreover, WST-1 assay indicated about 50% 
of cell death upon rotenone. We noted that Hb cells presented about 30% less viability 
in comparison to control cells upon drug treatments. (figure 20C). Furthermore, all 
these experiments indicated that in differentiated cells Hb overexpression is toxic 
upon rotenone treatment. In summary, differently from MPP+ stimulus, Hb cells 
appear to be more susceptible to rotenone in both undifferentiated and differentiated 
conditions.  
 
 
Cloning of mutant Hb 
To understand if protective and toxic functions of Hb were due to oxygen, we created 
a stable cell line overexpressing a mutant Hb that is unable to bind oxygen (Hb-mut). 
In details, we mutated the proximal histidine (F8) that is involved in the binding with 
heme on both α and β chains. Starting from pBUDCE4.1-β globin-MYC-IRES-eGFP, 
2xFLAG-α globin we mutated histidine 87 (nucleotide sequence CAT) on α chain in 
glycine (GGT) and histidine 92 (CAC) on β chain in glycine (GGC), as indicated in 
literature (Barrick et al., 1997). We decided to replace histidine by glycine because is 
the smallest and non-ligand aminoacid, creating a cavity in the proximal heme pocket. 
Glycine doesn’t allow the covalent bond with the iron of the heme group, which in 
physiological conditions is mediated by the ionic charges of histidine. In the presence 
of glycine, the binding site is altered, causing significant changes in the affinity for 
oxygen. In these conditions, it is believed that Hb is not working as oxygen carrier. 
The generation of pBUDCE4.1-β globin-MYC mut-IRES-eGFP, 2xFLAG-α globin 
mut was obtained by two progressive steps of mutagenesis (for technical details see 
material and methods). At each step, the effectiveness of the mutagenesis reaction 
was evaluated by sequencing the gene of interest.  
It was then possible to proceed with the analysis of the expression of the construct, 
carried out in HEK 293T cell line that lacks endogenous Hb. Cells have been 
transiently transfected with pBUDCE4.1-IRES-eGFP (control construct), 
pBUDCE4.1-β globin-MYC-IRES-eGFP, 2xFLAG-α globin (Hb construct) and 
pBUDCE4.1-β globin-MYC mut-IRES-eGFP, 2xFLAG-α globin mut (Hb-mut 
construct). 48 hours after transfection, we evaluated protein expression by Western 
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blot analysis. To discriminate α and β chains of Hb, two different antibodies were 
used: anti-FLAG antibody recognized specifically α globin while anti-MYC antibody 
recognized β globin. Moreover a third antibody anti-Hb was used to identify the 
global amount of Hb. Finally, anti-GFP antibody was used to evaluate the efficiency 
of transfection. 
As shown in figure 21A, transfected Hb and Hb-mut constructs gave rise to 34 kDa 
bands, as expected. It is important to note that, as in the case of Hb, also the Hb-mut 
protein has a band at 34 kDa. This molecular weight is higher than what we expected 
after a SDS-PAGE (17 kDa) and is compatible with the weight of Hb chains dimer. 
Previous studies in the laboratory have shown that the bicistronic vector pBUDCE4.1 
promotes the formation of a dimer resistant to denaturation. Moreover, the dimer 
contains α and β chains, as demonstrated by Biagioli and colleagues (Biagioli et al., 
2009). All together, these results indicate that the construct Hb-mut is able to express 
the protein correctly. 
Many of the functions of a protein depend on its cellular localization. Therefore, we 
performed an immunofluorescence experiment to verify the localization of Hb 
proteins. HEK 293T cells were transiently transfected with the vectors: Hb, Hb-mut 
and control. The cellular localization of Hb was analyzed 48 hours after transfection 
by immunofluorescence with anti-Hb antibody. As expected, control transfected cells 
were negative to staining with anti Hb (figure 21B). A clear signal for the expression 
of Hb was present both in the cells with Hb and Hb-mut contructs (Figure 21B). This 
result confirms that Hb-mut was expressed properly. Moreover, proteins were 
localized in the cytoplasm and in the nucleus (identified by DAPI staining). These 
data confirm earlier analysis carried out in HEK 293T cells (Biagioli et al., 2009). The 
localization of Hb does not change in the presence of histidine mutations and Hb-mut 
is expressed both in the nucleus and in the cytoplasm of cells, as wild type Hb. We 
also analyzed localization of Hb single chains. We performed double 
immunofluorescence in which individual chains were localized with anti-FLAG (α 
chain specific) and anti-MYC (specific for the β chain) antibodies. As shown in 
Figure 21C, α and β chains were both expressed in cells transfected with Hb and Hb-
mut constructs. The signal was absent in cells transfected with the vector only, as 
expected. α and β chains colocalized and were present in the cytoplasm and in the 
cells nucleus.  
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Figure 21. Expression of Hb, Hb-mut and control constructs in HEK 293T cells. 
HEK 293T cells were transfected with control, Hb and Hb-mut contructs. A. Western blot analysis of 
cell lysates. Immunoblot was carried out with anti-FLAG (that recognize α globin specifically), anti-
MYC (that recognize β globin specifically), anti-Hb (that recognize both α and β globins), anti-GFP (as 
control of transfection) and βactin (as loading control). B. Immunofluorescence performed with anti-
Hb antibody (red). Nuclei are marked by DAPI. Scale bar 10 µm. C. Double immunofluorescence 
performed with anti-FLAG (red) and anti-MYC (blue) antibodies. Scale bar 10 µm. 
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These data confirm previous results obtained with anti-Hb antibodies and demonstrate 
that Hb-mut maintains the expression and cellular localization of wild type Hb. 
 
 
Generation of Hb-mut iMN9D stable cell line 
In collaboration with professor Carlo Alberto Beltrami at the Department of Medical 
and Biological Sciences (DSMB), University of Udine in Udine, we decided to 
generate an iMN9D cell line that overexpresses Hb-mut construct, that we called Hb-
mut cells. We applied the same procedure that Biagioli and collegues used to create 
Hb and control cells (for technical details see material and methods). 
In order to verify the correct expression of Hb in Hb-mut cells, first of all we 
proceeded with Western blot analysis. The lysates were prepared from Hb cells, Hb-
mut cells and control cells. We tested the expression of Hb, α chain, β chain and GFP 
with specific antibodies. The expression of GFP was analyzed in order to verify the 
effectiveness of sorting and subsequent selection of positive cells. As shown in figure 
22A, the specific antibodies used (anti-FLAG, anti-MYC and anti-Hb) recognized a 
clear band at 34 kDa in Hb cells and Hb-mut cells, as expected. No bands in control 
cells were detected using anti-FLAG and anti-MYC antibodies. In control cells a 
weak band was detected with anti-Hb antibody, as expected because iMN9D cells 
expresses endogenous Hb. The observed molecular weight for the single chains was 
34 kDa. Furthermore, comparing the expressing levels of single chains with those of 
Hb, we observed that Hb-mut cells espressed lower levels of Hb, even if the GFP 
levels was comparable between Hb cells and Hb-mut cells. Probably this was due to 
the mutations inserted in the sequence of Hb-mut. Finally, it is interesting to note that 
control cells presented lower levels of GFP, although sorted by FACS with the same 
parameters. Biagioli and collegues had previously observed this aspect. Altogether 
these results demonstrate that Hb-mut cells correctly express mutant α and β chains, 
even if expressing levels were lower than Hb cells. 
In order to study the localization of mutant Hb in Hb-mut cells, we carried out 
immunofluorescence experiments, as previously described. First, we analyzed Hb 
staining. As shown in figure 22B, Hb levels were very low in control cells, as 
expected. Overexpressed Hb was present in the cytoplasm and in the nucleus of Hb 
cells. The same distribution was observed in Hb-mut cells. We then analyzed the 
localization of single globin chains. As shown in figure 22C, control cells didn’t 
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express FLAG and MYC tags. In Hb cells and Hb-mut cells tagged α and β chains 
(recognized by specific antibody) colocalized and were present in cytoplasm and 
nucleus of cells. 
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Figure 22. Analysis of Hb, Hb-mut and control cells. 
iMN9D cell lines stable transfected with Hb, Hb-mut and control constructs. A. Western blot analysis 
of cell lysates. Immunoblot was carried out with anti-FLAG (that recognize α globin specifically), anti-
MYC (that recognize β globin specifically), anti-Hb (that recognize both α and β globins), anti-GFP (as 
internal control) and βactin (as loading control). B. Immunofluorescence performed with anti-Hb 
antibody (red). Nuclei are marked by DAPI. Scale bar 10 µm. C. Double immunofluorescence 
performed with anti-FLAG (red) and anti-MYC (blue) antibodies. Scale bar 10 µm. D. Native PAGE of 
cell lysates. Immunoblot was carried out with anti-FLAG, anti-MYC and anti-Hb. 
 
We have recently showed that in Hb cells overexpressed Hb exists as an α2β2 tetramer 
(Russo et al., 2013). Therefore, we analyzed the tertiary structure of mutant Hb in Hb-
mut cells. We used anti-FLAG and anti-MYC antibodies to discriminate between the 
two chains in order to determine the presence of each chain within the Hb quaternary 
structure. In contrast to SDS–PAGE, native PAGE was performed in non-denaturing 
conditions allowing the separation of intact non-covalent protein complexes (for 
technical details see material and methods). We used this technique to determine the 
native molecular mass of Hb overexpressed in Hb-mut cells. As controls, we included 
protein extracts prepared from Hb and control cells. In Hb cells and Hb-mut cells both 
anti-FLAG and anti-MYC antibodies detected a single band with an estimated mass 
of 64 kDa, based on its mobility relative to native molecular weight markers (Figure 
22D). As expected, no bands were observed in control cells. These data indicate that 
overexpressed Hb-mut folds as a tetramer that contains two α and two β chains. The 
same result was obtained when the lysates were stained with an anti-Hb antibody, 
thus confirming that anti-tag antibodies detected Hb-containing bands. 
In conclusion, all these data demonstrated that Hb-mut cells express mutant Hb, even 
if the expressing levels were lower in comparison with Hb cells. Moreover, despite 
the presence of histidine mutations, Hb-mut is present a α2β2 tetramer and localizes 
both in the cytoplasm and in the nucleus of the cells, as wild type Hb in Hb cells.  
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Hb protection/toxicity does not depend on oxygen binding 
We then decided to compare the mortality of Hb, Hb-mut and control cells upon PD-
mimicking stimuli. Undifferentiated and differentiated cells were treated with MPP+ 
or rotenone. We analyzed mortality through the expression of cleaved Caspase 3, as a 
marker of neuronal death. 
As shown in figure 23A, Hb-mut maintained the protective capacity. Furthermore, 
Hb-mut didn’t revert Hb toxicity in comparison to controls (figure 23B,C,D). This 
result suggests that oxygen binding is not required in the protective/toxic process. We 
have to note that there was a slightly higher expression of cleaved Caspase 3 in Hb 
cells than Hb-mut cells. We hypothesised that this is due to the fact that Hb-mut cells 
expressed lower protein levels. Further investigation must be done in order to confirm 
that Hb protection/toxicity does not depend on oxygen binding. 
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Figure 23. Hb protection/toxicity doesn’t depend on oxygen binding. 
Undifferentiated (A,C) and differentiated (B,D) Hb cells (Hb), Hb-mut cells (Hb-mut) and control cells 
(control) were treated for 16 hours with 0.1mM and 1mM MPP+ (A,B) or with 10µM and 100 µM 
rotenone (C,D). A,B,C,D. Western blot analysis of cleaved Caspase 3 expression. α and β globin were 
detected with anti-FLAG and anti-MYC antibodies respectively βactin was used as loading control. 
(n=3) 
 
 
Quaternary structure of Hb (α2β2) is not altered upon neurotoxic stimuli 
In the blood Hb presents α2β2 tetrameric structure. This structure is essential for Hb 
function. We recently demonstrated that in Hb cells, overexpressed Hb exists as an 
α2β2 tetramer (Russo et al., 2013). We thus analyzed the quaternary structure of 
overexpressed Hb in Hb cells upon PD-mimicking insults.  
As shown in figure 24, quaternary structure of Hb did not change neither upon MPP+ 
nor upon rotenone treatments. This result indicates that α2β2 tetramer of Hb is 
maintained upon toxic stimuli. 
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Figure 24. Quaternary structure of Hb upon toxic stimuli in Hb cells. 
A. Undifferentiated Hb cells were treated for 16 hours with 1mM MPP+. Immunoblot of native PAGE 
of cell lysates was carried out with anti-FLAG and anti-MYC antibodies. (n=3) B. Differentiated Hb 
cells were treated for 16 hours with 1mM MPP+. Immunoblot of native PAGE of cell lysates was 
carried out with anti-FLAG and anti-MYC antibodies. (n=3) C. Undifferentiated Hb cells were treated 
for 16 hours with 10 µM rotenone. Immunoblot of native PAGE of cell lysates was carried out with 
anti-FLAG and anti-MYC antibodies. (n=3) D. Differentiated Hb cells were treated for 16 hours with 
10 µM rotenone. Immunoblot of native PAGE of cell lysates was carried out with anti-FLAG and anti-
MYC antibodies. (n=3) 
 
 
Hb accumulates in the nucleus upon neurotoxic stimuli 
The cellular localization of proteins is important for their functions. Previous data 
(Biagioli et al., 2009) demonstrated that Hb is localized in the cytoplasm and in the 
nucleus of DA neurons in vivo. This was recapitulated in Hb cells where 
overexpressed Hb is present in both cell compartments. Therefore we decided to 
perform cellular fractionation experiments in order to study the cellular distribution of 
Hb upon PD-mimicking insults (for technical details see material and methods). First, 
we decided to focus our attention on differentiated cells, as in previous experiments. 
We analyzed Hb cells upon MPP+ and rotenone treatments. Cellular fractionation 
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experiments demonstrated that in untreated conditions α and β globins were present 
both in the cytoplasm and in the nucleus, confirming previous data (figure 25A,B).  
Upon MPP+ treatment, α globin (visualized with anti-FLAG antibody) and β globin 
(visualized with anti-MYC antibody) increased in the nucleus, as confirmed by 34 
kDa band. Furthermore, in these conditions, α globin also showed a 17 kDa band, 
that, upon treatments, decreased in the cytoplasm and increased in the nucleus. 
Interestingly upon toxic stimuli a band of about 20 kDa appeared in the nucleus. This 
band was probably due to a post-translational modification and this modification may 
be associated with the toxic role of Hb in these conditions. 
In order to confirm cellular fractionation data, we carried out immunofluorescence 
experiments with identical experimental settings. As shown in figure 25C,D, 
untreated Hb cells presented α and β globins both in the cytoplasm and in the nucleus, 
confirming previous data. 
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Figure 25. Hb accumulates in the nucleus upon toxic stimuli in differentiated Hb cells. 
Differentiated Hb cells were treated for 16 hours with 0.1mM MPP+ (A,C) or with 10µM rotenone 
(B,D). A,B. Immunoblot of cellular fractionation was carried out with anti-FLAG (that recognized 
specifically α globin) and anti-MYC (that recognized specifically β globin) antibodies. Anti-TH and 
anti-UBF antibodies were used to visualize specifically cytoplasm and nucleus comportment 
respectively. βactin was used as loading control. (n=4) C,D. Representative images of double 
immunofluorescence performed with anti-FLAG (green) and anti-MYC (red) antibodies. Nuclei are 
marked by DAPI. Scale bar 10 µm. (n=3) 
 
Upon toxic stimuli α and β globins increased in the nucleus compartment, confirming 
cellular fractionation experiments. In conclusion, in differentiated Hb cells 
overexpressed Hb accumulates in the nucleus of cells upon exposure with MPP+ and 
rotenone. 
In order to exclude artefacts derivate from immonoblot analysis, we decided to 
performed cellular fractionation experiments. As shown in figure 26, anti-FLAG 
antibody revealed bands at different weights such as 17 kDa, 20 kDa and 34 kDa in 
Hb cells and not in control cells, demonstrating that these bands were specific. Anti-
MYC antibody recognized a single band at 34 kDa in Hb cells, proving the specificity 
of bands. 
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Figure 26. Exclusion of artefacts derivate from immoblot analysis. 
Differentiated Hb cells (Hb) and control cells (control) were treated for 16 hours with 10µM Rotenone. 
A. Immunoblot of cellular fractionation was carried out with anti-FLAG antibody that recognized 
specifically α globin. B. Immunoblot of cellular fractionation was carried out with anti-MYC antibody 
that recognized specifically β globin. 
 
 
Accumulation in the nucleus is associated to a toxic effect of overexpressed Hb 
Increased nuclear Hb may be associated to Hb toxicity upon neurotoxic stimuli. In 
order to confirm this hypothesis we performed cellular fractionation experiments in 
undifferentiated Hb cells, as described previously. In particular, we compared Hb 
cellular localization upon rotenone, where we demonstrated that Hb overexpression 
was toxic, and upon MPP+, where we demonstrated that Hb overexpression was 
protective. In undifferentiated Hb cells, α globin accumulated in the nuclear 
compartment upon rotenone (figure 27A). On the other hand, α globin did not 
increase in the nucleus upon MPP+ (figure 27B). These results suggest that increased 
nuclear Hb is associated to its toxic effects upon PD-mimicking drugs. 
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Figure 27. In undifferentiated Hb cells Hb accumulates in the nucleus upon rotenone and not upon 
MPP+. 
Undifferentiated Hb cells were treated for 16 hours with 10µM rotenone (A) or with 0.1mM MPP+ (B). 
A,B. Immunoblot of cellular fractionation was carried out with anti-FLAG (that recognized specifically 
α globin) antibody. Anti-TH and anti-UBF antibodies were used to visualize specifically cytoplasm and 
nucleus comportment respectively. βactin was used as loading control. (n=4) 
 
 
Accumulation of mutant Hb in the nucleus upon neurotoxic treatments 
In order to confirm that protection/toxicity of Hb upon neurotoxic stimuli is not 
oxygen dependent, we decided to analyze cellular compartment distribution of Hb-
mut upon PD-mimicking drugs. As shown in figure 28B,C,D, α globin accumulated in 
the nucleus of cells upon neurotoxin stimuli. These data confirmed our previous 
observation that Hb toxicity was not due to oxygen binding. Furthermore, we didn’t 
observe such accumulation in undifferentiated cells treated with MPP+ (figure 28A). 
In conclusion Hb protective/toxic mechanisms do not require oxygen binding. 
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Figure 28. Cellular compartment distribution of Hb-mut upon MPP+ and rotenone treatments in 
undifferentiated and differentiated Hb-mut cells. 
Undifferentiated (A,C) and differentiated (B,D) Hb-mut cells were treated for 16 hours with MPP+ 
(A,B) or with 10µM rotenone (C,D). A,B,C,D. Immunoblot of cellular fractionation was carried out 
with anti-FLAG (that recognized specifically α globin) antibody. Anti-TH and anti-UBF antibodies 
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were used to visualize specifically cytoplasm and nucleus comportment respectively. βactin was used 
as loading control. (n=3) 
 
 
Overexpression of Hb is associated with an impairment of autophagy upon 
neurotoxic stimuli 
Autophagy is a process responsible for the degradation of intracellular material. 
Recent reports indicate that autophagy plays a crucial role in many different 
neuropathologies, such as HD, AD and PD (Nixon, 2013). If cells cannot activate 
autophagy, protein synthesis predominates over protein degradation. Activation of 
autophagy could also be an effective way of eliminating altered agents that are present 
in the cytosol. Furthermore, in the laboratory of professor Gustincich microarray data 
indicated that in a thalassemic mouse model, in which β globin gene was deleted in 
heterozigosity, Atg4 gene, a major regulator of autophagy, was differentially 
expressed (Marcuzzi et al., unpublished data).  
 
Figure 29. Overexpression of Hb is associated with an impairment of autophagy upon neurotoxic 
stimuli in differentiated cells. 
Differentiated Hb cells (Hb) and control cells (control) were treated with MPP+ (A) and rotenone (B) 
for 16 hours. A,B. Western blot analysis of cell lysates. Immunoblot was carried out with anti-LC3. 
βactin was used as loading control. (n=6) 
 
Therefore, we decided to study the autophagy pathway in our cells’ system. In 
particular, we analyzed differentiated Hb and control cells upon MPP+ and rotenone 
treatments. First, we studied the expression of LC3 by Western blot analysis. LC3 is 
one of the key molecular components involved in autophagy.	  To date, LC3 is the only 
reliable marker of autophagosomes. Tracking LC3II expression is indicative of 
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autophagic activity. As shown in figure 29, in control cells it was observed an evident 
increased expression of LC3II upon both toxic stimuli, indicating an activation of 
autophagy; whereas in Hb cells we didn’t observe such increase. Our results suggest 
that Hb overexpression impairs autophagy induction upon PD-mimicking treatments. 
We then stained cells with Lysotracker RED, which permits to label acidic organelles 
in live cells, such autophagosome. 
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Figure 30. Overexpression of Hb is associated with an impairment of autophagy upon neurotoxic 
stimuli in differentiated cells . 
Differentiated Hb cells (Hb) and control cells (control) were treated with MPP+ and rotenone for 16 
hours. A,C. Lysotracker Red staining. Nuclei are marked by DAPI. Scale bar 10 µm. B,D. 
Quantification of autophasome. Autophagy activity was defined as follows: high: >10 Lysotracker 
RED foci/cell; medium: 6–10 Lysotracker RED foci/cell; low: <6 Lysotracker RED foci/cell. 
Lysotracker RED-positive foci in 100 randomly chosen cells were counted for quantification. Value are 
mean ± SD. Data were evaluated statistically by Student’s t-test. Statistical analysis is indicated as: * = 
p value ≤ 0.05, * *= p value ≤ 0.01, *** = p value ≤ 0.001. 
 
As shown in figure 30, quantification analysis of the number of Lysotracker RED-
positive foci per cell demonstrated a prominent rise of autophagosome density in 
control cells in comparison to Hb cells upon Rotenone treatment. Even if the trend 
was maintained there was no statistical difference in Hb and control cells upon MPP+. 
These results suggest that Hb overexpression impairs autophagy upon PD-mimicking 
insults. Further investigation must be done in order to assess if autophagy impairment 
is linked to Hb-mediated toxicity. 
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Cloning and generation of AAV9-2xFLAG-α globin and AAV9- β globin-MYC 
AAVs are commonly used to study the function of a protein in an in vivo model. To 
this purpose we decided to produce AAVs that encode for 2xFLAG-α globin and β 
globin-MYC to assess the role of Hb in a mouse model. Furthermore, we decided to 
use AAVs serotype 9 for its high affinity for neuronal cells (Zincarelli et al., 2008). In 
particular, we wanted to overexpress Hb in DA neurons of SNpc in the mouse brain to 
better understand what is the physiological role of Hb in DA neurons in vivo and what 
happens upon PD-mimicking stress conditions as well as MPTP treatment. 
Starting from pcDNA3-2xFLAG-α globin and pcDNA3.1--β globin-MYC we 
subcloned each coding sequences in pAAV-MCS vector (for technical details see 
material and methods). We tested the expression of the obtained constructs (pAAV-
2xFLAG-α globin and pAAV-β globin-MYC) by Western blot. We transiently 
transfected HEK 293T cells with pAAV-2xFLAG-α globin and pAAV-MCS, as 
control, and 48 hours later lysates were prepared. As show in figure 31A, pcDNA3-
2xFLAG-α globin correctly encoded for tagged α globin detected by anti-FLAG and 
anti-Hb antibodies. At the same time we carried out the same experiment to test 
pAAV-β globin-MYC. As shown in figure 31B, pAAV-β globin-MYC expressed 
tagged β globin detected by anti-MYC and anti-Hb antibodies. We observed that α 
and β globin presented a molecular weight of 17 kDa, as expected from a denaturated 
SDS-PAGE. We then proceeded with the generation of AAV9s, that we called 
AAV9-2xFLAG-α globin, AAV9-β globin-MYC and AAV9-control (for technical 
details see material and methods). 
 
Figure 31. Expression of pAAV-2xFLAG-α globin and pAAV-β globin-MYC in HEK 293T cells. 
A. HEK 293T cells were transfected with pAAV or pAAV-2xFLAG-α globin contructs. Western blot 
analysis was carried out using anti-FLAG and anti-Hb antibodies. βactin was used as loading control. 
B. HEK 293T cells were transfected with pAAV or pAAV- β globin-MYC contructs. Western blot 
analysis was carried out using anti-MYC and anti-Hb antibodies. βactin was used as loading control. 
 
Once obtained the AAV9-control, AAV9-2xFLAG-α globin and AAV9-β globin-
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MYC from the laboratory of professor Mauro Giacca at ICGEB in Trieste, we 
decided to test the expression of the AAV9s in vitro before performing in vivo 
experiments (see materials and methods for technical approach). In details, cells were 
detached, counted and plated. After 24 hours doxycycline were added to the colture 
medium to induce differentiation. After 96 hours cells were treated with 
Neuroaminidase and infected with AAV9-2xFLAG-α globin, AAV9-β globin-MYC 
or AAV9-control with a MOI of 108. 3 days after infection cells were recovered, cell 
lysates prepared and Western blot analysis performed. We used iMN9D cells 
transfected with pAAV-2xFLAG-α globin or pAAV-β globin-MYC as positive 
control and cells infected with AAV9-control as negative control. As shown in figure 
32, iMN9D cells were correctly infected by AAV9-2xFLAG-α globin or by AAV9-β 
globin-MYC and presented a clear band, as expected.  
 
Figure 32. Infection of iMN9D cells with AAV9-2xFLAG-α globin and AAV9-β globin-MYC. 
A. iMN9D cells were infected with AAV9-2xFLAG-α globin or AAV9-control. Western blot analysis 
was carried out using anti-FLAG antibody. iMN9D cells transfected with pcDNA3-2xFLAG-α globin 
were used as positive control. βactin was used as loading control. B. iMN9D cells were infected with 
AAV9-β globin-MYC or AAV9-control. Western blot analysis was carried out using anti-MYC 
antibody. iMN9D cells transfected with pcDNA3.1--β globin-MYC were used as positive control. 
βactin was used as loading control. 
 
 
Settings of stereotactic surgery 
Stereotactic surgery is a form of surgical intervention, which makes use of a three-
dimensional coordinates system to locate small targets inside the brain and to perform 
on them some actions as injection of viruses. We decided to use this technique in 
order to precisely infect DA neurons of SNpc of mouse brain (figure 33). 
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Figure 33. Schematic representation of stereotactic surgery. 
Red spot indicates the site of AAV9s injection, that corresponded to Substantia Nigra pars compacta 
(SNpc). This brain side is called ipsilateral side. The non-injected side is called controlateral side. 
 
 
Figure 34. Infection of SNpc of mouse brain with AAV9-GFP. 
A. Images of coronal sections of mouse brain. Substantia nigra was stained with anti-TH antibody 
(red). Infected cells were stained with anti-GFP antibody (green). Nuclei were visualized with DAPI. 
Scale bar 800 µm. B. Immunohistochemistry of coronal sections of mouse brain. SN was stained with 
anti-TH antibody (red). Infected cells were stained with anti-GFP antibody (green). Nuclei were 
visualized with DAPI. Scale bar 200 µm. Enlargement of ipsilateral side (scale bar 50 µm). C. Western 
blot analysis of dissected controlateral (contro) and ispilateral (ipsi) side of Substantia Nigra (SN) and 
of cortex (CTX). Immunoblot carried out with anti-GFP antibody. CTX was used as negative control. 
βactin was used as loading control. 
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We set up the stereotactic surgery using an AAV9-GFP, kindly provided by professor 
Mauro Giacca. Adult male C57Bl/6 mice were used for the study. Under anesthesia, 
the mice were injected stereotaxically with 2 µl of AAV9-GFP (3x1012 genome 
viral/ml) into the right SNpc (for technical details see material and methods). Animals 
were sacrificed after 3 weeks following AAV9-GFP infection. Brain tissue was 
processed for immunohistochemistry or for protein extraction using Trizol. As shown 
in figure 34B, we infected DA neurons of SNpc with AAV9-GFP. In particular, in the 
ipsilateral side about 50% of DA neurons were GFP positive. The controlateral side 
didn’t present any GFP positive cells. Moreover, Western blot analysis of dissected 
SN demonstrated the effective AAV9-GFP infection of SN ipsilateral (figure 34C). 
 
 
AAV9-mediated overexpression of α and β globin in SNpc 
We then tested the expression of AAV9-2xFLAG-α globin and of AAV9-β globin-
MYC in the SNpc of mouse brain. In details, 1µl AAV9-2xFLAG-α globin (2,2×1013 
viral genome particles/ml) and 1µl of AAV9-β globin-myc (2,2×1013 viral genome 
particles/ml) were injected together unilaterally into the right SNpc of C57Bl/6 mice. 
Three weeks after viruses injections, expression of 2xFLAG-α globin and β globin-
MYC was analyzed by histochemistry, biochemical and molecular analysis. In order 
to perform PCR and Western blot analysis we extracted protein and RNA using 
TRIzol from ipsilatreal and controlateral side of SN, CPu and CTX. 
First of all we studied mRNA expression of AAV9-2xFLAG-α globin and of AAV9-β 
globin-MYC by PCR. RNA extracted were retrotranscribed into cDNA. Oligos were 
specific for the coding sequence of tagged-globins. Figure 35A shows the expression 
of the transcripts in the ipsilateral SN. Furthermore, we noticed that SN controlateral 
and ipsilateral CPu express globin transcripts, while CTX did not. We hypothesized 
the presence of viral migration though brain neuronal connections. Furthermore, we 
performed PCR using oligos direct against TH transcript. 
Then, we analyzed protein extracted by Western blot (figure 35B). Immunoblot was 
carried out using an anti-FLAG antibody that discriminates α globin, an anti-MYC 
antibody that recognizes β globin and an anti-Hb antibody. SN ipsilateral expressed 
both α and β globins. Furthermore, controlateral SN and CTX didn’t express viral 
proteins. Moreover, Hb staining was evident in SN ipsilateral. In controlateral SN and 
CTX, a less intense band was also detected with anti-Hb antibody, as expected 
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because DA neurons and cortical astrocytes express endogenous Hb. 
 
Figure 35. Infection of SNpc of mouse brain with AAV9-2xFLAG-α globin and AAV9-β globin-MYC. 
A. PCR analysis of dissected controlateral and ispilateral side of Substantia Nigra (SN), striatum 
(CPu). Cortex (CTX) was used as negative control. Additional control were used: pcDNA3-2xFLAG-α 
globin and pcDNA3.1--β globin-MYC (control +) were used for the efficiently of PCR amplification; 
negative control of retrotranscription (control -) was included. B. Western blot analysis of dissected 
controlateral (contro) and ispilateral (ipsi) side of SN and CTX. Immunoblot carried out with anti-
FLAG, anti-MYC and anti-Hb antibodies. 
 
Then we studied the expression of the viruses by immunohistochemistry using 
antibodies direct against FLAG (specific for α globin) and MYC (specific for β 
globin). Figure 36A,B shows representative panels, demonstrating widespread 
expression of the virally transferred genes 2xFLAG-α globin and β globin-MYC in 
DA neurons of the injected side. The ratio of infection was about 40%. We observed 
that globins were present both in the cytoplasm and in the nucleus of the neuronal 
cells, demonstrating our previous results in iMN9D cells. Moreover, α and β globins 
colocalized in TH+ cells, proving the efficiency of coinfection (figure 36C).  
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Figure 36. Infection of SNpc of mouse brain with AAV9-2xFLAG-α globin and AAV9-β globin-MYC. 
A. Immunohistochemistry of coronal sections of mouse brain. SN was stained with anti-TH antibody 
(red). Infected cells were stained with anti-FLAG antibody (green). Nuclei were visualized with DAPI. 
Scale bar 200 µm. Enlargement of ipsilateral side (scale bar 50 µm). B. Images of coronal sections of 
mouse brain. SN was stained with anti-TH antibody (red). Infected cells were stained with anti-MYC 
antibody (green). Nuclei were visualized with DAPI. Scale bar 200 µm. Enlargement of ipsilateral side 
(scale bar 50 µm). C. Double immunohistochemistry performed with anti-FLAG (green) and anti-MYC 
(red) antibodies. Nuclei were visualized with DAPI. Scale bar 50 µm. 
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Finally, we analyzed Hb staining. As shown in figure 37, in ipsilateral side the 
fluorescent intensity of Hb-staining in TH+ cells was more evident in comparison to 
controlateral side, demonstrating that AAV9s infection took place correctly. 
 
Figure 37. Infection of SNpc of mouse brain with AAV9-2xFLAG-α globin and AAV9-β globin-MYC. 
A. Immunohistochemistry of coronal sections of mouse brain. SN was stained with anti-TH antibody 
(blue) and anti-Hb (red). Scale bar 50 µm. 
 
In conclusion, these results demonstrate that AAV9-2xFLAG-α globin and AAV9-β 
globin-myc are correctly expressed in DA neurons, even though the ratio of infection 
is about 40%. Moreover, we observe a partially migration of AAVs transcripts from 
ipsilateral side to controlateral side. 
 
 
AAV9-mediated overexpression of α and β globin does not increase MPTP-
induced DA neuron loss 
We decided to investigate the influence of Hb on MPTP-induced DA neuron loss in 
vivo. In details, male C57Bl/6 mice were injected with 1 µl of AAV9-2xFLAG-α 
globin (2,2×1013 viral genome particles/ml) and 1µl of AAV9-β globin-myc (2,2×1013 
viral genome particles/ml) together or 2 µl AAV9-control (2,2×1013 viral genome 
particles/ml) into SNpc of mouse brain. The contralateral SNpc remained uninjected. 
Three weeks after viruses injections, mice were divided into two subgroups, one 
treated with saline and the other with a subchronic regimen of MPTP. At 6 weeks 
after viruses delivery (9 days after the last MPTP injection) all mice were sacrificed. 
Brain tissue was processed for immunohistochemistry or for biochemical analysis. 
We first quantified DA neuron survival counting TH+ cells in SNpc, since the major 
effect of PD-mimicking drugs (MPTP) was the degeneration of DA neurons. First of 
all, we observed that the injection per se didn’t cause damage, since the number of 
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TH+ cells in ipsilateral and controlateral side of control-injected mice was equal 
(figure 38A,B). Moreover, MPTP-treated mice showed about 50% less DA neurons in 
both sides when compared to saline-treated mice. Hb infected-mice did not show 
statistical difference in comparison to control infected-mice both in saline and MPTP 
regime. In addition, we didn’t observe significance side effect in Hb-injected mice. 
However, there were more TH+ cells in Hb-injected side in comparison to non-
injected side in saline-treated mice, whereas there were less TH+ cells in Hb-injected 
side in comparison to non-injected side upon MPTP treatment. 
We then performed a densitometric analysis of TH+ fibres of striatum, since the 
striatum receives profuse DA innervation from the SN. In the striatum, MPTP 
injection led to a dramatic reduction in TH immunoreactivity (figure 38C,D). This 
reduction was not modified by overexpression of Hb. 
In conclusion, AAV9-mediated overexpression of α and β globin doesn’t alter MPTP-
induced DA neuron loss, even if there are some not statistical side-effects differences. 
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Figure 38. AAV9-mediated overexpression of α and β globin does not increase MPTP-induced DA 
neuron loss. 
A. Immunohistochemistry of coronal sections of mouse brain. SN was stained with anti-TH antibody 
(red). Scale bar 200 µm. B. Quantitative analysis of TH+ cells number. Values are expresses as number 
of TH+ cells/series relative to the controlateral side of control-injected mice treated with saline. Data 
are represented as mean±SEM (n= 8 mice/group). C. Immunohistochemistry of coronal sections of 
mouse brain. TH+ fibres in CPu were stained with anti-TH antibody (red). Scale bar 800 µm. D. 
Densitometric analysis of TH+ cells. Values are expresses as a percentage relative to the controlateral 
side of control-injected mice treated with saline (set arbitrary at 100%). Data are represented as 
mean±SEM (n= 8 mice/group). Data were evaluated statistically by ANOVA. Statistical analysis is 
indicated as: * = p value ≤ 0.05, * *= p value ≤ 0.01, *** = p value ≤ 0.001. 
 
In addition, we performed Western blot analysis to investigate changes in cleaved 
fragments of Caspase 3 in saline/MPTP-treated mice injected with AAV9-2xFLAG-α 
globin and AAV9-β globin-myc or AAV9-control. In saline-treated mice we didn’t 
reveal the expression of cleaved Caspase 3, as expected (figure 39A). In MPTP-
treated mice, Hb injected-mice manifest a trend, which exhibits an increase of cleaved 
Caspase 3 expression in comparison to control-injected mice. However no statistical 
difference was found (figure 39B,C). 
In conclusion, the overexpression of α and β globin does not change the susceptibly to 
neuronal loss caused by MPTP; even if we observed a trend, looking both at the 
number of TH+ cells and at the expression of cleaved Caspase 3. Further 
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investigations are needed to fully assess the issue. 
 
 
Figure 39. AAV9-mediated overexpression of α and β globin does not increase MPTP-induced 
cleavage of Caspase 3. 
A. Western blot analysis of cleaved Caspase 3 expression in saline-treated mice. βactin was used as 
loading control. (n=3 mice/group) B. Western blot analysis of cleaved Caspase 3 expression in MPTP-
treated mice. βactin was used as loading control. (n=3 control-injected mice and n=4 Hb-injected mice) 
C. Quantitative analysis of cleaved Caspase 3 expression. Values are expresses as a percentage relative 
to the controlateral side of control-injected mice treated with saline (set arbitrary at 100%). Data are 
represented as mean±SD. Data were evaluated statistically by Student’s t-test. Statistical analysis is 
indicated as: * = p value ≤ 0.05, * *= p value ≤ 0.01, *** = p value ≤ 0.001. 
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Discussion 
 
 
 
PD is a progressive worsening neurodegenerative disorder whose causes are still 
unknown. Its most evident neuropathological manifestation is the selective loss of 
neurons of SNpc. Despite the large amount of studies, the molecular aspects of the 
selective degeneration of A9 neurons in PD have not yet been elucidated. 
Therefore, in order to better understand the physiology of DA cells and the molecular 
differences or commonalities between A9 and A10 neurons, a detailed transcriptome 
analysis on RNA extracted from these cells was performed in the laboratory of Prof. 
Gustincich. By taking advantage of gene expression analysis, it has been found that 
transcripts of α and β chains of Hb were expressed in mDA neurons in the mouse 
brain. Moreover, Hb immunoreactivity decorated the majority of A9 cells, whereas 
only 5% of A10 neurons are Hb positive (Biagioli et al., 2009). 
Hb is a well-known blood-associated protein. The main function of Hb is the transport 
of oxygen throughout the body recovering the consequent carbon dioxide. The 
concept that globins have a functional role only as oxygen transporters was 
challenged in recent studies in which, in addition to blood cells, expression of Hb was 
observed in other districts. In particular, Hb was found in macrophages (Liu et al., 
1999), lung (Newton et al., 2006), kidney (Nishi et al., 2008), liver (Liu et al., 2011b), 
brain (Biagioli et al., 2009; Leffers et al., 2006; Richter et al., 2009) and tumours 
(Onda et al., 2005; Capulli et al., 2012; Li et al., 2013). Hb function in these tissues 
remains to be investigated. 
In this study, we have provided a model in which Hb expression may contribute to A9 
specific vulnerability in PD pathogenesis. We took advantages of dopaminergic 
neuroblastoma cell lines stably transfected with α and β chains of hemoglobin 
(Biagioli et al., 2009) and their differentiated cultures to evaluate the mechanism(s) 
involved in PD-mimicking insults, like MPP+ and rotenone. We used iMN9D cells 
because represents a well-accepted in vitro model to study dopaminergic cell 
physiology and dysfunction (Choi et al., 1991, 1999). 
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First, here we demonstrated that the impact of Hb overexpression depends on 
differentiation state of iMN9D cells upon MPP+ treatment (Langston et al., 1983). In 
particular, we observed that upon stimulus in undifferentiated iMN9D cells the 
presence of Hb is protective, whereas is toxic in differentiated cultures. Moreover, we 
showed that hemoglobin behaviour changes 48 hours after differentiation induction. 
We hypothesize that Hb overexpression influences gene expression profile 
conditioning the healthy state of iMN9D cells. This is extremely important because it 
allows us to understand what are the specific prosurvival mechanisms. 
Furthermore, we analyzed the involvement of Hb in PD using another PD-mimicking 
drug that is rotenone. Rotenone, together with MPP+, is one of the common drugs 
used to induce neuronal cell death (Panov et al., 2005; Sherer et al., 2003). In details, 
we observed that Hb overexpression increases susceptibility to cell death in both 
undifferentiated and differentiated DA cells. Together with previous data, this is 
strong evidence that the presence of Hb in DA cells is detrimental upon typical PD-
stimuli. This may be a suggestive mechanism to explain why only A9 neurons 
degenerate in PD. 
Furthermore, we observed a caspase3-dependent cell death in every conditions we 
tested (Giordano et al., 2012), suggesting a common cell death mechanism in iMN9D 
cells. 
Moreover, in undifferentiated iMN9D cells Hb overexpression triggers diverse cell 
fate depending on the type of treatment. As mentioned before, Hb overexpression-
induced cell death takes place only in the presence of rotenone and not of MPP+. Both 
drugs are known to inhibit complex I of the mitochondrial electron transport chain 
concomitant with a decrease of ATP reserve (Panov et al., 2005; Choi et al., 2011). 
However, there are conflicting studies regarding ROS generation (Lotharius and 
O’Malley, 2000; Li et al., 2005). Rotenone induced significant cell death, whereas 
MPP+ exhibited a different behaviour with less pronounced effects. Interestingly, it is 
well known that MPP+, unlike rotenone, stimulates bioenergetics reserve capacity 
(Giordano et al., 2012). It remains to clarify the precise mechanism of toxicity and the 
main difference of action of the two drugs. Our in vitro model could provide a system 
to study differences between these PD-mimicking drugs. 
The main function of hemoglobin is the transport of oxygen. We generated mutant 
hemoglobin that theoretically does not bind oxygen. In particular the replacement of 
the highly conserved proximal histidine F8 residue by a glycine should result in a low 
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affinity for the heme group and a loss of the allosteric properties (Barrick et al., 
1997). In these conditions, we observed that Hb protection/toxicity doesn’t depend on 
oxygen binding. In details, mutant Hb doesn’t revert the characteristic phenotype of 
Hb, which we previously described. These results confirm the idea that Hb doesn’t 
have a functional role exclusively as oxygen transporter or storage. 
Hb acts as α2β2 structure. Our results demonstrated that the quaternary structure of Hb 
is not altered upon neurotoxic stimuli. This result indicates that α2β2 tetramer of Hb is 
maintained upon toxic stimuli, probably indicating that Hb-mediated protection or 
toxicity is managed by its structure. 
The localization of a protein is an indicator of its potential function. Hb is present in 
cytoplasmic and nuclear compartments both in vitro models and in vivo. Furthermore, 
Hb-induced toxicity is concomitant with an increase in the nucleus of globin chains. 
The nucleus is the place where gene expression regulation takes place. In addition we 
observe a hypothetical post-translational modification of α globin upon stimuli. It’s 
well known that some post-translational modifications, such as glycosylation, 
monoubiquitination and SUMOylation, are signal for the nuclear transport of 
cytosolic proteins (Guinez et al., 2005; Trotman et al., 2007; Truong et al., 2012). In 
literature there are a lot of examples of modifications that occurs in Hb, like 
glycosylation (Bunn, 1984; Woodi et al., 2009). We thus speculate that upon PD-
mimicking insults Hb is modified, moves to the nucleus and there acts as transcription 
factor or cofactor in order to regulate gene expression positively or negatively. 
Further investigation must be done in order to confirm this hypothesis.  
Recently, many works have come out demonstrating the relationship between PD and 
autophagy. In details, dysregulation of the autophagy pathway has been observed in 
the brains of PD patients and in animal models of PD, indicating the emerging role of 
autophagy in this disease (Lynch-Day et al., 2012). Indeed, autophagy is increasingly 
implicated in a number of pathophysiologies, including various neurodegenerative 
diseases such as AD, HD and ALS (Nixon, 2013). Furthermore, it has been 
demonstrated that rapamycin (a drug that is an autophagy enhancer) protects against 
cell death caused by MPTP and rotenone (Pan et al., 2009; Liu et al., 2011). In our 
study we show that Hb overexpression is associated with autophagy impairment upon 
PD-like stimuli. For the time being we couldn’t assess if autophagy impairment is 
linked to Hb-mediated toxicity. However we analyzed potential interactors of Hb by 
Ingenuity Systems, which is a software that analyze complex biological systems. One 
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of these interactors may be GATE-16. GATE-16 together with LC3 and GABARAP 
belong to mammalian Atg8-related proteins. The role of this family remains to be 
fully elucidated. However LC3, GABARAP and GATE-16 are indispensable for the 
autophagic process. Briefly, LC3 is involved in elongation of the autophagic 
membrane whereas GABARAP/GATE-16 are essential for a later stage in 
autophagosome maturation (Weidberg et al., 2010). Therefore we can hypothesis that 
Hb sequesters GATE-16, through binding, causing an alter autophagosome biogenis. 
Finally, we studied the overexpression of Hb in an in vivo mouse model of PD. 
Preliminary data demonstrated that upon stimulus Hb overexpression doesn’t 
influence significantly DA cell death, even if there is a trend. This phenotype could be 
due to a low expression of AAV9-overexpressing Hb in A9 cells. Moreover, AAV9-
overexpressing Hb infects A9 neurons and, to a less extent, closer cells, such as 
astrocytes and oligodentrocytes. Indeed these type of cells present endogenues Hb 
(Biagioli et al., 2009) and the presence of exogenous Hb may interfere with the 
surrounding environment influencing the survival of DA neurons. Further 
investigations must be done. 
Our findings support a model in which Hb expression may contribute to A9 specific 
vulnerability in PD pathogenesis. It will thus be extremely interesting to asses the 
relationship between Hb levels in vivo and PD susceptibility in positioning Hb as an 
unexpected new therapeutic target. 
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TRAF6 promotes atypical ubiquitination of mutant
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Parkinson’s disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in
the Substantia Nigra and the formation of ubiquitin- and alpha-synuclein (aSYN)-positive cytoplasmic
inclusions called Lewy bodies (LBs). Although most PD cases are sporadic, families with genetic mutations
have been found. Mutations in PARK7/DJ-1 have been associated with autosomal recessive early-onset PD,
while missense mutations or duplications of aSYN (PARK1, PARK4) have been linked to dominant forms of
the disease. In this study, we identify the E3 ubiquitin ligase tumor necrosis factor-receptor associated factor
6 (TRAF6) as a common player in genetic and sporadic cases. TRAF6 binds misfolded mutant DJ-1 and aSYN.
Both proteins are substrates of TRAF6 ligase activity in vivo. Interestingly, rather than conventional K63
assembly, TRAF6 promotes atypical ubiquitin linkage formation to both PD targets that share K6-, K27-
and K29- mediated ubiquitination. Importantly, TRAF6 stimulates the accumulation of insoluble and polyubi-
quitinated mutant DJ-1 into cytoplasmic aggregates. In human post-mortem brains of PD patients, TRAF6
protein colocalizes with aSYN in LBs. These results reveal a novel role for TRAF6 and for atypical ubiquitina-
tion in PD pathogenesis.
INTRODUCTION
Parkinson’s disease (PD) is one of the most common neurode-
generative disorders. It is characterized by loss of dopamin-
ergic (DA) neurons in the Substantia Nigra (SN) and the
presence of cytoplasmic inclusions called Lewy bodies
(LBs) (1). Most PD cases are sporadic, but a minority of
forms is associated to familial transmission. Among them,
PARK7/DJ-1 has been linked to autosomal recessive PD,
whereas PARK1/PARK4/alpha-synuclein (aSYN) is found in
dominant forms. aSYN is a major component of LBs providing
a molecular link between sporadic and genetic cases. The
accumulation of misfolded proteins into cellular aggregates is
a prominent feature common to most neurodegenerative
diseases. These insoluble proteinaceous deposits contain ubiqui-
tin and components of the ubiquitin–proteasome system, includ-
ing those encoded by genes mutated in familiar cases, like the
ubiquitin ligase parkin/PARK2 and ubiquitin C-terminal
hydrolase-L1 (UCH-L1/PARK5) (2–5). These data suggest
that cellular handling of misfolded and aggregation-prone
proteins play a central role in PD pathogenesis.
Substrate ubiquitination is a signal for diverse cellular func-
tions. Polyubiquitin chains can be formed through covalent
conjugation using any of the seven lysines present in the ubi-
quitin moiety. Ubiquitination through K48 generally targets
proteins for degradation, whereas K63 linkage plays a role
in signaling and protein trafficking (6). Recent data indicate
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that degradative and nondegradative functions of protein ubi-
quitination can be also associated with atypical chain for-
mation. All lysine residues, with the exception of K63,
accumulate in response to proteasome inhibition (7). K11
has been implicated in endoplasmic reticulum-associated
degradation (7), while K27 and K29 appear to be connected
to lysosomal localization and degradation (8,9). K6, K27,
K29 and K33 have also been proven to have nondegradative
functions on selected substrates (10–12).
We previously showed that tumor necrosis factor-receptor
associated factor 6 (TRAF6)-binding protein TRAF- and
TNF-receptor associated protein (TTRAP) (13) is a novel inter-
actor of DJ-1 able to bind the PD-associated mutant L166P
more strongly than wild type (wt) (14). TRAF6 is an E3 ubiqui-
tin ligase that promotes K63-specific chain assembly in the
signal transduction pathway that ultimately leads to nuclear
factor-kB (NFkB) activation (15). Although in the immune
system it has an essential role in tumor necrosis factor and
interleukin-1/Toll-like receptors signaling, in the brain,
TRAF6 activity has been associated with the transduction
cascade of the neurotrophin receptors p75 and TrkA (16–18).
So far, the only evidence that supports a role for TRAF6 in neu-
rodegeneration has been limited to its colocalization with tau in
brains of Alzheimer’s disease (AD) patients (19).
In the current study, we provide evidence that TRAF6 inter-
acts with and ubiquitinates mutant DJ-1 and aSYN. Unexpect-
edly, TRAF6 promotes an atypical mode of polyubiquitin
chain formation onto its PD-associated target proteins that
share K6, K27 and K29 ubiquitination. We also show that
TRAF6-mediated ubiquitination stimulates the accumulation
of mutant DJ-1 into insoluble aggregates. In post-mortem
brains of sporadic PD patients, TRAF6 is present in LBs.
Altogether, our data imply a novel role for TRAF6 in med-
iating atypical ubiquitination of proteins relevant for sporadic
and familial PD.
RESULTS
TRAF6 binds to and ubiquitinates misfolded mutant DJ-1
We have previously shown that TTRAP is a potent interactor
of PD-associated mutant DJ-1, with misfolded L166P being
the stronger partner (14). Since TTRAP was originally ident-
ified as a TRAF-interacting protein with highest selectivity
for TRAF6 (13), we analyzed whether TRAF6 itself could
associate with DJ-1.
We performed coimmunoprecipitation experiments using
HEK cells transfected with HA–TRAF6 and FLAG–DJ-1
wt or PD-linked L166P mutant. Although protein levels
were significantly lower than those of wt protein, misfolded
DJ-1 mutant could specifically associate with TRAF6 in
untreated conditions (Fig. 1A). Since proteasome inhibition
stabilizes L166P levels, we then analyzed the binding capabili-
ties of wt and mutant proteins in conditions of proteasome
block. Coimmunoprecipitation in cells treated with MG132
revealed an enhanced binding of TRAF6 to L166P and con-
firmed not detectable binding with wt DJ-1, proving that
TRAF6 is able to discriminate misfolded mutant DJ-1. Inter-
action data were confirmed by reverse immunoprecipitation
with HA–TRAF6 and FLAG–DJ-1 (Fig. 1B) as well as by
the use of different protein tags (Fig. 1C). To identify which
portion of TRAF6 binds to misfolded DJ-1, we expressed wt
and mutant form of TRAF6 lacking the N-terminal RING
domain in HEK cells and verified binding to L166P. Similar
to other TRAF6-binding proteins (16), the C-terminal TRAF
domain was sufficient to mediate its association with mutant
DJ-1 (Fig. 1D). Together, our data indicate that TRAF6
binds misfolded mutant DJ-1, but not wt protein.
Since TRAF6 is an E3 ubiquitin ligase, we investigated
whether mutant DJ-1 might be substrate of TRAF6 activity.
To test this hypothesis, we performed in vivo ubiquitination
assays. HEK cells were transfected with MYC–DJ-1 wt or
L166P with HA–ubiquitin in the presence or absence of
FLAG–TRAF6. Controls were included with HA–ubiquitin
alone or with FLAG–TRAF6 to avoid artifacts due to a
general increase in polyubiquitination. We found that, in the
absence of exogenous TRAF6, both wt and mutant DJ-1
could be ubiquitinated, even though at very low levels
(Fig. 2A). Overexpression of TRAF6 had no effect on the ubi-
quitination of wt DJ-1, but significantly enhanced ubiquitina-
tion of L166P, as expected from their interaction pattern.
Mutant DJ-1 was mainly observed in the polyubiquitinated
form. To provide further support on the role of TRAF6 in
mediating misfolded DJ-1 ubiquitination, we performed
in vivo ubiquitination assays with a form of TRAF6 lacking
the N-terminal ubiquitin ligase RING domain (DN) (Sup-
plementary Material, Fig. S1A). The effects on wt DJ-1
were used as internal control. We found that overexpression
of TRAF6–DN abolished L166P ubiquitination (Fig. 2B).
Therefore, E3 ligase activity of TRAF6 is required for
mutant DJ-1 polyubiquitination.
To examine the specificity of TRAF6-mediated effects on
L166P, we compared TRAF6 activity with that of TRAF2,
another E3 ligase that belongs to the TRAF family. MYC–
L166P was transfected with HA–ubiquitin and FLAG–
TRAF2 wt or DN mutant. FLAG–TRAF6 wt and DN were
included in the same experiment as internal reference. The
amount of polyubiquitinated L166P by TRAF2 was much
less than by TRAF6 (Fig. 2C). These results indicate that
the effects of TRAF6 are specific, but not exclusive.
TRAF6-mediated ubiquitination of L166P involves
atypical chain linkage
E3 ligases can promote the formation of polyubiquitin chains
on target substrates through any of the lysines present on ubi-
quitin molecules. TRAF6 activity has been widely associated
with chain formation mainly via K63-specific linkage. There-
fore, we investigated whether K63 or canonical K48 linkages
were used for mutant DJ-1 ubiquitination by TRAF6. We used
ubiquitin mutants in which either of these residues was substi-
tuted with an arginine (K48R and K63R). An ubiquitin mutant
with all lysines substituted with arginine was also included as
negative control (K0). HEK cells were thus transfected with
MYC–L166P with HA–wt or mutant ubiquitin in the pres-
ence of FLAG–TRAF6. As expected, a robust polyubiquitina-
tion of L166P with wt ubiquitin was promoted by TRAF6
overexpression, while it was abolished in the presence of K0
mutant. Strikingly, we found that TRAF6-mediated ubiquiti-
nation of L166P was maintained with K48R and K63R
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mutants (Fig. 3A). We then generated ubiquitin mutants with
only one lysine available for polymerization. Consistent with
the data obtained with K48R and K63R, neither K63 nor
K48 were used by TRAF6 for mutant DJ-1 ubiquitination.
Instead, TRAF6 promoted a robust polyubiquitination of
L166P in the presence of K27 and K29 mutants. Weaker but
reproducible ubiquitination was also induced with K6 and
K33 ubiquitins. Background signals were observed with K0
(Fig. 3B).
Altogether, our data indicate that TRAF6 promotes atypical
polyubiquitination of misfolded mutant DJ-1 by using K6,
K27, K29 and K33 as isotype linkages.
TRAF6 ubiquitination promotes the accumulation
of mutant DJ-1 into insoluble aggregates
One fundamental question was to determine whether TRAF6-
mediated atypical ubiquitination of L166P might trigger its
degradation. Human neuroblastoma SH–SY5Y cells stably
expressing FLAG–L166P were transfected with FLAG–
TRAF6 wt or DN, and the steady-state levels of misfolded
DJ-1 were followed by western blot. TRAF6 had no effect
on L166P protein levels, indicating that its activity has a non-
degradative role (Supplementary Material, Fig. S2A).
Similarly, pulse chase experiments with cyclohexamide
showed no evident effects of TRAF6 ubiquitination on
L166P stability (Supplementary Material, Fig. S2B). Since
nondegradative ubiquitination has been previously associated
with altered solubility of PD-associated aSYN and synphilin-1
(20,21), we next investigated whether TRAF6-mediated
ubiquitination of L166P might have an impact on its bio-
chemical status. MYC–L166P and HA–ubiquitin were
co-expressed in HEK cells in the presence or absence of
FLAG–TRAF6 wt or DN. Lysates were separated into
Triton X-100 soluble and insoluble fractions. We found that
nonubiquitinated forms of L166P were distributed in both
fractions and TRAF6 had no effect on total levels of soluble
mutant DJ-1. In contrast, polyubiquitinated misfolded DJ-1
Figure 1. TRAF6 interacts with mutant DJ-1. (A) HEK cells were transfected with HA-TRAF6 alone or with FLAG-DJ-1 wt (W) or L166P (L) and left untreated
or incubated with 5 mM MG132 for 16 h. Lysates were immunoprecipitated (IP) with anti-FLAG agarose beads and bound proteins were revealed by immunoblot
(IB) with anti-HA and anti-FLAG antibodies. Lysates were tested for the expression of TRAF6 and DJ-1 proteins. b-actin was used as loading control. (B) Cells
were transfected with FLAG–DJ-1 wt (W) or L166P (L) and HA–TRAF6 and treated with MG132. Lysates were subjected to coimmunoprecipitation with
anti-HA antibody. Immunoprecipitates and lysates were analyzed with anti-FLAG, anti-HA and beta-actin antibodies. (C) Coimmunoprecipitation
with FLAG–TRAF6 and MYC–DJ-1 constructs. Experiment was performed as in (A) with HEK cells treated with MG132. (D) Cells were transfected with
MYC–L166P alone or with full length (WT) or N-terminally deleted (DN) FLAG–TRAF6. Lysates were immunoprecipitated with anti-FLAG agarose
beads. Bound proteins and lysates were analyzed with anti-MYC and anti-FLAG antibodies.
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was present only in Triton-insoluble fraction (Fig. 4A). Con-
sistent with our in vivo ubiquitination data, we observed a
potent increase in the amount of ubiquitinated L166P only
when TRAF6 wt, but not DN, was overexpressed.
To assess whether the increased insolubility of L166P
induced by TRAF6 is associated with a propensity to form
protein aggregates, we monitored the effects of TRAF6
overexpression on L166P inclusion formation. We created
wt–TRAF6 and DN–TRAF6 fused to GFP (Supplementary
Material, Fig. S1B) and used these constructs with
FLAG–L166P and HA–ubiquitin. The formation of ubiquitin-
and L166P-positive aggregates was followed by double immu-
nofluorescence coupled with GFP autofluorescence. To detect
only insoluble inclusions, a permeabilization protocol was
performed (14). L166P showed a diffused pattern when
expressed alone or with ubiquitin (Fig. 4B). Addition of
ligase-competent TRAF6 generated larger insoluble L166P-
containing aggregates in .90% of the cells. These were posi-
tively stained for TRAF6 and ubiquitin. No aggregates were
observed when TRAF6 DN was used, proving that inclusion
Figure 2. Mutant DJ-1 is substrate of TRAF6 ubiquitin ligase activity. (A) For in vivo ubiquitination assay, HEK cells were transfected with HA–ubiquitin,
FLAG–TRAF6 and MYC–DJ-1 wt (W) or L166P (L) and treated with 10 mM MG132 for 3 h. Ubiquitinated DJ-1 was visualized with anti-HA antibody
after immunoprecipitation with anti-MYC. Immunoprecipitated DJ-1 was verified by anti-MYC immunoblot. Inputs were checked with anti-FLAG,
ant-MYC and anti-HA antibodies. (B) Cells were transfected with HA–ubiquitin and MYC–DJ-1 wt or L166P with WT or DN FLAG–TRAF6. Ubiquitination
assay was performed as in (A). (C) Ubiquitination experiment was done with HA–ubiquitin, MYC–L166P and FLAG–TRAF6 (wt and DN) or FLAG–TRAF2
(wt and DN). Immunoprecipitates and lysates were analyzed with anti-HA, anti-MYC and anti-FLAG antibodies.
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formation is a consequence of TRAF6 activity on mutant
DJ-1. As expected, wt DJ-1 staining was not altered by ubiqui-
tin or TRAF6 expression (Fig. 4B). To prove that TRAF6
action on L166P involved atypical ubiquitination, we carried
out analogous experiments with ubiquitin mutants that were
shown to be involved in L166P ubiquitination (K27 and
K29). As controls, K0 was used as well as K11 and K48
ubiquitins. These are mutants that mediate poly-chain for-
mation, but are not TRAF6 substrates. K27 and K29, but not
K0, K11 and K48, were able to recapitulate the phenotype
observed with wt ubiquitin, proving the specificity of TRAF6
activity (Fig. 4C). Experiments were also carried out with dif-
ferentially tagged mutant DJ-1 and all the remaining ubiquitin
mutants (Supplementary Material, Fig. S3). Together, these
Figure 3. TRAF6 mediates atypical ubiquitin chain formation on mutant DJ-1. (A) HA–ubiquitin constructs with either wt or mutated K48 (48R) and K63 (63R)
lysine residues were used for ubiquitination assay with MYC–L166P and FLAG–TRAF6. A polyubiquitination incompetent mutant (K0) was used as control.
Immunoprecipitates and lysates were analyzed with anti-FLAG, anti-MYC and anti-HA antibodies. (B) HA–ubiquitin mutants in which only the indicated lysine
residue is available for chain formation were used. Wt and K0 ubiquitin constructs were used as positive and negative controls. Ubiquitination assay was per-
formed as in (A).
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Figure 4. TRAF6 promotes the accumulation of ubiquitinated mutant DJ-1 in insoluble aggregates. (A) HEK cells were transfected with HA–ubiquitin, MYC–
L166P and FLAG–TRAF6 (wt or DN). After treatment with 10 mM MG132 for 3 h, Triton X-100 soluble and insoluble fractions were separated. Lysates were
analyzed with anti-MYC, anti-HA, anti-FLAG and anti-actin antibodies. (B) Cells were transfected with HA–ubiquitin wt, FLAG–L166P and GFP–TRAF6 (wt
or DN) and treated as in (A). Before fixation, cells were permeabilized with Triton X-100. Insoluble aggregates were analyzed by double immunofluorescence
coupled with GFP autofluorescence. (C) HA–ubiquitin wt or K0, K11 K27, K29 and K48 mutants were used with FLAG–L166P and GFP–TRAF6 wt to follow
insoluble aggregate formation. Double immunofluorescence coupled with GFP autofluorescence was performed as in (B) on permeabilized cells.
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data provide evidence that TRAF6-mediated atypical ubiquiti-
nation of DJ-1 L166P increases its propensity to accumulate
into insoluble aggregates.
TRAF6 binds to and ubiquitinates aSYN with atypical
linkage formation
It has been shown that the ubiquitin ligase seven in absentia
homolog (SIAH)-1 binds to and ubiquitinates aSYN and
aSYN-binding protein synphilin-1 (4). Structural studies
proved that members of the SIAH family possess a domain
highly similar to the TRAF-C region of TRAF proteins (22).
To study a potential role of TRAF6 in PD sporadic cases,
we analyzed the interplay between TRAF6 and aSYN. Coim-
munoprecipitation experiments were carried out using MYC–
aSYN and FLAG–TRAF6. Both wt and PD-associated A53T
mutant aSYN constructs were tested. aSYN was found to
specifically interact with TRAF6 (Fig. 5A). No preferential
binding toward the wt or mutant form of aSYN could be
observed, suggesting a potential role of TRAF6 in both spora-
dic and aSYN-linked genetic cases.
The interaction between TRAF6 and aSYN raised the possi-
bility that aSYN might be an additional PD-associated target
of TRAF6 ligase activity. We thus performed in vivo ubiquiti-
nation assay with HA–ubiquitin and MYC–aSYN wt or A53T
with or without FLAG–TRAF6 wt and DN. In this exper-
iment, the level of aSYN polyubiquitinated species was sig-
nificantly enhanced by TRAF6 overexpression (Fig. 5B). No
accumulation of ubiquitinated aSYN was observed when
TRAF6 DN was used. Both wt and A53T mutant were
targets of TRAF6.
We then evaluated whether TRAF6 activity on aSYN might
involve atypical ubiquitin chain formation (Fig. 5C). We thus
performed ubiquitination assay with all ubiquitin mutants.
TRAF6 supported aSYN ubiquitination mainly via K6, K27
and K29 chains. Importantly, these are shared motifs with mis-
folded mutant DJ-1.
TRAF6 is present in LBs and accumulates in PD brains
To gain further insights into the relevance of TRAF6 for PD
pathogenesis, we analyzed the presence of endogenous
TRAF6 in SN DA neurons in human post-mortem brains. As
shown in Fig. 6A, TRAF6 is expressed in the cytoplasm of
DA neurons, as identified by tyrosine hydroxylase (TH) stain-
ing. Some TRAF6 immunoreactivity was also found in
non-DA neurons, proving a quite broad distribution in mid-
brain cell populations.
Several E3 ligases, including Parkin, carbxyl terminus of
Hsc70-interaction protein (CHIP) and SIAH, have been
shown to be part of LBs in surviving DA neurons in PD
brains. Therefore, we examined human post-mortem brains
of pathologically confirmed cases of sporadic PD. Exper-
iments were performed on brain samples from two different
patients. LBs were identified using an aSYN antibody. Inter-
estingly, virtually all nigral LBs were immunoreactive for an
anti-TRAF6 antibody in both individuals (Fig. 6B and Sup-
plementary Material, Fig. S4). TRAF6 was expressed through-
out the cytoplasm, but the protein was clearly accumulated
at the border of LBs, a site where aSYN staining was more
prominent. The specificity of TRAF6 accumulation in LBs
was verified using three antibodies directed against N- or C-
terminal epitopes of the protein (Supplementary Material,
Fig. S4). No immunoreactivity was detected with unrelated
IgG (data not shown).
In response to an excess burden of misfolded proteins,
neurons tend to increase the expression of E3 ligases and
downregulate the level of deubiquitinating enzymes as pre-
viously shown in PD post-mortem brains for Parkin and
UCH-L1 (23–26). Therefore, we tested TRAF6 mRNA
levels in sporadic PD (n ¼ 6) and healthy control (n ¼ 3)
brains (27). RNA was extracted selectively from SN, the site
of PD pathogenesis. Quantitative real-time polymerase chain
reaction (qPCR) amplification showed that the amount of
TRAF6 mRNA was statistically increased in sporadic PD
samples when compared with normal controls (P , 0.02),
with an average 1.7-fold upregulation (Fig. 6C).
To strengthen the significance of the increased amount of
TRAF6 expression in PD, we also checked for the status of
regulators of TRAF6 activity. By qPCR analysis, we found
no significant differences in the expression of p62, CYLD
and A20 between PD and control samples (Supplementary
Material, Fig. S5). Overall, our results show that the ubiquitin
ligase TRAF6 is present in DA neurons in the midbrain of both
normal and PD brains. In sporadic patients, TRAF6 coloca-
lizes with aSYN within LBs and the amount of its mRNA
seems increased in SN.
DISCUSSION
The description of the molecular components of LBs and the
discovery of new players in the recruitment of these molecules
to aggregates are important for the understanding of the mol-
ecular mechanisms of PD and for the identification of new
drug targets. More than 76 proteins have been described so
far as localized in LBs (28–30) and the significance of their
relocalization may depend on protein identity.
Ubiquitin ligases are responsible for the formation of poly-
ubiquitin chains in substrate proteins and are frequently
associated with neurodegenerative diseases for their presence
in intracellular aggregates and their role in aggregate for-
mation. The E3 ligases Parkin, CHIP and SIAH have been
found to accumulate in LBs of PD patients (2,4,5). While
their enzymatic activities may be important for protein recruit-
ment into the aggregates, their sequestration may decrease the
quantity of soluble, active enzymes inducing a ‘loss of func-
tion’ phenotype for the lack of appropriate physiological ubi-
quitination of targets. Interestingly, they ubiquitinate
misfolded L166P DJ-1 and aSYN with degradative or nonde-
gradative effects on either of PD substrates (4,5,21,31).
Structural studies proved that members of the SIAH family
possess a domain highly similar to the TRAF-C region of
TRAF proteins (22). In this study, we demonstrate that the ubi-
quitin E3 ligase TRAF6 is a component of LBs. Virtually all
LBs in the post-mortem brains of two individuals were posi-
tive for TRAF6. Three different antibodies against both the
N- and C-terminals of the protein have been used.
TRAF6 ligase activity has been extensively characterized in
the context of NFkB activation (15). In the brain, TRAF6 has
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been previously linked to K63-specific polyubiquitination of
AD-associated protein tau (19) and in nerve growth factor-
receptor signaling (18). Most importantly, TRAF6 localizes
in tau-containing, intracellular aggregates in AD post-mortem
brains, suggesting that TRAF6 sequestration may be a
common mechanism in neurodegeneration (19).
In post-mortem brains of non-PD individuals, we show that
TRAF6 protein is expressed in DA cells of SN. In the mouse
brain, TRAF6 mRNA is present at comparable levels in DA
cells from SN and Ventral Tegmental Area, a site that is
spared in PD (32). This is consistent with the hypothesis that
TRAF6 expression per se is not related to cellular vulner-
ability.
TRAF6 interacts with mutant L166P DJ-1 and aSYN to
promote their ubiquitination via atypical ubiquitin chain for-
mation involving residues K6, K27, K29 and K33. Surpris-
ingly, none of the PD targets that we tested were modified
via TRAF6 canonical activity with K63 specificity. Noncon-
ventional ubiquitination of L166P is sufficient for its accumu-
lation into insoluble inclusions.
In a quantitative proteomic analysis of atypical ubiquitin
chains in yeast, substrates for K6, K27, K29 and K33 have
been shown to accumulate upon proteasome block, although
to a lower extent than for K48, suggesting their potential
role in protein degradation (7). Interestingly, these four ubiqui-
tin moieties showed some functional redundancy. Unfortu-
nately, the low cellular concentrations of their substrates
have limited so far their identification in yeast or in ex vivo
mammalian samples (7).
TRAF6 substrate L166P DJ-1 is very unstable and its
expression level, both in transfection studies and in patient
lymphoblasts, is lower than wt (33). This suggests that
L166P mutation may induce a loss of DJ-1 function.
However, L166P disrupts DJ-1 protein conformation resulting
Figure 5. TRAF6 binds aSYN and enhances its ubiquitination with atypical chains. (A) HEK cells were transfected with FLAG–TRAF6 and MYC–aSYN wt or
A53T (mut). Lysates were immunoprecipitated with anti-FLAG agarose beads and bound proteins were revealed with anti-MYC and anti-FLAG antibodies.
Inputs were tested for the expression of TRAF6 and aSYN proteins. (B) Cells were transfected with HA–ubiquitin, MYC–aSYN (wt or A53T) and FLAG–
TRAF6 (wt or DN). For in vivo ubiquitination assay, lysates were immunoprecipitated with anti-MYC antibody. Immunoprecipitates and lysates were analyzed
with anti-MYC, anti-FLAG and anti-HA antibodies. (C) HA–ubiquitin mutants in which only the indicated lysine residue is available for chain formation were
used. Wt and K0 ubiquitin were included as controls. In vivo ubiquitination of aSYN wt was performed as in (B).
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in a misfolded protein that is prone to assemble into multi-
meric structures (34–36). Indeed, by gel filtration and other
assays, L166P has been previously shown to be present
mostly as a high-molecular-weight complex that may
contain either DJ-1 oligomers and/or aggregates with other
proteins (31,33,36). According to this model, L166P may be
prone to aggregation in both healthy individuals heterozygous
for the mutation and in PD patients. Several hypotheses may
be formulated to account for these phenotypes. L166P may
be recruited to cytoplasmic aggregates by TRAF6 to avoid
toxicity in heterozygosity so that neurodegeneration occurs
only in the absence of a functional DJ-1. In this context, wt
DJ-1 may protect against cellular stress elicited by L166P.
In physiological conditions, aggresomes may then be cleared
in vivo by autophagy. The aggresome–autophagy pathway is
increasingly recognized as a specialized type of induced
autophagy that mediates selective clearance of misfolded
and aggregated proteins under the conditions of proteotoxic
stress (37,38). While TRAF6 has been recently involved in
autophagy in macrophages (39), the E3 ligase parkin seems
to be a key regulator of this pathway triggering L166P aggre-
gation in an HDAC6-dependent manner (31). One can specu-
late that atypical ubiquitination might function in the
recruitment to autophagic and/or storage vescicles as proved
for K27 ubiquitination of Jun and K29 of Deltex (8,9). It
must be noted that, to the best of our knowledge, no investi-
gation of DJ-1 L166P has been done in post-mortem brains
of PD patients carrying this mutation or in knock-in animal
models.
Components of LBs are candidate aSYN interactors.
Despite major efforts, the mechanisms of aSYN-induced neu-
rodegeneration in vivo remain unclear. Although some genes
have been isolated for their ability to suppress aSYN-mediated
toxicity in invertebrate models (40–42), there is still the need
to identify aSYN interactors that may regulate aSYN confor-
mation, subcellular localization and biochemical properties.
Figure 6. TRAF6 colocalizes with aSYN in LBs and accumulates in PD post-mortem brains. (A) Cryo-sections of post-mortem brain tissues were taken from
healthy individuals and endogenous TRAF6 was visualized by immunohistochemistry. DA neurons were identified with anti-TH antibody. (B) TRAF6 was ana-
lyzed by immunohistochemistry in SN of PD patients. LBs were visualized with anti-aSYN antibody. (C) Total RNA was extracted from SN of six PD and three
control brains. TRAF6 mRNA was measured by qPCR relative to b-actin. Significance between PD and control group was calculated with t-test.
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Both SIAH (4) and CHIP (5) bind to aSYN and regulate its
levels and aggregation properties (21,43,44). Here we identify
TRAF6 as a new aSYN modifier through unconventional ubi-
quitination.
LBs contain phosphorylated, ubiquitinated and nitrated
aSYN (45–47). The type of ubiquitin moieties covalently
attached to aSYN in PD and control brains remains unclear.
Interestingly, only 10% of aSYN is ubiquitinated with evi-
dences for conjugation of one, two or three ubiquitins (44).
Monoubiquitination by SIAH has been proposed to act as a
seed for further protein aggregation (48).
In our experimental settings, we failed to trigger aSYN
aggregates by TRAF6 overexpression. Its induction in cell cul-
tures depends on many factors including a permissive cellular
environment, expression of synphilin-1 (49) and a proteolytic
cleavage that releases an inhibitory domain at the C-terminal
(50). It will be interesting to assess whether TRAF6 may
trigger aggregation of aSYN in these conditions. It also
remains unclear the role of TRAF6-mediated atypical ubiqui-
tination in the degradation of aSYN via the lysosomal/autop-
hagy pathways (51).
Interestingly, TRAF6 expression seems increased in SN of
sporadic PD brains. These data need to be validated in a
larger sample size since the reproducibility of gene expression
analysis of human post-mortem brains may suffer from
sampling a heterogeneous tissue. If confirmed, this expression
may be part of a cellular response to an excess burden of
unfolded proteins, as shown for other E3 ubiquitin ligases.
However, TRAF6 may also ubiquitinate soluble aSYN in
the brain and thus be important for aSYN physiological func-
tion and not necessarily for its recruitment to LBs. In this
model, the increased expression of TRAF6 may be a response
to its sequestration to LBs to maintain the appropriate post-
translational modifications of its targets including aSYN.
Further experiments are needed to verify this hypothesis.
In conclusion, our data indicate a role for TRAF6 in PD for
its localization in LBs and handling of aggregation-prone mis-
folded proteins as atypical ubiquitin E3 ligase. These results
pose new exciting questions about the role of atypical ubiqui-
tination in cellular physiology and dysfunction.
MATERIALS AND METHODS
Further experimental details are provided as Supplementary
Material.
Immunoprecipitation and western blot
For coimmunoprecipitation experiments, cells were lysed in
TRAF6 (200 mM NaCl, 50 mM Tris, pH 7.5, 0.5% NP40,
10% glycerol) or aSYN (150 mM NaCl, 50 mM Tris, pH 7.5,
0.5% CHAPS) buffers supplemented with anti-protease cock-
tail (Roche) and 5 mM N-ethyl-maleimide (NEM). Cell lysates
were incubated with anti-FLAG agarose beads (Sigma) or with
the appropriate antibody. After washing, immunoprecipitated
proteins were eluted with 2× sodium dodecyl sulphate
(SDS) sample buffer, boiled and analyzed by western blot.
The following antibodies were used: anti-FLAG 1:2000
(Sigma), anti-MYC 1:4000 (Cell Signaling), anti-HA 1:1000
(from ibridoma supernatant, kindly provided by Dr. Licio
Collavin), anti-b-actin 1:5000 (Sigma). For detection, anti-
mouse-horseradish peroxidase (HRP) and anti-rabbit-HRP
(Dako) or protein A-HRP (Upstate) in combination with
enhanced chemiluminescence (ECL) (GE Healthcare) were
used.
In vivo ubiquitination assay
For in vivo ubiquitination assays, HEK cells were transfected
with HA–ubiquitin and the indicated DJ-1, aSYN, TRAF6 or
TRAF2 constructs. After transfection, cells were either left
untreated or incubated with 10 mM MG132 for 3 h. Cells
were then lysed with radioimmunoprecipitation assay (RIPA)
buffer (150 mM NaCl, 50 mM Tris, pH 7.5, 1% Triton X-100,
1% deoxycholic acid and 0.1% SDS) and samples were
briefly sonicated. After centrifugation, clear lysates were
immunoprecipitated with anti-MYC, anti-FLAG or anti-GFP
(Invitrogen) antibodies. Immunocomplexes were analyzed by
western blot using anti-HA antibody to detect ubiquitin conju-
gates. For development, protein A-HRP was used.
Cell fractionation
Transfected HEK cells were lysed in a buffer containing
150 mM NaCl, 50 mM Tris, pH 7.5, and 0.2% Triton X-100,
supplemented with protease inhibitor cocktail and 5 mM
NEM (Sigma). Lysates were centrifuged at 20 000 g for
30 min at 48C and separated into Triton X-100 soluble (super-
natant) and insoluble (pellet) fractions. Insoluble pellets were
resuspended in boiling sample buffer, sonicated and used for
western blot analysis.
Immunocytochemistry and immunohistofluorescence
To detect insoluble aggregates of mutant DJ-1, immunocyto-
chemistry was performed as previously described (14). After
permeabilization, cells were fixed in 4% paraformaldehyde
and indirect immunofluorescence was carried out following
standard methods. Anti-FLAG (1:1000) and anti-ubiquitin
(Dako) (1:50) antibodies were used. For detection, Alexa
Fluor-405-labeled (blu) or -594-labeled (red) (Invitrogen) anti-
mouse or anti-rabbit antibodies were used while GFP fluor-
escence was evidenced at 488 laser. Immunohistofluorescence
on human post-mortem brain sections was performed as
reported (52). Anti-TRAF6 antibodies were from Abnova
(PAB0279) and Santa Cruz (sc-8409 and sc-7221). Mouse
monoclonal (#2647) and rabbit polyclonal (#2628) anti-aSYN
antibodies were from Cell Signaling. All images were col-
lected using a confocal microscope (LEICA TCS SP2).
Post-mortem human brain samples
Brain samples are from the brain bank at the Institute of Neu-
ropathology, Bellvitge Hospital (University of Barcelona,
Spain). Samples were dissected at autopsy with the informed
consent of patients or their relatives and the institutional
approval of the Ethics Committee of the University of Barce-
lona. Brains were obtained from Caucasian, pathologically
confirmed PD cases and age-matched controls (27). Briefly,
10 Human Molecular Genetics, 2010
 at SISSA on August 3, 2010 
http://hm
g.oxfordjournals.org
D
ow
nloaded from
 
all cases of PD had suffered from classical PD, none of them
had cognitive impairment and their neuropathological charac-
terization was made according to the established criteria.
Control healthy subjects showed the absence of neurological
symptoms and of metabolic and vascular diseases, and the
neuropathological study disclosed no abnormalities, including
lack of AD and related pathology. The time between death and
tissue preparation was in the range of 3–5 h. The ventral mid-
brain region was sectioned horizontally. The dark-pigmented
zones of the SN were readily apparent from all surrounding
structures and were then isolated from the ventral midbrain.
SN autopsy tissues were immediately frozen for RNA extrac-
tion. For histological analysis, samples were cryoprotected
with 30% sucrose in 4% formaldehyde, frozen in dry ice
and stored at 2808C until use.
Quantitative real-time polymerase chain reaction
Total RNA from SN of six pathologically confirmed and three
control subjects (27) was isolated using the TRIZOL reagent
(Invitrogen). cDNA was obtained from 1 mg of purified
RNA using the iSCRIPTTM cDNA Synhesis Kit (Bio-Rad).
qPCR was performed using SYBR-Green PCR Master Mix
(Applied Biosystem). Expression of TRAF6, CYLD, A20
and p62/SQSTM1 was analyzed using specific oligonucleo-
tides.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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Huntington disease (HD) is a neurodegenerative disorder
caused by an expansion of polyglutamines in the first exon of
huntingtin (HTT), which confers aggregation-promoting prop-
erties to amino-terminal fragments of the protein (N-HTT).
Mutant N-HTT aggregates are enriched for ubiquitin and con-
tain ubiquitin E3 ligases, thus suggesting a role for ubiquitina-
tion in aggregate formation.Here,we report that tumornecrosis
factor receptor-associated factor 6 (TRAF6) binds to WT and
polyQ-expanded N-HTT in vitro as well as to endogenous full-
length proteins in mouse and human brain in vivo. Endogenous
TRAF6 is recruited to cellular inclusions formed by mutant
N-HTT. Transient overexpression of TRAF6 promotesWT and
mutant N-HTT atypical ubiquitination with Lys6, Lys27, and
Lys29 linkage formation. Both interaction and ubiquitination
seem to be independent from polyQ length. In cultured cells,
TRAF6 enhances mutant N-HTT aggregate formation, whereas
it has no effect on WT N-HTT protein localization. Mutant
N-HTT inclusions are enriched for ubiquitin staining onlywhen
TRAF6 and Lys6, Lys27, and Lys29 ubiquitin mutants are
expressed. Finally, we show that TRAF6 is up-regulated in post-
mortem brains from HD patients where it is found in the insol-
uble fraction. These results suggest that TRAF6 atypical ubiq-
uitination warrants investigation in HD pathogenesis.
Huntington disease (HD)2 is a dominantly inherited neu-
rodegenerative disorder caused by the expansion of a poly-
morphic CAG sequence in the first exon of the gene encod-
ing for huntingtin (HTT) protein (1). The onset of HD
symptoms, including motor dysfunction and cognitive
decline, occurs when the length of CAG exceeds 36 repeats
(2). CAG triplets are translated into a series of uninterrupted
glutamine residues (polyQ) at the N terminus of HTT, a
ubiquitously expressed protein of 350 kDa. HTT is found
both in the nucleus and in the cytoplasm where it associates
with a variety of organelles, including endoplasmic reticu-
lum, Golgi apparatus, and mitochondria (3–5). This wide-
spread subcellular localization, associated with the ability to
interact with a large number of proteins, implicates HTT in
diverse cellular activities ranging from transcription and
energy metabolism to vesicle trafficking (6).
The elongation of the polyQ sequence in HTT protein
induces HD pathogenesis largely through a gain-of-function
mechanism. One hallmark of HD is the presence of neuronal
aggregates that contain N-terminal fragments of polyQ HTT
(N-HTT). Aggregates or inclusions are found primarily in the
striatum and in the cortex of HD patients and are located
mainly in nuclear, perinuclear, and cytoplasmic regions of
affected neurons (7). Although it is still unclear whether inclu-
sions are protective or detrimental for cell viability, their for-
mation seems to be strikingly connected to the propensity of
polyQN-HTT tomisfold. In addition tomutant N-HTT, inclu-
sions are enriched for components of the protein quality con-
trol machinery, such as ubiquitin, proteasome subunits, and
chaperones (7, 8).
An extensive proteomic study has demonstrated that global
changes to the ubiquitin system are associated with HD pathol-
ogy (9). Although the E3 ligase Hdr1 and the ubiquitin-conju-
gating enzymes E2–25K interact and ubiquitinate bothWTand
mutant HTT (10, 11), parkin and CHIP (C terminus of Hsc70-
interacting protein) selectively act on the mutant protein (12,
13). All of these are localized in the aggregates of HD post-
mortem brains and are able to decrease aggregate formation in
vitro.
Ubiquitin contains seven lysine residues, and it is assumed
that all of these can be involved in the formation of polyubiqui-
tin chains on target proteins. Canonical Lys48- and Lys63-linked
polyubiquitination has been related respectively to proteasome
degradation of the substrate and to cell signaling or aggresome
formation (14). The role of nonconventional chains via Lys6,
Lys11, Lys27, Lys29, and Lys33 is much less clear (15). It has been
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shown that Lys6-specific modification can protect substrates
from proteolysis (16, 17) or regulate their enzymatic activity
(18). Similarly, nondegradative functions have been associated
with Lys27 and Lys29 chains, which have been shown to control
subcellular localization and activity of targeted proteins
(19–21).
Tumor necrosis factor receptor-associated factor 6 (TRAF6)
is an E3 ubiquitin ligase that promotes Lys63-specific chain
assembly in the signal transduction pathway that leads ulti-
mately toNFB activation (22). In the brain, TRAF6 activity has
been associated with the transduction cascade of the neurotro-
phin receptors p75 and TrkA (23, 24). Interestingly, TRAF6
localizes to Tau inclusions and Lewy bodies in brains of
Alzheimer disease and Parkinson disease (PD) patients, respec-
tively (25, 26), supporting the idea that E3 ligases tend to accu-
mulate at the site of protein inclusions. Furthermore, TRAF6
was found to promote atypical Lys6-, Lys27-, and Lys29-medi-
ated poly-ubiquitination of mutant DJ-1 and -synuclein, pro-
teins relevant for PD pathogenesis. Atypical ubiquitin ligase
activity of TRAF6 was shown to induce mutant DJ-1 aggrega-
tion (26).
In the current study, we provide evidence that TRAF6 inter-
acts with and ubiquitinatesWT andmutantHTT. In analogy to
PD targets, TRAF6 promotes an atypical mode of polyubiquitin
chain formation onto N-HTT proteins with selective choice of
Lys6, Lys27, and Lys29 linkages. We also show that both overex-
pressed and endogenous TRAF6 is recruited at the site of
mutant N-HTT aggregates. Furthermore, TRAF6-mediated
ubiquitination stimulates the formation of mutant N-HTT
inclusions. Only when atypical Lys6, Lys27, and Lys29 ubiquitins
are expressed,N-HTTaggregates are strongly positive for ubiq-
uitin. Finally, in post-mortem brains of HD patients, TRAF6
expression is induced, and the protein preferentially accumu-
lates in the insoluble fraction. Altogether, our data imply a
novel role for TRAF6 and atypical ubiquitination in HD
pathogenesis.
EXPERIMENTAL PROCEDURES
Plasmids and Cells—N-HTT-GFP Gln21 and Gln150 con-
structs were described previously (27). N-HTT-GFP Gln60
was a serendipitous construct obtained during Gln150 plas-
mid preparation. It was sequence-verified and controlled
during each preparation. FLAG-TRAF6 (WT and DN) and
HA-ubiquitin (WT and mutants) were described elsewhere
(26).
HEK 293 cells (Sigma) were maintained in culture in DMEM
(Invitrogen) with 10% FBS (Sigma). Transfections were per-
formed with the standard calcium phosphate method or with
Lipofectamine 2000 (Invitrogen), as required.
Immunoprecipitation and Western Blot—For co-immuno-
precipitation experiments, cells were lysed in TRAF6 buffer
(200 mM NaCl, 50 mM Tris, pH 7.5, 0.5% Nonidet P-40, 10%
glycerol) supplemented with anti-protease mixture (Roche
Applied Science) and 5 mM N-ethylmaleimide. Cell lysates
were incubated with anti-FLAG-agarose beads (Sigma) or
with anti-GFP antibody (Invitrogen). For co-immunopre-
cipitation of endogenous proteins anti-HTT mouse mono-
clonal (Chemicon, catalog nos. MAB 2166 and MAB 5490)
and rabbit polyclonal HP1 (27) antibodies were used. Cortex
was dissected from homozygous HdhQ111 knock-inmice (28)
or control littermates, snap-frozen on liquid nitrogen, and
stored at80 °C. Parietal cortex from HD patients was used
for co-immunoprecipitation of endogenous proteins in the
human brain sample. Lysates were prepared homogenizing
tissue in modified TRAF6 buffer (150 mM NaCl, 50 mM Tris,
pH 7.5, 0.5% Nonidet P-40, 10% glycerol) supplemented with
anti-protease mixture. Total protein content was measured,
and an equivalent amount was used for co-immunoprecipi-
tation. After washing, immunoprecipitated proteins were
eluted with 2 SDS sample buffer, boiled, and analyzed by
Western blot. The following antibodies were used: anti-
FLAG (1:2000; Sigma), anti-GFP (1:1000; Invitrogen),
anti-HA (1:1000; from hybridoma supernatant, kindly pro-
vided by Dr. Licio Collavin), anti-HTT (Chemicon, catalog
no.MAB 2166), anti-TRAF6 (Santa Cruz Biotechnology, cat-
alog no. sc-7221), and anti--actin (1:5000; Sigma). For
detection, anti-mouse-HRP and anti-rabbit-HRP (Dako) or
protein A-HRP (Upstate) in combination with ECL (GE
Healthcare) were used. For total protein extracts, cells were
lysed directly in 2 SDS sample buffer and analyzed by
Western blot.
Cell-based Ubiquitination Assay—For cell-based ubiquitina-
tion assays, HEK cells were transfected with HA-ubiquitin,
FLAG-TRAF6 (WTorDN), andN-HTT-GFP constructs. After
transfection, cells were lysed with radioimmune precipitation
assay buffer (150 mM NaCl, 50 mM Tris, pH 7.5, 1% Triton
X-100, 1% deoxycholic acid, 0.1% SDS), and samples were
briefly sonicated.After centrifugation, clear lysateswere immu-
noprecipitated with anti-GFP or anti-FLAG antibodies. Immu-
nocomplexes were analyzed by Western blot using anti-HA
antibody to detect ubiquitin conjugates. For development, pro-
tein A-HRP was used.
Immunocytochemistry—Indirect immunofluorescence was
carried out following standard methods (29). Anti-FLAG
(1:1000; SIGMA), anti-ubiquitin (1:50; Dako) and anti-
TRAF6 (1:100; catalog no. sc-8409, Santa Cruz Biotechnol-
ogy) antibodies were used. For detection, Alexa Fluor 405
(blue) or 594 (red) (Invitrogen) labeled anti-mouse or anti-
rabbit antibodies were used. All images were collected using
a confocal microscope (Leica TCS SP2). The analysis of
aggregates was performed on high resolution images using
ImageJ software. At least 200 cells from two independent
experiments were counted and scored for percentage of cells
with aggregates. For the analysis of aggregate size, only cells
(n  200) with comparable levels of TRAF6 expression, as
determined by fluorescence intensity normalized to cell
area, were used. N-HTT cytoplasmic staining was quantified
on the same cells on a randomly selected area. Background
fluorescence was quantified from an area placed outside the
cells and was subtracted to each signal.
Human Post-mortem Brain Samples—Control and HD post-
mortem brain tissues used in this study were collected by the
Harvard Brain Tissue Resource Center, McLean Hospital (Bel-
mont, MA) and described previously (30). HD brains were
assigned Vonsattel grade 3 pathology (31). Post-mortem inter-
vals were from 12 to 32 h for controls and from 8 to 30 h for HD
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brains. Total proteins were extracted from parietal cortex in
10% SDS. Fractionation in soluble and insoluble protein
extracts was performed from the cortex as follows; soluble frac-
tions were extracted in 150 mM sucrose, 15 mM Hepes, pH 7.9,
60 mM KCl, 15 mM NaCl, 5 mM EDTA, 1 mM EGTA, 1% Triton
X-100), supplemented with protease inhibitors (Roche Applied
Science). After centrifugation, the soluble fraction was
removed, and the insoluble fractions were extracted from pel-
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lets in 10% SDS. For Western blot analysis, anti-TRAF6 poly-
clonal (Santa Cruz Biotechnology, catalog no. sc-7221) and
monoclonal (Santa Cruz Biotechnology, catalog no. sc-8409)
antibodies were used.
Quantitative Real-time PCR—Total RNA from cortex of
pathologically confirmed HD and control subjects was isolated
using the TRIzol reagent (Invitrogen). cDNA was obtained
from 1 g of purified RNA using the iSCRIPTTM cDNA Syn-
thesis Kit (Bio-Rad). Quantitative real-time PCR was per-
formed using SYBR-Green PCR Master Mix (Applied Biosys-
tem). Expression of TRAF6 was analyzed as already described
(26).
Statistical Analysis—All experimentswere repeated in dupli-
cate or more. Confocal images were analyzed with ImageJ soft-
ware. Western blot scans were quantified with Adobe Photo-
shop CS3. Data represent the mean with standard deviation.
When necessary, each group was compared individually with
reference to the control group using Student’s t test (Microsoft
Excel software).
RESULTS
E3 Ubiquitin Ligase TRAF6 Interacts withWT andMutant
HTT and Associates with Polyglutamine Aggregates—To
evaluate whether TRAF6might have a role in HD, we studied
its ability to bind huntingtin amino-terminal fragments (res-
idues 1–171) fused to green fluorescent protein (N-HTT-
GFP), with either a physiological (Gln21), or short (Gln60) or
long (Gln150) pathological polyQ stretch. N-HTT-GFP con-
structs were transfected in HEK 293 cells with FLAG-TRAF6
or FLAG-empty vector, as control. Immunoprecipitation of
transfected cell lysates revealed a specific binding between
TRAF6 and N-HTT with no evident selectivity for polyQ
length (Fig. 1a). Reverse co-immunoprecipitation of trans-
fected proteins confirmed that TRAF6 physically associated
with N-HTT with a physiological and pathological polyQ
stretch (Fig. 1b).
We then performed co-immunoprecipitation experiments
in HEK 293 cells on endogenous proteins proving TRAF6
interaction with full-length WT HTT in vitro (Fig. 1c). The
cortex from control WT and HdhQ111 knock-in mice were
also analyzed, showing that TRAF6 specifically binds full-
length HTT in vivo with no preference for WT or expanded
polyQ-containing protein (Fig. 1d). This interaction was
confirmed in vivo in the parietal cortex from HD post-mor-
tem brains (Fig. 1e).
We then analyzed TRAF6 localization in cells that express
WT or mutant N-HTT. WT N-HTT was located both in the
cytoplasm and the nucleus, with a diffused staining through-
out the cell. TRAF6 was mainly present in the cytoplasm and
partially in the nucleus, where it co-localized with WT
N-HTT (Fig. 1, f and g). Similar data were obtained with
overexpressed and endogenous TRAF6. Overexpression of
WT N-HTT did not alter TRAF6 cellular localization (data
not shown). When transfected in cells, mutant N-HTT-GFP
(Gln60 and Gln150) developed fluorescent aggregates, as
expected, located in the cytoplasm and concentrated in peri-
nuclear regions. The presence of mutant N-HTT aggregates
induced the recruitment of TRAF6 at the site of N-HTT
inclusions, with a more prominent accumulation at the bor-
der (Fig. 1, f and g).
Altogether, these results demonstrate that TRAF6 binds
huntingtin in vitro and in vivo in a polyQ length-independent
FIGURE1.TRAF6 interactswithWTandmutantN-HTT in vitroand full-lengthproteins in vivoandaccumulates inmutantN-HTTaggregates.a, HEK293
cells were transfected with FLAG-TRAF6, and the huntingtin N-terminal fragment fused to GFP (N-HTT-GFP) with WT (Gln21, Q21) or mutated (Gln60, Q60 and
Gln150, Q150) polyglutamine expansion. Lysates were immunoprecipitated (IP) with anti-FLAG beads, and bound proteins were revealed by immunoblot (IB)
with anti-GFP,Q150andanti-FLAGantibodies. Lysateswere tested for theexpressionof TRAF6andN-HTTproteins.Molecularmassmarkers (kDa) are indicated
on the left.b, cellswere transfectedwith FLAG-TRAF6 andN-HTT-GFP constructs as indicated. Lysateswere immunoprecipitatedwith anti-GFP. Boundproteins
and lysates were analyzed with anti-FLAG and anti-GFP antibodies. An asterisk represents N-HTT bands from previous development of the same gel. #
represents an unspecific band. c, HEK 293 cell lysates were immunoprecipitated with anti-HTT or control IgG (as indicated), and bound endogenous proteins
were revealed with anti-TRAF6 and anti-HTT antibodies. d, the cortex from WT and homozygous HdhQ111 (mut) mice was dissected, lysed, and used for
immunoprecipitation of endogenous TRAF6 and full-length HTT proteins. e, the parietal cortex from HD post-mortem brain was lysed and processed for
co-immunoprecipitation of endogenous proteins as in d. f, HEK 293 cells were transfected as in a. TRAF6 was visualized by indirect immunofluorescence with
anti-FLAG antibody (red). N-HTTwas visible by GFP autofluorescence (green). Nuclei were visualizedwith DAPI (blue). g, cells were transfectedwith N-HTT-GFP
constructs. Endogenous TRAF6 was stained with anti-TRAF6 antibody (red).
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FIGURE 2. TRAF6 enhances ubiquitination of WT and mutant N-HTT. For
ubiquitination assay, HEK 293 cells were transfected with HA-ubiquitin and
N-HTT-GFP Gln21 (Q21), Gln60 (Q60), and Gln150 (Q150) constructs with WT or
DN FLAG-TRAF6. Lysates were immunoprecipitated (IP) with anti-GFP anti-
body, and ubiquitinated N-HTT protein was revealed with anti-HA. Input
lysates were analyzed with anti-HA, anti-GFP, and anti-FLAG antibodies.
Molecular mass markers (kDa) are indicated on the left. HC, heavy chain; IB,
immunoblot; Ub, ubiquitin.
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manner. Furthermore, mutant protein can sequester TRAF6
into cellular aggregates.
TRAF6 Facilitates Atypical Polyubiquitination of WT and
MutantN-HTT—The interaction betweenTRAF6 andN-HTT
and their co-localization in polyglutamine aggregates raised the
possibility that N-HTT might be target of TRAF6 E3 ubiquitin
ligase activity. To test this hypothesis, we performed ubiquiti-
nation assay in HEK 293 cells. Cells were transfected with HA-
ubiquitin, N-HTT-GFP with 21, 60, or 150 polyQ segment and
with or without FLAG-TRAF6. A TRAF6mutant deleted of the
N-terminal E3 ligase domain (DN) alsowas included as control.
We found that overexpression of WT TRAF6, but not of DN
mutant, facilitated the formation of high molecular weight
polyubiquitinated forms of N-HTT (Fig. 2). TRAF6 activity was
evident toward N-HTT with physiological length of polyQ
stretch (Gln21) and for pathological mutants (Gln60 and
Gln150). Therefore, TRAF6 ubiquitin-ligase activity did not
seem to be polyQ-dependent, as already seen for its binding
capability.
Because we have shown recently that TRAF6 can promote
unconventional ubiquitin linkages on target proteins (26), we
investigated the mode of polyubiquitination mediated by
TRAF6 onto N-HTT. We thus took advantage of a set of ubiq-
uitinmutants that we have generatedwith only one lysine avail-
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FIGURE 3. TRAF6 promotes atypical ubiquitination of WT and mutant N-HTT. HA-ubiquitin (Ub) mutants were used in which only the indicated lysine is
available for chain formation. WT and Lys0 ubiquitin were included as controls. HEK 293 cells were transfected with HA-ubiquitin mutant (as indicated),
FLAG-TRAF6, and N-HTT-GFP Gln21 (Q21) (a), Gln60 (Q60) (b), and Gln150 (Q150) (c). Ubiquitination was monitored with anti-HA, anti-GFP, and anti-FLAG
antibodies. IB, immunoblot; IP, immunoprecipitation; HC, heavy chain.
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able for chain formation (remaining lysine residues were sub-
stituted with arginine). An ubiquitin mutant with all lysines
substituted with arginine was also included as negative control
(Lys0). Cell-based ubiquitination assay was performed with all
N-HTT constructs with or without TRAF6 and in combination
with ubiquitin mutants. TRAF6 promoted a robust polyubiquiti-
nation of WT N-HTT in the presence of Lys6, Lys27, and Lys29
mutants.BackgroundsignalswereobservedwithLys0mutant (Fig.
3a). Similar results were obtainedwithmutantN-HTTwith short
(Gln60) or long (Gln150) polyQ stretch (Fig. 3, b and c).
Therefore, we conclude that TRAF6 promotes an atypical
polyubiquitination of WT and mutant N-HTT that is inde-
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FIGURE 4. TRAF6 enhances aggregate formation. a, HEK 293 cells were transfected with N-HTT-GFP alone (C, control), or with FLAG-TRAF6 (WT or DN), as
indicated. Immunofluorescence was performed with anti-FLAG (red) antibody. Nuclei were visualized with DAPI (blue). GFP was followed by autoflorescence.
Confocal images from two independent experiments were scored for percentage of cells with aggregates (b), aggregate average size (c), and N-HTT cytoplas-
mic diffuse staining (d). At least 200 cells per experimental condition were counted. Data were analyzed with ImageJ software. Statistical analysis was
performed with a t test. NS, not significant. AU, arbitrary units.
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pendent from polyQ length. Lys6, Lys27, and Lys29 are the pre-
ferred lysine residues for linkage formation.
TRAF6-mediated Ubiquitination Increases Mutant N-HTT
Aggregates—When expressed in cells, Gln60 andGln150mutant,
but not Gln21 N-HTT, generated aggregates, with an average
size and number that correlate with polyQ length. We exam-
ined the influence of TRAF6-mediated ubiquitination on
mutant N-HTT aggregation by transient transfection in HEK
293 cells. We included WT N-HTT as an internal reference in
all our experiments. Only cells with comparable levels of
TRAF6 expression (WT and DN), as determined by fluores-
cence intensity normalized to cell area, were used for analysis of
aggregate number and size. The residual diffuse cytoplasmic
staining was also quantified as additional indication of protein
segregation into aggregates. TRAF6 overexpression had no
influence on WT N-HTT cellular localization, with a diffuse
cytoplasmic and nuclear staining as expected (Fig. 4a). Mutant
N-HTT formed cytoplasmic and perinuclear aggregates, whose
number and size correlated with polyQ length (Fig. 4a). Over-
expression of TRAF6 increased the percentage of cells with
aggregates and promoted the formation of inclusions with an
average larger size (Fig. 4, b and c). This is likely due to a redis-
tribution of the mutant protein to inclusions, as total protein
levels were not affected byTRAF6 (supplemental Fig. S1) (com-
patible with a nondegradative role of atypical ubiquitination)
and diffuse cytoplasmic staining decreased when aggregate
number and size increased (Fig. 4d). The expression of TRAF6
DN mutant had no effect on percentage, size, and distribution
of N-HTT aggregates, thus indicating that TRAF6 E3 ligase
activity is required for its function onmutant N-HTT inclusion
formation.
Because TRAF6 is recruited at the site of N-HTT aggregates
and affects inclusion formation, we asked whether mutant pro-
tein might affect TRAF6 E3 ligase activity. To do so, we fol-
lowed TRAF6 autoubiquitination by immunoprecipitation
assay. We included WT N-HTT as an internal control. We
found no differences in the levels of ubiquitinated TRAF6when
Gln21, Gln60, or Gln150 N-HTT was expressed (supplemental
Fig. S2). Altogether, these data suggest a scenario in which
TRA6-mediated ubiquitination may control N-HTT recruit-
ment into aggregate structures without affecting its steady-
state levels.
TRAF6-mediated Atypical Ubiquitination Is Involved in
Mutant N-HTT Aggregates—To functionally link TRAF6-me-
diated atypical ubiquitination with mutant N-HTT aggregates,
HEK 293 cells were transfected with HA-ubiquitin, FLAG-
TRAF6, and N-HTT-GFP Gln150. Aggregates were analyzed by
double immunofluorescence coupled with GFP autofluores-
cence. First, we set the system using WT ubiquitin (Fig. 5a).
Overexpression of ubiquitin per se enhanced N-HTT inclusion
formation, as expected for the well established role of the UPS
in mutant N-HTT aggregation. Nonetheless, under these con-
ditions, ubiquitin staining was diffuse throughout the cell and
did not accumulate at the site of N-HTT inclusions (Fig. 5a,
upper panels).When TRAF6 was added to the system, all of the
components coalesced into the aggregates, which appeared
strongly stained with both ubiquitin and TRAF6 (Fig. 5a, lower
panels). To prove that TRAF6 action onmutant N-HTT aggre-
gates involved atypical ubiquitination,we carried out analogous
experiments with ubiquitin mutants that were shown to be
involved in N-HTT ubiquitination (Lys6, Lys27, and Lys29). As
control, we used a Lys11 mutant that mediates polychain for-
mation but is not used by TRAF6. Lys6, Lys27, and Lys29 were
able to recapitulate the phenotype observed withWT ubiquitin
(Fig. 5b). On the contrary, the Lys11 mutant did not accumulate
into N-HTT inclusions. Together, these data provide evidence
that TRAF6-mediated atypical activity is involved in control-
ling the composition of mutant N-HTT aggregates.
TRAF6 Is Up-regulated in Post-mortem Brains from HD
Patients and Accumulates in Insoluble Protein Fraction—To
obtain further evidence supporting the role of TRAF6 in HD
pathogenesis, we assessed the expression of TRAF6 in
human post-mortem brains from patients and age-matched
healthy controls. First, TRAF6 mRNA expression was mon-
itored by quantitative real-time PCR in RNA extracted from
parietal cortex of controls and HD (Vonsattel grade 3 neu-
ropathology) brains. TRAF6 mRNA levels were significantly
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FIGURE 5. Atypical ubiquitination by TRAF6 is localized at the aggre-
gates. a, HEK 293 cells were transfected with Gln150 N-HTT-GFP with
FLAG-TRAF6 and HA-ubiquitin (Ub) WT. Localization of ubiquitin (blue)
and TRAF6 (red) at N-HTT aggregates were analyzed by double immuno-
fluorescence coupledwith GFP autofluorescence. b, cells were transfected
with Gln150 N-HTT-GFP, FLAG-TRAF6, and HA-ubiquitin mutants Lys6,
Lys27, Lys29, and Lys11 as indicated. Aggregates were analyzed by immu-
nofluorescence as in a.
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up-regulated in HD compared with controls, with an average
increase of 1.6-fold (Fig. 6a). We then tested whether TRAF6
up-regulation also was present at the protein level. Samples
dissected from the parietal cortex of HD and control patients
were used to prepare total protein extracts. Lysates were
analyzed by Western blotting. To avoid artifacts due to
unspecific signals, experiments were carried out using two
different, commercially available anti-TRAF6 antibodies.
Endogenous TRAF6 protein was slightly up-regulated in HD
versus control samples (Fig. 6b). Quantification of TRAF6
signal demonstrated that the increase was statistically signif-
icant (Fig. 6c).
Because we found that mutant N-HTT promotes TRAF6
accumulation at the aggregates in cell culture system, TRAF6
distribution was studied in soluble and insoluble protein frac-
tions prepared from human brain samples. Loading was nor-
malized for total protein quantity in each of the two fractions.
InHD and controls, TRAF6was presentmainly in the insoluble
fraction. In this compartment, there was a statistically signifi-
cant accumulation of TRAF6 inHD versus controls. Altogether,
these data suggest an effect of mutant huntingtin on TRAF6
expression and solubility.
DISCUSSION
The ubiquitin proteasome system is under intense scrutiny
in the study of neurodegenerative diseases. Different E2 conju-
gating enzymes and E3 ligases have been shown to ubiquitinate
aggregate-prone mutant proteins via Lys48 and Lys63 moieties.
In the present study, we have found that the E3 ubiquitin
ligase TRAF6 interacts withWT andmutant N-HTT in vitro as
well as with endogenous full-length proteins in vivo and ubiq-
uitinates bothWT andmutant N-HTT through conjugation of
atypical ubiquitin chains linked at Lys6, Lys27, and Lys29.
Unconventional ubiquitination recently has provided new
moieties to regulate cell signaling, intracellular trafficking, and
biochemical activities (15). A variety of cellular functions have
been associated to atypical ubiquitination with Lys6, Lys27, and
Lys29 linkages that includeproteindegradation, regulationofpro-
teasomeactivityaswell as controlof targetprotein localizationand
function. TheE3ubiquitin ligase parkin, foundmutated in genetic
cases of PD, is an HTT interactor that has been shown to act with
atypical Lys27 linkage on mitochondrial target VDAC1 to control
mitophagy (32). Transcriptional activity of androgen receptor,
another polyQ containing protein, is regulated by Lys6 and Lys27
ubiquitination through modulation of cofactor recruitment to a
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FIGURE6. InHDpost-mortembrain, TRAF6expression is increased, andTRAF6proteinaccumulates in the insoluble fraction.a, total RNAwas extracted
fromparietal cortex of HD and control brains. TRAF6mRNAwasmeasured by quantitative real-time PCR relative to-actin. b, total protein lysates fromHDand
controls were prepared, and endogenous TRAF6 expression wasmonitoredwith anti-TRAF6 antibody. Loadingwas normalized by protein quantification and
verified with anti--actin antibody. Representative images from three independent experiments are shown. c, densitometric analysis of protein bands was
performedusingAdobePhotoshopCS3. Expressionof endogenous TRAF6 in total lysateswas normalized relative to-actin. Statistical analysiswasperformed
with a Student’s t test. d, soluble and insoluble fractions from HD and control brains were prepared and analyzed for TRAF6 distribution. Lysates were
normalized for total protein content. Anti-TRAF6 and actin antibodies were used. Images are representative of three independent experiments. e, quantifica-
tion of TRAF6 expression in insoluble fraction was done as described in c.
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subset of androgen receptor target genes (21). In both cases, atyp-
ical ubiquitination regulates protein function without affecting its
degradation rate.
Interestingly, we found that both WT and mutant N-HTT
are ubiquitinatedwith no evident selectivity for polyQ length. It
is conceivable to hypothesize that atypical ubiquitination of
N-HTT might exert diverse functions when associated to WT
or mutant polyQ stretch even if the mode of ubiquitination is
maintained. Although the ubiquitination of mutant N-HTT by
TRAF6 was found to induce aggregate formation, the role of
this post-translational modification in WT N-HTT is unclear
and deserves further investigation.
Recent data have proven the accumulation of ubiquitinated
proteins with unconventional ubiquitin linkages in the brain of
HD mouse models (9). In HD, it is well established that neuro-
nal inclusions that contain mutant HTT in human post-mor-
tem brains and in mouse models are stained heavily for ubiqui-
tin (7, 33). In vitro, our data demonstrated that atypical
ubiquitin, N-HTT, and TRAF6 were all localized to the aggre-
gates. Differently from all of the ubiquitin ligases studied so far
in HD, TRAF6 promoted aggregate formation and segregated
ubiquitin at the site of N-HTT inclusion. This is in agreement
with previous studies showing that TRAF6 elicited aggresome
formation of the PD-associated mutant DJ-1 L166P (26).
An important debate is ongoing on the effects of aggregate
formation on cell viability in vivo. Among the various functional
consequences, it has been hypothesized that inclusions can act
as a sink for prosurvival proteins, thus depleting the neuronal
cell of soluble, active molecules. In HD postmortem brains, we
found that TRAF6 was up-regulated and accumulated in the
insoluble protein fraction. For the majority of the ubiquitin
ligases found trapped in cellular inclusions, a concomitant
increase in expression has been measured in post-mortem
brains, suggesting a homeostasis response aimed to preserve a
physiological concentration of themolecule. Under this model,
we speculate that TRAF6 sequestration in vivomay deplete sol-
uble TRAF6 in neurons impairing some of its physiological
functions.
In vitroTRAF6was able to increase both the number and size
of intracellular aggregates via an atypical mode of ubiquitina-
tion. In general, larger aggregates tend to be disposed by the
autophagy/lysosomal pathway. TRAF6 recently has been
shown to be involved in autophagy via its Lys63-specific activity
on Beclin-1 in the context of innate immunity (34). Further-
more, TRAF6 was able to bind p62/SQSTM1 (25), which
anchors aggregated structures to LC3 and autophagosomes.
Importantly, p62 is a component of the ubiquitinated proteins
found in the inclusions of exon 1mice and in cells overexpress-
ing the N-terminal fragment of mutant HTT (35, 36). Because
Lys27 ubiquitination of Jun and Lys29 of Deltex have been
recently involved in their recruitment to autophagic and/or
storage vesicles (20, 37), it will be interesting to study whether
TRAF6 atypical ubiquitin ligase activity has an impact on
autophagy in neurodegenerative disorders. It recently has been
demonstrated that, similarly to Lys63, Lys27-linked ubiquitin
chains are recognized by p62/SQSTM1 to label target proteins
for autophagy (32). Our preliminary results (data not shown)
indicate that TRAF6 is able to bind LC3 in transfected cells,
further supporting our hypothesis that TRAF6 and atypical
ubiquitination may favor alternative fates of misfolded aggre-
gated proteins.
In the future, the generation of reagents to discriminate
among Lys6, Lys27, and Lys29 ubiquitin chains and the improve-
ment of proteomic techniques to be used on small amount of
human autoptic samples will definitely help the study of atypi-
cal ubiquitination in various cellular processes in vivo and from
diseased brains.
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Abstract
Mutations in PARK7/DJ-1 gene are associated to autosomal recessive early onset forms of Parkinson’s disease (PD). Although
large gene deletions have been linked to a loss-of-function phenotype, the pathogenic mechanism of missense mutations is
less clear. The L166P mutation causes misfolding of DJ-1 protein and its degradation. L166P protein may also accumulate
into insoluble cytoplasmic aggregates with a mechanism facilitated by the E3 ligase TNF receptor associated factor 6
(TRAF6). Upon proteasome impairment L166P activates the JNK/p38 MAPK apoptotic pathway by its interaction with TRAF
and TNF Receptor Associated Protein (TTRAP). When proteasome activity is blocked in the presence of wild-type DJ-1,
TTRAP forms aggregates that are localized to the cytoplasm or associated to nucleolar cavities, where it is required for a
correct rRNA biogenesis. In this study we show that in post-mortem brains of sporadic PD patients TTRAP is associated to
the nucleolus and to Lewy Bodies, cytoplasmic aggregates considered the hallmark of the disease. In SH-SY5Y
neuroblastoma cells, misfolded mutant DJ-1 L166P alters rRNA biogenesis inhibiting TTRAP localization to the nucleolus and
enhancing its recruitment into cytoplasmic aggregates with a mechanism that depends in part on TRAF6 activity. This work
suggests that TTRAP plays a role in the molecular mechanisms of both sporadic and familial PD. Furthermore, it unveils the
existence of an interplay between cytoplasmic and nucleolar aggregates that impacts rRNA biogenesis and involves TRAF6.
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Introduction
The accumulation of misfolded proteins is a common feature to
a wide range of neurodegenerative diseases [1]. A neuropatho-
logical hallmark of Parkinson’s disease (PD) is the presence of
proteinaceous aggregates, known as Lewy Bodies (LBs), in the
cytoplasm of dopaminergic (DA) neurons of the Substantia Nigra,
the major target of neurodegeneration. In Huntington’s disease
(HD), N-terminal fragments of mutant huntingtin (N-HTT) form
intracellular aggregates in the brain [2].
Several evidences implicate malfunction of the ubiquitin-
proteasome system (UPS) in both idiopatic and familial PD [3].
Key UPS elements are altered in PD post-mortem brains [4],
while synthetic proteasome inhibitors preferentially affect cate-
cholaminergic neurons in vitro and in vivo leading to cell death [5,6].
DJ-1 is a ubiquitously expressed protein that is mutated in
autosomal recessive early onset forms of PD (PARK7) [7]. DJ-1 is
an anti-oxidant protein [8] involved in mitochondrial integrity [9],
autophagy [10] and hypoxia [11,12]. Together with phenotypes
due to large gene deletions, the exact pathogenic mechanism of
PD-causing missense mutations remains unclear. In the most
studied case, L166P disrupts DJ-1 protein activity and dimer
formation, resulting in a misfolded protein that undergoes
degradation [13]. However, mutant DJ-1 may also accumulate
into insoluble cytoplasmic aggregates [14,15] and acquire a gain-
of-function property that may co-exist with its loss of physiological
activity, as previously found for mutant HTT in HD [16] and
superoxide dismutase 1 (SOD1) missense mutations in amyotro-
phic lateral sclerosis (ALS) [17].
The formation of L166P-containing aggregates is facilitated by
atypical ubiquitination carried out by the TNF associated protein
6 (TRAF6) [15], a component of LBs in PD post-mortem brains.
Interestingly, TRAF6 activity also triggers aggregate formation of
mutant HTT suggesting a broader role of this E3 ligase in
neurodegenerative diseases [18].
TRAF and TNF Receptor Associated Protein (TTRAP) is a 59-
tyrosyl DNA phosphodiesterase that repairs topoisomerase-2-
induced DNA breaks [19]. In physiological conditions in neurons
TTRAP is a nuclear protein associated to PML Nuclear Bodies
(PML-NBs) [20]. It was originally described as involved in signal
transduction for its interaction with TNF receptors (TNFR) family
members and TNFR-associated factors (TRAFs), including
TRAF6 [21], as well as in transcriptional regulation for its
binding to ETS-related proteins [22]. TTRAP has been linked to
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PD for its ability to specifically interact with L166P DJ-1. When
UPS activity is inhibited, TTRAP mediates L166P toxicity via
JNK/p38 MAPK pathways providing the molecular basis for
L166P gain-of-function properties [23]. Interestingly, TTRAP
forms aggregates both in the cytoplasm and in nucleolar cavities, a
region of the nucleolus devoid of ribosomal markers [24]. Under
these conditions, TTRAP is neuroprotective and required for a
correct rRNA biogenesis [20].
The structure and function of the nucleolus have been recently
found altered in PD and essential to the survival of DA neurons in
vivo [25,26].
In this paper we show that in PD post-mortem brains TTRAP is
associated to LBs in the cytoplasm or accumulated in the nucleolus
in a portion of surviving DA neurons. In a cellular model of
familial PD linked to mutant DJ-1 L166P, accumulation of
misfolded proteins impairs rRNA biogenesis in vitro by inhibiting
TTRAP localization into nucleolar cavities. This is concomitant
with an increase in the number and size of cytoplasmic aggregates
containing both L166P and TTRAP. This phenotype depends, at
least in part, on TRAF6 E3 ligase activity.
Materials and Methods
Human post-mortem brains
Brain samples were obtained from the brain bank at the
Institute of Neuropathology, Bellvitge Hospital (University of
Barcelona, Spain). Samples were dissected at autopsy with the
informed consent of patients or their relatives and the institutional
approval of the Ethics Committee of the University of Barcelona.
Brains were obtained from Caucasian, pathologically confirmed
PD cases and age-matched controls [27]. Briefly, all cases of PD
had suffered from classical PD, none of them had cognitive
impairment and their neuropathological characterization was
made according to established criteria. Control healthy subjects
showed absence of neurological symptoms and of metabolic and
vascular diseases, and the neuropathological study disclosed no
abnormalities, including lack of Alzheimer disease and related
pathology. The time between death and tissue preparation was in
the range of 3 to 5 hours. The ventral midbrain region was
sectioned horizontally. The dark pigmented zones of the
Substantia Nigra were readily apparent from all surrounding
structures and were then isolated from the ventral midbrain. For
histological analysis, samples were cryoprotected with 30% sucrose
in 4% formaldehyde, frozen in dry ice and stored at 280uC until
use.
Immunohistochemistry
Immunohistochemistry was performed on three controls and six
PD human post-mortem brains. Only Substantia Nigra was
dissected and analyzed. Tissue processing and histology were
performed as previously described [15]. The following primary
antibodies were used: anti-TTRAP (1:50) [23] and anti-alpha-
synuclein (1:100, Cell Signaling Technology). Nuclei were
visualized with DAPI. DA neurons in the Substantia Nigra were
identified by neuromelanin staining with transmitted light.
Cell culture and transfections
Human neuroblastoma SH-SY5Y cells (ATCC) were maintained
in culture as suggested by the vendor. SH-SY5Y cells stably
transfected with pCDNA3-FLAG-DJ-1 wt and L166P or empty
vector control and with pSuperior-siDJ-1 or pSuperior-Scramble
were previously described [11,23]. All stably transfected SH-SY5Y
cells were kept in culture with neomycin selection. Proteasome
inhibition was performed for 16 hours with 5 mM MG132 (z-Leu-
Leu-al) (Sigma Aldrich). DJ-1 silencing was obtained by adding
2.5 mg/ml of Doxycicline Hyclate (Sigma Aldrich) every 48 hours
for a total of 10 days. GFP-TRAF6 (wt and DN) and N-HTT-GFP
Gln21 and Gln150 were previously described [15,18]. Transfections
were performed with Lipofectamine reagent (Invitrogen).
For silencing endogenous TRAF6 specific oligonucleotides
(Sigma Aldrich, EHU147511) were transiently transfected with
Oligofectamine (Invitrogen). Immunofluorescence and western
blot experiments were performed 72 hours after transfection.
Immunofluorescence
For immunofluorescence experiments, cells were fixed in 4%
paraformaldehyde directly added to culture medium for 10 min-
utes, then washed in PBS two times, treated with 0.1 M glycine for
4 minutes in PBS and permeabilized with 0,1% Triton X-100 in
PBS for another 4 minutes. After washing with PBS and blocking
with 0.2% BSA, 1% NGS, 0,1% Triton X-100 in PBS (blocking
solution), cells were incubated with the indicated antibodies
diluted in blocking solution for 90 minutes at room temperature.
To detect insoluble TTRAP, immunocytochemistry was per-
formed as described earlier [23].
We used anti-FLAG (1:1000, Sigma Aldrich), anti-TTRAP
(1:100), anti-NPM (1:100, Invitrogen), anti-Nucleolin (1:100,
Invitrogen), anti-PML (PG-M3) (1:100, Santa Cruz Biotechnolo-
gy), anti-p53 (DO1, Santa Cruz Biotechnology). For detection,
cells were incubated with Alexa Fluor-488 or -594 (Molecular
Probes, Invitrogen) labeled anti-mouse or anti-rabbit secondary
antibodies. For nuclear staining, cells were incubated with DAPI
(1 mg/ml) for 5 minutes. Triple immunofluorescence was per-
formed using Zenon technology: anti-NPM antibody was labeled
with Zenon Alexa Fluor 405 Mouse IgG(1) labeling reagent
(Invitrogen), according to manufacturer’s instructions. Cells were
washed and mounted with Vectashield mounting medium
(Vector). All images were collected using a confocal laser scanning
microscopy LEICA TCS SP2. The analysis of aggregates was
performed on high-resolution images using ImageJ software. At
least 100 cells from two independent experiments were counted
and scored for percentage of cells with aggregates and average
aggregate size.
RNA isolation, reverse transcription and qPCR
Total RNA was isolated using the TRIZOL reagent (Invitrogen)
following the manufacturer’s instructions. Single strand cDNA was
obtained from 1 mg of purified RNA using the iSCRIPTTM cDNA
Synthesis Kit (Bio-Rad) according to manufacturer’s instructions.
Quantitative real time PCR (qPCR) was performed using SYBR-
Green PCR Master Mix (Applied Biosystem) and an iCycler IQ
Real time PCR System (Bio-Rad). Primers for rRNA biogenesis
A0, 1 and 4 [20], and for housekeeping genes beta-actin and
GAPDH [15] were previously described.
32P-orthophosphate in vivo labeling and RNA analysis
Metabolic labeling and analysis of rRNA was carried out as
previously described [20]. Briefly, mutant DJ-1 L166P and empty
control cells were treated with 5 mM MG132 for 16 h or left
untreated. Drug was maintained in the medium during the whole
time of the procedure. Cells were incubated with phosphate-free
medium supplemented with 10% dialyzed FBS (labeling medium)
for 1 h prior to labeling with 32P-orthophosphate (15 mCi/ml) in
labeling medium for 1 h (pulse). Medium was then replaced with
complete medium for 3 h (chase). Total RNA was extracted using
TRIZOL reagent (Invitrogen) and 1 mg of purified RNA was
separated on 1% agarose-formaldehyde gel. After electrophoresis,
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28S and 18S rRNA forms were controlled under UV light and gels
were dried. rRNA species were detected by autoradiography.
Proliferation and viability assays
Cell proliferation was measured by flow-cytometry (FACS)
upon propidium iodide staining. Briefly, SH-SY5Y cells stably
transfected with L166P and control cells were either left untreated
or treated with 5 mM MG132 for 16 hours. After treatment, cells
were collected, fixed with ice-cold 70% ethanol, treated with
RNase A (0.2 mg/ml), and stained with propidium iodide
(0.04 mg/ml). Samples were analyzed on a flow cytometer
(FacsCalibur, BD). FACS data were processed using FlowJo
software, and cell cycle profiles were determined using the Watson
pragmatic model (Tree Star).
Cell viability was measured using WST-1 reagent (Roche),
following manufacturer’s instructions and reading absorbance at
440 nm using a standard spectrophotometer. Percentage of live
cells after treatment with 5 mM MG132 for 16 hours was
calculated relative to DMSO-treated cells (set as 100% for each
cell line).
Cell fractionation and Western blot analysis
SH-SY5Y stable cells were lysed in a buffer containing 150 mM
NaCl, 50 mM Tris pH 7.5 and 0.2% TRITON X-100,
supplemented with protease inhibitor cocktail (Roche). Lysates
were centrifuged at 20 000 g for 30 min at 4uC and separated into
Triton X-100 soluble (supernatant) and insoluble (pellet) fractions.
Insoluble pellets were resuspended in boiling sample buffer,
sonicated and used for western blot analysis. The following
antibodies were used: anti-FLAG 1:2000 (Sigma), anti-TTRAP
1:1000, anti-TRAF6 (Santa Cruz), anti-beta-actin 1:5000 (Sigma).
For detection, anti-mouse-HRP or anti-rabbit-HRP (Dako) in
combination with ECL (GE Healthcare) were used.
Statistical analysis
All experiments were repeated in triplicate or more. For stably
transfected cells, at least two independent clones were used for
each cell line in all experiments. Data represent the mean with
standard deviation. When necessary, each group was compared
individually with reference control group using Student’s t-Test
(Microsoft Excel software).
Results
TTRAP is present in cytoplasmic LBs and in the nucleolus
of surviving dopaminergic neurons of PD post-mortem
brains
To study TTRAP localization in sporadic PD, we performed
immunohistochemical analysis in human post-mortem brains. A
total of six PD patients and three controls were examined
(Figure 1A). In normal conditions, TTRAP is expressed mainly in
the nucleus of DA neurons, identified for the presence of
neuromelanin. A weaker cytoplasmic staining is observed. Low
levels of TTRAP expression can also be found in non-DA neurons.
No staining was detected when control rabbit immunoglobulins
were used (data not shown). In human brain sections of sporadic
PD cases TTRAP expression was heterogeneous throughout
mesencephalic cells identifying at least four phenotypes. While a
small quantity of cells (15–20%) presented a nuclear distribution as
in controls, in the majority of DA neurons (80%) TTRAP was
exclusively relocalized to the cytoplasm, almost completely
emptying the nucleus. In about 1–20% of the cells, TTRAP
accumulated in large cytoplasmic aggregates. Double immunohis-
tochemical analysis using anti-alpha-synuclein antibody demon-
strated that these are bona fide LBs (Figure 1B). The patient-to-
patient variability, in conjunction with an uneven distribution of
aggregates in the Substantia Nigra, reflected the heterogeneous
distribution of LBs in post-mortem brains. In addition, in 1–2% of
surviving DA neurons, TTRAP diffuse cytoplasmic localization
was concomitant with the presence of TTRAP in the nucleolus, as
shown by lack of DAPI staining.
Altogether these data show that TTRAP is present in
cytoplasmic LBs as well as in the nucleolus in surviving
dopaminergic neurons of sporadic PD brains.
L166P mutant DJ-1 inhibits TTRAP localization in
nucleolar cavities
When SH-SY5Y neuroblastoma cells are treated with protea-
some inhibitors in vitro, TTRAP forms aggresome-like structures in
the cytoplasm and in the nucleolus where it participates in rRNA
biogenesis [20,23]. In these conditions it binds L166P, the protein
product of the most studied missense DJ-1 mutation in familial
PD. To test whether L166P binding might have an effect on
TTRAP localization, SH-SY5Y cells stably expressing FLAG-
tagged wt DJ-1 or PD-associated L166P were treated with
MG132. When nucleoli were visualized with the marker
Nucleophosmin (NPM), TTRAP was detected in the nucleolus
of about 60% of control cells upon proteasome block (Figure 2A,
2B) [20]. This localization was also observed when more specific
inhibitors of proteasome activity were used like epoxomicin and
lactacystin (Figure S1). No staining was observed in cells with
knock-down TTRAP expression (Figure S1). While overexpression
of wt DJ-1 had no effect on TTRAP nucleolar localization, the
presence of misfolded L166P mutant almost completely inhibited
TTRAP recruitment to the nucleolus (Figure 2A, 2B and figure
S2). No differences in TTRAP localization were observed in
untreated conditions, thus indicating that overexpression of wt or
mutant DJ-1 per se does not alter TTRAP subcellular distribution
(Figure 2B and Figure S2). Since L166P DJ-1 is expressed at lower
levels than wt protein and is generally associated to a loss-of-
function phenotype, we asked whether silencing DJ-1 expression in
SH-SY5Y cells could recapitulate the phenotype observed in
L166P expressing cells. We performed similar immuno-fluores-
cence experiments in SH-SY5Y cells with inducible loss of DJ-1
expression [11] by using two independent siDJ-1 (A, B) and
scramble (a, b) clones. The lack of DJ-1 protein did not affect
TTRAP localization, neither in untreated or MG132-treated cells
(Figure 2C, 2D, 2E and Figure S3).
To evaluate whether TTRAP exclusion from the nucleolus was
a phenotype common to other misfolded proteins involved in
neurodegenerative diseases, we studied TTRAP localization in a
cellular model of Huntington’s disease. SH-SY5Y cells were
transfected with huntingtin amino-terminal fragment (residues 1–
171) fused to green fluorescent protein (N-HTT-GFP) with either
a physiological (Gln21) or a pathological (Gln150) polyglutamine
(polyQ) stretch. N-HTT aggregates triggered by polyQ expansion
inhibited TTRAP nucleolar localization upon proteasome impair-
ment (Figure 2F, 2G), while no effects were observed when wt
Gln21 N-HTT was used.
These data indicate that misfolding-causing mutations in
neurodegenerative diseases impact TTRAP nucleolar localization
upon proteasome inhibition.
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Figure 1. TTRAP is present in cytoplasmic Lewy bodies and in the nucleolus in surviving dopaminergic neurons in PD post-mortem
brains. (A) TTRAP localization in normal and PD dopaminergic neurons. Cryo-sections of post-mortem brain tissues were taken from Substantia Nigra
of healthy individuals and PD patients, as indicated. Immunohistochemistry was performed with anti-TTRAP antibody (green). Nuclei were stained
with DAPI (blue). Dopaminergic neurons were identified by neuromelanin (black) in transmitted light (TL). Overlays of fluorescence (merge) and
fluorescence with TL (TL merge) are shown. Panels are representative images showing TTRAP nuclear, cytoplasmic diffused, cytoplasmic aggregated
and nucleolar localization. The percentage of dopaminergic neurons with nuclear, cytoplasmic or nucleolar TTRAP staining is indicated on the right.
Bars, 15 mM. (B) TTRAP-containing cytoplasmic aggregates are Lewy bodies. Immunohistochemistry of Substantia Nigra from PD brains was
performed with anti-TTRAP (green) and anti-alpha-synuclein (red) antibodies. Images at low (16) and high (106) magnification are shown.
doi:10.1371/journal.pone.0035051.g001
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Figure 2. Mutant DJ-1 L166P inhibits TTRAP nucleolar localization after proteasome inhibition. (A) TTRAP nucleolar localization is
inhibited in L166P expressing cells. SH-SY5Y cells stably transfected with empty vector (c), FLAG-DJ-1 wt (W) or L166P (L) were treated with 5 mMMG132
for 16 h. Triple immunofluorescence was performedwith anti-NPM (blue), anti-TTRAP (green) and anti-FLAG (red) antibodies. Images are representatives
of three independent experiments. Data have been confirmed on two independent clones for each cell line. Bars, 10 mm. (B) Quantification of TTRAP
nucleolar localization. Cells as in A. At least 200 cells from two independent experiments were counted and scored for TTRAP in the nucleolus (*, p,0.05).
(C) Localization of TTRAP is unaffected in cells depleted of endogenous DJ-1. SH-SY5Y cells stably expressing an inducible short-hairpin RNA targeting
DJ-1 (siDJ-1, clones A and B) or a scramble shRNA control (scramble, clones a and b) were treated with doxycycline for 10 days to induce silencing of DJ-1
expression. Then cells were treated with 5 mM MG132 for 16 h. Immunofluorescence was performed with anti-TTRAP (green) and anti-NCL (red)
antibodies. Nuclei were visualized with DAPI (blue). Images are representatives of two independent experiments. Bars, 10 mm. (D) Quantification of
TTRAP nucleolar localization in siDJ-1 cells. Data were collected as in B. (NS, not-significant). (E) DJ-1 is efficiently depleted in siDJ-1 cells. Total protein
lysates were prepared from cells as in C. Levels of endogenous DJ-1 were measured by western blot with anti-DJ-1 antibody. Beta-actin was detected as
loading control. (F) TTRAP nucleolar localization is altered by mutant huntingtin. SH-SY5Y cells were transfected with huntingtin N-terminal fragment
fused to GFP with WT (Gln21, Q21) or mutated (Gln150, Q150) polyglutamine expansion. Endogenous TTRAP was visualized by indirect
immunofluorescence (red). N-HTT was visible by GFP autofluorescence. Nuclei were visualized with DAPI (blue). Bars, 10 mm. (F) Quantification of
TTRAP nucleolar localization in N-HTT expressing cells. Data were collected as in B on GFP-positive cells (*, p,0.05; NS, not-significant).
doi:10.1371/journal.pone.0035051.g002
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L166P alters rRNA biogenesis in response to proteasome
inhibition
Since we have previously found that nucleolar TTRAP
regulates rRNA biogenesis in conditions of proteasome inhibition
[20], we analyzed the levels of precursor rRNA molecules (pre-
rRNA) and of rRNA processing intermediates in SH-SY5Y stable
cells for wt DJ-1, mutant L166P and empty vector as control. Cells
were treated with MG132 and rRNA biogenesis was measured by
qPCR with A0, 1 and 4 primers as previously described [28,29,30]
[20]. A scheme of rRNA processing events and positioning of
qPCR primers on processing intermediates is shown in figure 3A.
In untreated conditions, A0, 1 and 4 probes detected no changes
dependent on wt or mutant DJ-1 overexpression (Figure 3B).
Upon proteasome inhibition, the levels of pre-rRNA containing
A0 sites were significantly increased (p,0.05). This pattern was
maintained in cells expressing wt DJ-1. On the contrary,
concomitant with the disappearance of nucleolar TTRAP, in
L166P cells the quantity of A0 sites was strongly reduced (p,0.05).
Furthermore, the amount of rRNA processing intermediates,
measured by oligonucleotides targeting 1 and 4 cleavage sites,
dramatically increased in L166P cells compared to wt DJ-1 and
controls (Figure 3B). No detectable alterations in pre-rRNA levels
were observed in inducible si-DJ-1 cells (Figure S4). Importantly,
no gross alterations in the structure of nucleoli were induced by
overexpression of L166P as proved with NPM staining (Figure S5).
To further investigate ribosome biogenesis in mutant DJ-1 cells,
we measured nascent rRNA by pulse-chase labeling with 32P-
orthophosphate. Untreated cells were used as controls. Metabol-
ically labeled rRNA species were visualized by autoradiography
(Figure 3C, upper panel) and loading was verified with ethidium
bromide (Figure 3C, lower panel). No differences in rRNA
processing were detected in untreated conditions between control
and mutant DJ-1 cells, thus confirming qPCR data. While
proteasome inhibition caused a marked reduction of 28S and
18S mature forms in both cell lines, mutant DJ-1 L166P
expression caused an increase in pre-rRNA precursors (47S/45S)
and an accumulation of the 32S processing intermediate.
Altogether, these results suggest that misfolded DJ-1 expression
has an impact both on the initial events of transcription and on the
conversion of intermediate to mature forms (47S to 45S and 32S to
28S). This phenotype resembles the one observed in neuroblas-
toma cells lacking TTRAP expression [20]. Analysis of cell
proliferation in untreated and treated conditions could not detect
any difference between control and mutant cells (Figure S6). A
small, but significant, decrease in cell viability could be observed in
L166P cells exposed to MG132 as compared to control cells
(Figure S6).
L166P-mediated exclusion of TTRAP from nucleolar
cavities does not depend on PML
The presence of PML and the integrity of PML-NBs in
nucleolar cavities are fundamental for TTRAP to be recruited to
the nucleolus in response to proteasome inhibition [20].
Therefore, we asked whether L166P-mediated exclusion of
TTRAP from nucleolar cavities might depend on L166P action
on PML-NBs. SH-SY5Y cells expressing wt, L166P or an empty
vector were treated with MG132 and PML localization was
followed by immunofluorescence using NPM as nucleolar marker
(Figure 4A). The number of cells with nucleolar PML-NBs was
scored in duplicates in two independent clones for each cell line (at
least 100 cells per experiment) (Figure 4B). Total levels of PML
protein were measured by western blot analysis (Figure 4C, 4D).
We found that L166P, similarly to wt and control cells, did not
impact PML expression or PML-NBs accumulation in nucleolar
cavities. Therefore, L166P inhibition of TTRAP nucleolar
accumulation is independent from PML. To further support this
model, we also checked whether MG132-induced nucleolar
localization of p53, another marker of nucleolar cavities, was
altered by L166P. Similarly to PML staining, we couldn’t observe
any change in p53 localization induced by overexpression of
misfolded mutant DJ-1, or in controls (Figure 4E, 4F). No changes
in TTRAP, PML and p53 localization were observed in untreated
cells (Figure S7).
Altogether our data indicate that L166P overexpression does
not impact the overall structure of nucleolar cavities but
specifically alters nucleolar localization of L166P-binding protein
TTRAP.
L166P enhances TTRAP accumulation into insoluble
cytoplasmic aggresomes
As MG132 treatment accumulates TTRAP into cytoplasmic
insoluble aggresome-like structures [23], we analyzed TTRAP
localization in cells that express wt DJ-1 or L166P after
permeabilization with Triton X-100 before fixation. In all cell
lines analyzed, endogenous TTRAP formed aggresome-like
structures in the cytoplasm, as expected (Figure 5A), whereas no
aggresomes were visible in untreated conditions (data not shown).
Interestingly, overexpression of L166P increased the percentage of
cells with TTRAP-containing cytoplasmic aggregates and pro-
moted the formation of inclusions with an average larger size
(Figure 5A, 5B, 5C).
In about half of SH-SY5Y cells stably transfected with DJ-1 wt
or empty vector, TTRAP was also present in the insoluble fraction
of the nucleolus. As expected, TTRAP accumulation in insoluble
nucleolar granules was almost completely inhibited in presence of
L166P mutant (Figure 5A). Interestingly, L166P itself was present
in TTRAP-positive cytoplasmic aggregates (figure 5A), whereas no
DJ-1 aggregates were visible in wt overexpressing cells.
Since mutant L166P promotes TTRAP accumulation in
cytoplasmic aggregates upon MG132 treatment, we analyzed
TTRAP distribution into insoluble fractions by western blot
analysis, proving a more evident accumulation in L166P-
expressing cells (Figure 5D) [23].
Altogether, these data demonstrate that L166P depletes
TTRAP from nucleolar cavities and enhances its recruitment into
L166P-containing insoluble cytoplasmic aggregates.
TRAF6 E3 ligase activity contributes to L166P-mediated
exclusion of TTRAP from nucleolar cavities
Since TTRAP and L166P co-localize in cytoplasmic insoluble
inclusions, we hypothesized that factors that promote L166P
aggregation might control TTRAP distribution between the
cytoplasm and the nucleolus. In a previous work, we have shown
that atypical ubiquitination by the E3 ligase TRAF6 enhances
L166P aggregate formation [15]. Therefore, we tested whether
TRAF6 E3 ligase activity might contribute to L166P-induced
TTRAP mislocalization. To this purpose we took advantage of a
TRAF6 mutant deleted of the N-terminal E3 ligase RING domain
(TRAF6 DN), that acts as dominant negative [31]. We transfected
SH-SY5Y cells stably expressing L166P with TRAF6 DN or wt
fused to GFP (Figure 6A, 6B). Cells expressing wt DJ-1 or empty
vector were used as controls. TTRAP localization in nucleolar
cavities was scored only in those cells with equivalent expression of
transfected constructs. Overexpression of wt TRAF6 had no effect
on TTRAP exclusion from nucleolar cavities induced by L166P.
Instead, TTRAP nucleolar localization was restored in about 20%
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of cells when TRAF6 DN was used (Figure 6A, 6B). This
phenotype was only partially penetrant. Overexpression of
TRAF6 or TRAF6 DN in stable cells for wt DJ-1 or empty
vector had no effects on TTRAP localization (Figure 6B). No
differences in TTRAP localization were observed in untreated
condition (Figure S8), thus indicating that overexpression of wt or
mutant TRAF6 per se does not alter TTRAP subcellular
distribution.
To further support the role of TRAF6 in excluding TTRAP
from nucleolar cavities, endogenous TRAF6 was silenced in
L166P-expressing cells with specific siRNA oligonucleotides.
Scramble siRNA and wt DJ-1 cells were used as controls.
Figure 3. Processing of rRNA is altered in L166P overexpressing cells. (A) Schematic diagram showing pre-rRNA structure and processing
steps. Positioning of A0, 1 and 4 cleavage sites on rRNA processing intermediates is shown. ETS, external transcribed spacer; ITS, internal transcribed
spacer. (B) Analysis of steady-state levels of rRNA precursor and processing intermediates. SH-SY5Y cells stably expressing wt DJ-1 (W), L166P (L) and
empty vector (c) were treated with Bars, 5 mM MG132 for 16 h, or left untreated. Total RNA was extracted and levels of pre-rRNA and processing
intermediates were analyzed by qPCR with primers targeting A0 , 1 and 4 cleavage sites. Standard deviations are calculated on four replicas from two
independent experiments. *, p,0.05. (C) Analysis of rRNA processing by metabolic labeling. L166P (L) and control (c) cells were treated as in A. After
treatment, cells were pulse-labeled with 32P-orthophosphate for 1 h and chased with cold medium for 3 h. RNA was extracted and equal quantities
were separated on denaturing agarose gel. Nascent rRNA was visualized by autoradiography after gel drying (upper panel). rRNA processing
intermediates and mature forms are indicated on the right. Loading was verified with ethidium bromide staining (lower panel).
doi:10.1371/journal.pone.0035051.g003
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Knocking-down TRAF6 expression recapitulated the phenotype
observed with TRAF6-DN, with partial recovery of nucleolar
TTRAP localization (Figure 6C, 6D and 6E). In line with partial
rescue of TTRAP nucleolar localization, knockdown of TRAF6
could also partially recover rRNA biogenesis defects in mutant DJ-
1 cells exposed to proteasome inhibition, although not all
processing intermediates were affected to the same extent (Figure
S9); this observation is also compatible with a DJ-1/TTRAP
independent role of TRAF6 in regulating ribosome biogenesis in
response to proteotoxic stress.
In any case, our data indicate that TRAF6 E3 ligase activity
contributes to TTRAP partitioning between cytoplasmic and
nucleolar aggregates in the presence of misfolded mutant DJ-1.
Discussion
L166P presents a structural rearrangement that interferes with
dimer formation favoring oligomerization and protein instability
[13,32]. This led to the hypothesis that DJ-1 deletions and
missense mutations share a common phenotype based on a loss-of-
function model. However, increasing evidences indicate that
missense mutations like L166P may also present gain-of-function
properties. L166P has exerted dominant-negative effects on the
antioxidant wt DJ-1 activity [33]. Gene profiling experiments in
DJ-1 KO and in L166P-NIH3T3 cells [34] have shown that
L166P affects the expression of a larger number of genes with no
common genes between these two conditions. Furthermore, tau
Figure 4. Mutant DJ-1 L166P does not inhibit nucleolar localization of PML and p53 upon proteotoxic stress. (A) Nucleolar localization
of PML. SH-SY5Y cells stably expressing wt DJ-1 (W), L166P (L) or empty vector (c) were treated with 5 mM MG132 for 16 h. Endogenous TTRAP
(green), PML (red) and NPM (blue) localization was analyzed by triple immunofluorescence. Images are representatives of two separate experiments
performed on two independent clones for each cell line. (B) Quantification of PML nucleolar localization. Cells were treated as in A. 200 cells from two
independent experiments were counted and scored for PML in the nucleolus (*, p,0.05). (C) Mutant DJ-1 L166P does not affect levels of endogenous
PML. SH-SY5Y cells stably expressing wt DJ-1 (W), L166P (L) or empty vector (c) were treated with 5 mM MG132 for 16 h or left untreated, as indicated.
The expression of endogenous PML and overexpressed FLAG-DJ-1 were measured with anti-PML and anti-FLAG antibodies, respectively. Beta-actin
was detected as loading control. (D) Quantification of PML levels. Densitometric analysis of protein bands was performed on two independent
experiments. Relative expression of endogenous PML was normalized to beta-actin. Data are expressed as the percentage of untreated condition in
empty cells (c). (E) Nucleolar localization of p53. Cells were exactly as in A. Localization of endogenous p53 (green), NPM (blue) and FLAG-DJ-1 (red)
were analyzed by triple immunofluorescence. Bars, 10 mm. (F) Quantification of p53 nucleolar localization. Analysis was performed as in B (NS, non
significant).
doi:10.1371/journal.pone.0035051.g004
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promoter was directly upregulated by L166P, in conditions when
wt DJ-1 was acting as a repressor. In this context, we have
previously shown that upon proteasome impairment L166P
blocked the neuroprotective property of TTRAP to MG132
treatment inducing JNK and p38 MAPKs apoptotic pathways
[23].
Here we provide evidences for a novel pathogenic mechanism
of mutant DJ-1 mediated by the sequestration of TTRAP. Upon
proteasome inhibition, L166P triggers alterations of rRNA
biogenesis by selectively excluding TTRAP from nucleolar cavities
and sequestering it into cytoplasmic aggregates. Inhibition of
TTRAP nucleolar localization by accumulated misfolded proteins
is not restricted to mutant DJ-1, but can also be observed for
aggregates of mutant huntingtin.
rRNA biogenesis is a complex process that requires the
transcription of rDNA genes by polymerase I, nucleolytic
cleavages and chemical modification of precursor rRNAs and
ultimately leads to the assembly of mature ribosomes [35]. It is
subjected to rigorous quality control mechanisms [36,37] and
stressful events elicit homeostatic responses that involve the
majority of its steps [38,39]. We have previously found that
TTRAP regulates rRNA biogenesis under proteasome impair-
ment. TTRAP down-regulation leads to a decrease of pre-rRNA
and a concomitant increase of processing species thus suggesting it
might function at multiple steps [20]. Accumulation of processing
intermediates might be due to impaired cleavage or to reduced
degradation of cleaved fragments, while the effects on pre-rRNA
levels may unveil a role of TTRAP at rDNA loci or may be
secondary to changes in rRNA processing [40].
Here we show that misfolded mutant DJ-1 expression
recapitulates this phenotype affecting the initial events of
transcription and the conversion of intermediate to mature forms
(47S to 45S and 32S to 28S). While both qPCR and pulse-chase
labeling with 32P-orthophosphate indicate an increase in the
amount of rRNA processing intermediates, the quantity of A0 sites
was strongly reduced when measured with qPCR while seemed
increased in pulse-chase experiment. To reconcile these data we
hypothesize that PCR amplification of the 59 ETS region of rRNA
precursors may detect illegitimate small RNA species due to
abortive transcription initiation that are not visible by gel
electrophoresis.
Several human genetic diseases, collectively defined as riboso-
mopathies, are caused by mutations in genes involved rRNA
biogenesis and ribosome assembly [41]. Surprisingly, few studies
so far have analyzed the status of protein synthesis, ribosome
biogenesis and of the nucleolus in human post-mortem brains of
neurodegenerative diseases. Alteration of protein synthesis capa-
bility due to ribosome dysfunction has been shown to be an early
event in Alzheimer’s disease [42]. A nucleolar protein involved in
ribosome biogenesis was found induced in post-mortem brains of
Huntington’s disease patients [43]. Nucleolin was identified as an
interactor of the PD-associated proteins DJ-1 and alpha-synuclein
and its protein expression was found reduced in Substantia Nigra
of human PD brains [25]. More recently, genetic ablation of
rRNA transcription caused an alteration of the nucleolus
architecture and ultimately neurodegeneration both in hippocam-
pal and dopaminergic neurons [26,44].
An analysis of rRNA biogenesis in post-mortem brains of
familial PD cases and in animal models of the disease is thus
Figure 5. L166P enhances TTRAP accumulation into insoluble
cytoplasmic aggresomes. (A) Cytoplasmic localization of TTRAP. SH-
SY5Y cells stably expressing wt DJ-1 (W), L166P (L) or empty vector (c)
were treated with 5 mM MG132 for 16 h. Before fixation, cells were
permeabilized with Triton X-100 and double immunofluorescence was
performed with TTRAP (green) and anti-FLAG (red) antibodies. Nuclei
were visualized with DAPI. Confocal images from two independent
experiments were scored for percentage of cells with aggregates (B),
and aggregate average size (C). At least 50 cells per experimental
condition were counted (*, p,0.05). (D) Mutant DJ-1 L166P promotes
accumulation of TTRAP in insoluble fraction. Cells were as in A. After
treatment with MG132, cells were lysed, and Triton X-100 insoluble
fraction was prepared. Endogenous TTRAP was analyzed by western
blotting with anti-TTRAP antibody. Protein loading was controlled by
beta-actin.
doi:10.1371/journal.pone.0035051.g005
L166P DJ-1 Inhibits Nucleolar TTRAP via TRAF6
PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35051
needed. Interestingly, the association of TTRAP to the nucleolus
of DA cells in sporadic PD brains increases the list of changes in
the nucleolar composition in PD. Their functional effects remain
to be investigated.
Recently, nucleolar aggregates have been identified as a novel
form of nuclear stress bodies that occupy nucleolar cavities
[20,28]. They contain polyadenylated RNA, unconjugated
ubiquitin and several nucleoplasmic proteasome target proteins
[28]. Their formation was relieved by an excess of free cytoplasmic
ubiquitin and occurred with both wt and triple mutant ubiquitins
lacking K48, K29 and K63 lysines, proving that atypical
ubiquitination is involved. This led to the hypothesis that a
cross-talk between cytoplasmic and nucleolar aggregates regulates
the subcellular localization of atypically ubiquitinated misfolded
proteins.
The partitioning of TTRAP between nucleolar and cytoplasmic
aggregates is modulated by TRAF6. This E3 ligase binds both
TTRAP and mutant DJ-1 promoting atypical ubiquitination of
L166P and its accumulation in cytoplasmic aggregates [15]. When
TRAF6 ligase activity is lacking, L166P inclusions are smaller and
TTRAP is relieved to relocate, at least in part, into the nucleolus.
Other E3 ubiquitin ligases, such as parkin [45], have been
Figure 6. TRAF6 E3 ligase activity contributes to L166P-mediated exclusion of TTRAP from nucleolar cavities. (A) Expression of TRAF6
DN partially rescues TTRAP nucleolar localization in L166P cells. SH-SY5Y cells stably expressing mutant DJ-1 were transfected with GFP-tagged TRAF6
(wt or deleted of the N-terminus, DN), or with empty vector control, as indicated. After 24 h from transfection, cells were treated for 16 h with MG132.
TTRAP localization was followed by indirect immunofluorescence coupled with GFP autofluorescence. Bars, 10 mm. (B) Quantification of TTRAP
nucleolar localization. Cells were as in A. At least 100 transfected cells with comparable GFP levels from two independent experiments were counted
and scored for TTRAP in the nucleolus (*, p,0.05). (C) Knock-down endogenous TRAF6 expression partially rescues TTRAP nucleolar localization. SH-
SY5Y cells stably transfected with mutant DJ-1 L166Pwere transfected with siRNA oligonucleotides targeting endogenous TRAF6 (siTRAF6) or with a
scramble control siRNA (Scr). After 72 h from transfection, cells were treated for 16 h with MG132. Immunofluorescence was performed with anti-
TTRAP (green), anti-TRAF6 (red), anti-NPM (blue). Bars, 15 mm. (D) Quantification of TTRAP nucleolar localization. Cells were as in C. Analysis was
performed as in B on cells with reduced TRAF6 expression (*, p,0.05). (E) Total cell lysates were prepared from SH-SY5Y cells transfected as in C. Cells
were treated with MG132 for 16 h or left untreated. Expression of endogenous TRAF6 and TTRAP was measured with specific antibodies. Protein
loading was controlled by beta-actin. Molecular weight markers (MWM) are indicated for each gel (kDa). Images are representative of two
independent experiments.
doi:10.1371/journal.pone.0035051.g006
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demonstrated to act on mutant DJ-1, possibly accounting for
additional TRAF6-independent regulation. TRAF6, as other E3
ubiquitin ligases, is accumulated in LBs [15]. In this context, the
aberrant localization of TTRAP in LBs and in the nucleolus of
sporadic PD post-mortem brains may suggest the existence of this
regulatory pathway in vivo. On the other hand, the impact of
TTRAP sequestration and consequent alteration in rRNA
biogenesis in familial cases will ultimately depend on the level of
L166P protein, which remains unknown. In summary this work
demonstrates a novel role for misfolded mutant DJ-1 in the
homeostasis of rRNA biogenesis and suggests the existence of a
functional interplay between cytoplasmic and nucleolar aggregates
that may regulate nucleolar functions in neurodegenerative diseases.
Supporting Information
Figure S1 Quantitative analysis of TTRAP nucleolar
localization. (A) TTRAP localizes to the nucleolus upon
proteotoxic stress. SH-SY5Y cells were treated with increasing
concentration of Epoxomycin or Lactacystin, as indicated.
Untreated cells were used as controls. TTRAP was visualized
with indirect immunofluorescence with anti-TTRAP antibody
(green). Nuclei were visualized with DAPI (blue). Nucleolar
TTRAP was scored in DAPI-negative regions in .100 cells.
Representative images are shown for cells treated with 1 mM
Epoxomycin and 25 mM Lactacystin. (*, p,0.05). (B) TTRAP
staining is specific. SH-SY5Y cells stably expressing a short-hairpin
RNA targeting TTRAP (siTTRAP #1 and #2) or a scrambled
shRNA control (scramble #1 and #2) were treated for 16 h with
5 mMMG132. TTRAP (green) and nuclei (blue) were stained as in
A.
(TIF)
Figure S2 Altered TTRAP nucleolar localization in
L166P mutant cells upon treatment with MG132. SH-
SY5Y cells stably transfected with empty vector (c), FLAG-DJ-1 wt
(W) or L166P (L) were treated with 5 mM MG132 for 16 h or left
untreated. TTRAP localization was analyzed by immunofluores-
cence with anti-TTRAP (green) and anti-FLAG (red) antibodies.
Nuclei were visualized by DAPI staining (blue). Low magnification
images are shown. Nucleolar TTRAP is evident in DAPI-negative
regions of the nucleus (white arrows). Images are representatives of
three independent experiments from two independent clones for
each cell line.
(TIF)
Figure S3 Analysis of DJ-1 expression in siDJ-1 and
scramble SH-SY5Y cells. SH-SY5Y cells stably expressing a
doxycyclin-inducible short-hairpin targeting DJ-1 (siDJ-1, clones A
and B) or a scramble shRNA control (scramble, a and b) were
treated with doxycycline for 10 days. Endogenous DJ-1 expression
was analyzed by immunofluorescence with anti-DJ-1 antibody.
(TIF)
Figure S4 Depletion of DJ-1 does not alter transcription
and processing of ribosomal RNA. SH-SY5Y stably
expressing a doxycyclin-inducible shRNA targeting DJ-1 (siDJ-1,
clones A and B) or a scramble shRNA control (scramble, a and b)
were induced 10 days with doxyciclin and then treated with 5 mM
MG132 for 16 h, or left untreated. Total RNA was extracted and
levels of pre-rRNA and processing intermediates were analyzed by
qPCR. Amplicons are those described in figure 3. Standard
deviations are calculated from two independent experiments.
Differences between a, b, A and B are not statistically significant
(*, P,0.05. NS, not significant).
(TIF)
Figure S5 Analysis of the effects of wild-type and
mutant DJ-1 on nucleolar integrity. SH-SY5Y cells stably
expressing wt DJ-1 (W), L166P (L) or empty vector (c) were treated
with 5 mM MG132 for 16 h. Immunofluorescence was performed
with anti-NPM antibody and NPM nucleoplasmic staining was
measured with ImageJ software on a randomly selected area.
Background fluorescence was quantified from an area placed
outside the cells and was subtracted for each signal. At least 100
cells from two separate experiments were counted (NS, not
statistically significant). Representative zoomed images are shown
for each cell line.
(TIF)
Figure S6 Analysis of the effects of mutant DJ-1 L166P
on cell proliferation and viability. (A) Expression of L166P
does not affect the cell cycle. SH-SY5Y cells stably expressing the
L166P mutant and control cells were treated for 16 h with 5 mM
MG132, or DMSO as control. Cell proliferation was analyzed by
flow-cytometry (FACS) after propidium iodide (PI) staining.
Graphs show the overlay of representative FACS profiles for each
sample. (B) Quantification of the cell cycle distribution in control
and L166P cells treated as in A. Data are from three independent
experiments (error bars, standard deviation). (C) Expression of
L166P DJ-1 moderately sensitizes cells to death induced by
proteasome inhibition. Identical numbers of L166P and control
cells were seeded in 96-well plates. After 24 hours, cells were
treated with DMSO or 5 mM MG132 for additional 16 h. Cell
viability was measured by WST-1 assay. Data are normalized to
WST activity in untreated cells. Standard deviations are calculated
from four independent experiments (*, p,0.05).
(TIF)
Figure S7 Localization of PML and p53 is not affected
by the expression of DJ-1 L166P mutant in untreated
cells. (A) Localization of PML. SH-SY5Y cells stably expressing
FLAG-tagged DJ-1 wt (W), or mutant (L) or empty vector (c) were
stained by triple immunofluorescence with anti-TTRAP (green),
anti-PML (red) and anti-NPM (blue) antibodies. (B) Localization of
p53. Cells were stained by triple immunofluorescence with anti-
NPM (blue), anti-p53 (green) and anti-FLAG (red) antibodies.
Bars, 10 mm.
(TIF)
Figure S8 TRAF6 expression does not alter TTRAP
localization in untreated cells. SH-SY5Y stably expressing
L166P were transfected with GFP-TRAF6 (wt and DN), as
indicated. Cells were left untreated. TTRAP localization was
analyzed by immunofluorescence with anti-TTRAP (red) anti-
body. Bars, 10 mm.
(TIF)
Figure S9 Analysis of rRNA biogenesis in mutant DJ-1
L166P cells with knock-down of TRAF6 expression. SH-
SY5Y cells stably transfected with mutant DJ-1 L166P were
transfected with oligonucleotides targeting endogenous TRAF6
(siRNA TRAF6) or a scramble control sequence (siRNA
Scramble). After 72 h from transfection, cells were treated for
16 h with MG132 or DMSO as control. Total RNA was extracted
and levels of pre-rRNA and processing intermediates were
analyzed by qPCR with primers targeting A0, 1 and 4 cleavage
sites, as indicated. Efficiency of TRAF6 knock-down was
monitored with specific primers (TRAF6). Standard deviations
are calculated from four independent experiments (*, P,0.05).
(TIF)
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Dopaminergic neurons
Hemoglobin
Mouse
Native structureHemoglobin is the oxygen carrier in blood erythrocytes. Oxygen coordination is mediated by α2β2 tetrameric
structure via binding of the ligand to the heme iron atom. This structure is essential for hemoglobin function
in the blood. In the last few years, expression of hemoglobin has been found in atypical sites, including the
brain. Transcripts for α and β chains of hemoglobin as well as hemoglobin immunoreactivity have been
shown in mesencephalic A9 dopaminergic neurons, whose selective degeneration leads to Parkinson's disease.
To gain further insights into the roles of hemoglobin in the brain, we examined its quaternary structure in dopa-
minergic neurons in vitro and in vivo. Our results indicate that (i) in mouse dopaminergic cell line stably
over-expressing α and β chains, hemoglobin exists as an α2β2 tetramer; (ii) similarly to the over-expressed
protein, endogenous hemoglobin forms a tetramer of 64 kDa; (iii) hemoglobin also forms highmolecular weight
insoluble aggregates; and (iv) endogenous hemoglobin retains its tetrameric structure inmousemesencephalon
in vivo. In conclusion, these results suggest that neuronal hemoglobin may be endowed with some of the
biochemical activities and biological function associated to its role in erythroid cells. This article is part of a
Special Issue entitled: Oxygen Binding and Sensing Proteins.
© 2013 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
Hemoglobin (Hb) is the major heme-containing protein of erythro-
cytes, where it mediates the transport of oxygen and carbon dioxide in
the blood. Hb is an assembly of four globular protein subunits each
containing a heme moiety. In adult humans the most common type of
Hb is a hetero-tetramer consisting of two α and two β subunits held
together by non-covalent interactions (α2β2). The expression of α and
β chains and their post-translational assembly into α2β2 tetramers is
fundamental for Hb to function. As a consequence, strong evolutionary
pressure has favored the expression of equal amounts ofα andβ chains,
supporting the evidence that all the functional properties displayed by
Hb, as cooperativity, pH sensitivity, and anionic regulation, occur only
in the α2β2 tetramers [1].erms of the Creative Commons
which permits non-commercial
d theoriginal author and source
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013.05.005It has long been thought that Hb expression is restricted to erythro-
cytes and precursor cells of the erythroid lineage. This notion has been
extensively revised in recent years. Hb α and β chains have been
found co-expressed in alveolar cells [2], mesangial cells of the kidney
[3], retinal ganglion cells [4], hepatocytes [5], and neurons [6–8]. Endo-
thelial and peripheral catecholaminergic cells express exclusively theα
chain [9] whilemacrophages present the β chain only [10]. Importantly,
Hb expression has been associated to various types of cancer [11–13].
In the brain, Hb can be detected in mesencephalic A9 dopaminergic
neurons,whose selective degeneration is the primary cause of Parkinson's
disease [14], in cortical and hippocampal astrocytes as well as in virtually
allmature oligodentrocytes [6]. Similar pattern ofHb staining is present in
mouse, rat and human central nervous systems [6,7]. Importantly, altered
Hb levels have been observed in neurodegenerative diseases post-mortem
brains. Hb expression is increased in pyramidal neurons in the cortex of
multiple sclerosis's patients [15], whereas it is decreased in neurons of
Alzheimer's and Parkinson disease brains [16]. Elevated levels of Hb can
be found in extracellular amyloid plaques and aged brains, possibly due
to compromised brain-blood barrier [17].
The speciﬁc function of Hb in neurons remains unclear. We have
previously showed that Hb regulates genes involved in oxygen
homeostasis and oxidative phosphorylation, linking Hb expression
to mitochondrial activity [6]. This is particularly relevant in the con-
text of mesencephalic A9 dopaminergic neurons, since these cells
speciﬁcally express genes involved in energy metabolism andserved.
nical α2β2 tetramer in dopaminergic neurons, Biochim. Biophys. Acta
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tive stress [18,19]. These features are believed to be important for
cells' selective vulnerability in Parkinson disease.
In red blood cells Hb functions are achieved through tetrameric
structure, but so far no evidence is available for neuronal Hb.
To gain further insights into the biochemical activities and biological
functions of Hb in the brain, we have examined the quaternary structure
of Hb in dopaminergic neurons in vitro and in vivo. In this study,wedem-
onstrate for theﬁrst time that Hb exhibits aα2β2 hetero-tetrameric state
inmouse and human neuronal cell lines aswell as inmousemesenceph-
alon. These results may have important implications in the physiology
and pathology of the brain given the many deﬁned roles inherent to
the structure of Hb including gas exchange, NOmetabolism, and protec-
tion against oxidative and nitrosative stress.
2. Materials and methods
2.1. Cell culture
Mouse dopaminergic neuroblastoma iMN9D cells weremaintained in
culture using Dulbecco's Modiﬁed Eagle Medium (DMEM)/ F12 medium
(Invitrogen) supplementedwith 10% fetal bovine serum(Sigma-Aldrich),
100 μg/mL penicillin and 100 μg/mL streptomycin. Neuro2a mouse
neuroblastoma cells were cultured in Eagle's minimal essential medium
(EMEM) with 10% fetal bovine serum (FBS), 1% GlutaMAX, 1% non-
essential amino acids (NEAA) and antibiotics.
2.2. Cell lysis, protein extraction and protein assay
Cells were harvested and lysed by osmotic shock in Nonidet P-40
(NP-40) lysis buffer (150 mM NaCl, 50 mM Tris-Cl pH 7.5 and 0.5%
NP-40) with the addition of protease inhibitor mixture (Roche). Ly-
sates were then cleared by centrifugation (14,000 ×g, 30 min, 4 °C)
and supernatants were transferred in new tubes. The total amount
of solubilized protein was estimated with the Bio-Rad protein assay
kit, according to the manufacturer's instructions. Insoluble proteins
were also collected upon resuspending the pellets in sample buffer.
Soluble and insoluble protein extracts were used for Western blot
analysis. For competition assay, the anti-Hb (1:1000, Cappel) antibody
was incubated with puriﬁed human Hb (HbA) (Sigma-Aldrich) at
1 mg/mL for 2 h at 4 °C. Nitrocellulosemembraneswere then incubated
for 2 h at room temperature with the appropriate antibody–protein so-
lutions, and subjected to Western blot detection as already described.
2.3. Native PAGE Electrophoresis
Native PAGE was performed on gradient polyacrylamide gel
electrophoresis (10–12–17% of acrylamide) for approximately 3 h.
Standard proteins were loaded using Native Mark Unstained Protein
Standard (Sigma-Aldrich). The proteins supplied in the kit have a
molecular mass range of 14.2–545 kDa.
For Western Blot analysis, proteins were transferred to nitrocellu-
lose membrane (GE Healthcare). Membrane was blocked with 5% non-
fat milk in Tris buffered saline (TBS) solution (TBS + 0.1% Tween-20),
then incubated with primary antibodies overnight at 4 °C or at room
temperature for 2 h. Proteins were detected by horseradish peroxidase
(HRP)-conjugated secondary antibodies and enhanced chemilumines-
cence reagents (ECL) (GE Healthcare).
2.4. Primary antibodies
The following antibodies were used in this study for Western blot:
anti-FLAG (1:1000, Sigma-Aldrich), anti-MYC (1:2000, Cell Signaling),
anti-Hb (1:1000, Cappel), anti-β-actin (1:5000, Sigma). For detection,
anti-mouse-HRP or anti-rabbit-HRP (Dako) in combination with ECL
(GE Healthcare) was used.Please cite this article as: R. Russo, et al., Hemoglobin is present as a cano
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Cells were extensively washedwith ice-cold phosphate-buffered sa-
line (PBS) (pH 8.0) to remove amine-containing culture media. Cells
were incubated with 5 mM of the homobifunctional amine-reactive
crosslinking reagent disuccinimidyl suberate (DSS) (Pierce Biotechnol-
ogy) for 30, 60 or 360 min at room temperature. The reaction was
quenched by incubation with 50 mM Tris-HCl, pH 7.5, for 15 min at
room temperature. Samples were diluted in loading buffer and separat-
ed on homogenous 10–12–17% SDS–PAGE gels. The electrophoresis and
Western blot were conducted as previously described for native PAGE
and analyzed with an anti-Hb antibody.
2.6. Animals
All animal experimentswere performed in accordancewith European
guidelines for animal care and following SISSAEthical Committee permis-
sions and SISSA veterinary service. Mice were housed and bred in SISSA
non-speciﬁc pathogen free (SPF) animal facility, with 12 h dark/light cy-
cles and controlled temperature and humidity.Mice had ad libitum access
to food and water.
2.7. Extraction of native Hb from mouse midbrain
C57BL6 mice (n = 4), 12 months-old, were deeply anesthetized
with a single intra-peritoneal injection of urethane (ethyl carbamate,
Sigma, Cat. No. U2500) at the dose of 2 g/kg. Prior to brain sample col-
lection, mice were extensively perfused with saline buffer through
the circulatory system. Brieﬂy, a cannula tip was inserted through
the left ventricle and connected to a perfusion apparatus that utilizes
a pump with ﬁxed pressure ﬂow to quickly reach every organ using
the natural vascular network. The perfusion pump was set to match
physiological pressure. After perfusion, mice were sacriﬁced by cervi-
cal dislocation and the ventral midbrain was dissected and immedi-
ately frozen in liquid nitrogen. Tissues were homogenized brieﬂy
with the aid of a mechanical homogenizer in NP-40 lysis buffer
(150 mM NaCl, 50 mM Tris-Cl pH 7.5 and 0.5% NP-40) and complete
protease inhibitor cocktail (Roche). Extraction volumewas 1.5 mL. All
steps were performed at 4 °C, in the absence of any detergent or
denaturant. Following homogenization, the samples were subjected
to centrifugation at 350 ×g for 20 min at 4 °C, and the supernatants
and pellets were collected. Protein concentration was determined in
the total lysate with the Bio-Rad protein assay kit, according to the
manufacturer's instructions. The samples were maintained on ice at
all times during preparation, avoiding freezing and thawing steps.
Total lysate (TL), pellet (P) and supernatants (S) were loaded on
SDS–PAGE and native Page as previously described.
3. Results and discussion
3.1. Hemoglobin is an α2β2 tetramer in murine dopaminergic iMN9D cells
In the blood, functional Hb folds as a tetramer composed by two α
and twoβ chains. To study the structure of Hb in neurons, we ﬁrst deter-
mined the assembly of α and β chains in mouse dopaminergic iMN9D
cells, a well-accepted in vitromodel to study dopaminergic cell physiol-
ogy and dysfunctions [20]. In a previous studywe generated iMN9D cells
stably expressing tagged version of α and β chains of mouse Hb [6].
Since most antibodies raised against mouse Hb do not discriminate be-
tween the two chains, we used anti-FLAG and anti-MYC monoclonals
to determine the presence of each chainwithin Hb quaternary structure.
In contrast to SDS–PAGE, native PAGE is performed in non-denaturing
conditions and thus permits separation of intact non-covalent protein
complexes [21,22]. We used this technique to determine the native mo-
lecular mass of Hb extracted from iMN9D cells expressing FLAG-α and
MYC-β chains. As control, we included protein extracts prepared fromnical α2β2 tetramer in dopaminergic neurons, Biochim. Biophys. Acta
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and anti-MYC antibodies detected a single band with an estimated
mass of ~64 kDa, based on its mobility relative to native molecular
weight markers (Fig. 1). As expected, no bands were observed in
cells expressing an empty control vector. These data indicate that
over-expressed Hb folds as a tetramer that contains twoα and β chains.
Interestingly, highmolecular weight (HMW) complexes have been also
detected. The same result was obtained when the lysates were probed
with an anti-Hb speciﬁc antibody, thus conﬁrming that anti-tag mono-
clonals detected Hb-containing bands.
Altogether these data demonstrate that Hb, when overexpressed
in mouse dopaminergic cell line, is present as α2 β2 tetramer.
3.2. In-cell cross-linking assay
Since the migration of a protein on native PAGE does not depend
solely on its mass but also on its conformation and charge, we stabi-
lized α and β subunits within Hb with the bifunctional cross-linking
reagent disuccinimidyl suberate (DSS). Protein chains that are in qua-
ternary structure become covalently linked and their molecular mass
can be determined by denaturing SDS–PAGE. We ﬁrst examined
DSS-mediated cross-linking on freshly prepared protein lysates,
using a standard protocol [23]. Under these conditions, we noticed
that the efﬁciency of chemical ligation was extremely low and only
dimers could be observed (data not shown). The presence of α/β
heterodimers upon in vitro cross-linking nonetheless conﬁrms previ-
ous data showing physical interaction between the two chains by
co-immunoprecipitation experiments [6].
To improve the efﬁcacy of DSS ligation, we resorted to in-cell
cross-linking. DSS is a membrane permeable molecule, and therefore
can be added directly to the cell culturemedium.Under these conditions,
the proximity-induced cross-linking took place in the protein own
cellular milieu. We applied in-cell cross-linking to iMN9D cells stably
expressing tagged α and β chains of Hb or to empty vector-expressing
cells as control. After protein extraction, lysates were subjected to
SDS–PAGE followed by immuno-blot analysis. Anti-FLAG and anti-MYC
monoclonals detected multiple unspeciﬁc bands and high background
in denaturing conditions (data not shown), so anti-Hb antibody wasanti-MYC anti-FLAG anti-Hb 
66 KDa
*
HMW
aggregates
14 KDa
markers
Fig. 1. Hb overexpressed in iMN9D dopaminergic cells is present as α2β2. Native PAGE
of dopaminergic iMN9D cells over-expressing FLAG-tagged α and MYC-tagged β
chains. Lysates from iMN9D cells expressing empty vector were included as control.
Puriﬁed proteins were used as markers, as indicated (BSA, bovine serum albumin;
LALBA, α-lactalbumin). Relative molecular weights are indicated on the right (kDa).
Anti-MYC, anti-FLAG and anti-Hb antibodies were used for immune-staining, as
indicated. The asterisk indicates non-speciﬁc band. Images are representative of four
independent experiments.
Please cite this article as: R. Russo, et al., Hemoglobin is present as a cano
(2013), http://dx.doi.org/10.1016/j.bbapap.2013.05.005used for detection. As shown in Fig. 2A, a protein band could be observed
at about 32 kDa, compatible with themolecular size of covalently linked
globin dimers thus conﬁrming data obtained with previous protocols.
We also observed SDS-stable Hb bands migrating at the expected posi-
tions of a trimer (∼48 kDa) and tetramer (∼64 kDa). Relative ratio
between trimer and tetramer bands was strongly in favor of a trimeric
structure, probably as a consequence of facilitated cross-linking for less
complex structures as observed with α/β heterodimers. This conclusion
is also supported by titration assays, showing an increasing proportion of
oligomers (trimer and tetramers) with decreasing levels of monomers
along with longer incubation times (Fig. 2B).
It has to be noted that bands of lower intensities but same molec-
ular weight could be observed in empty control cells (Fig. 2A). Since
these are revealed with an anti-Hb antibody, these data indicate
that endogenous Hb protein is expressed in dopaminergic neuronal
iMN9D cells. Importantly, chemical cross-linking indicates that the
endogenous Hb can be detected as trimer and tetramer.
Altogether, these experiments further prove that overexpressed
Hb has an α2β2 fold and support the existence of native tetramers
in dopaminergic neuronal cells.
3.3. Endogenous hemoglobin is a tetramer in neuronal cell lines
To further study the status of endogenous Hb, we used native PAGE
to examine the protein expressed in dopaminergic (iMN9D) and in a
non-dopaminergic (Neuro2a) neuronal cell lines. We choose Neuro2a
since we have previously detected the expression of globin α and β
chains mRNAs by RT-PCR (data not shown). Soluble extracts were sep-
arated from detergent-insoluble proteins to determine the distribution
of Hb and its folding within biochemically-deﬁned sub-cellular frac-
tions. A clear band at ~64 kDa, corresponding to Hb tetramer, was ob-
served in the soluble fractions of iMN9D as well as Neuro2a cells
(Fig. 3A). Signal speciﬁcity was veriﬁed by competition assay, using pu-
riﬁed HbA to compete for binding (Fig. 3A). Interestingly, both cell lines
presented HMW complexes where multiple species could be detected.
To gain further insights into the existence of HMW aggregates of
endogenous Hb in neuronal cells, we prepared detergent-insoluble
fractions from iMN9D and Neuro2a cells. As shown in Fig. 3B, when
equal amounts of total proteins were loaded, insoluble fractions
revealed a much fainter signal at ~64 kDa, as expected for a globular
soluble protein. The band corresponding to tetrameric Hb was almost
undetectable. Instead, a clear smear in the region of HMW could be
measured, thus indicating that Hb exists as part of large insoluble
aggregates in neuronal cells in vitro.
Insoluble aggregates play an important role in neurodegenerative
diseases, albeit their exact contribution to neuronal cell death is always
under intense debate. Endogenous Hb has been detected in proteina-
ceous aggregates in human post-mortem brains from Alzheimer's
disease [24], Parkinson's disease and Dementia with Lewy Body disease
[16] patients as well as in neuroﬁbrillary tangles in mouse models of
familial Alzheimer's disease [17]. It will be interesting in the future to
assess whether Hb aggregates are neuroprotective or neurotoxic and
what are the molecular mechanisms underlying their formation.
3.4. Endogenous hemoglobin is expressed as a tetramer in vivo in the
mouse brain
We then sought to assess the quaternary structure of endogenous
Hb expressed in themouse ventralmidbrain, the region that is enriched
of dopaminergic neurons and whose selective degeneration leads to
Parkinson's disease. The ventral midbrain region was dissected from
12-months old C57BL6 mice. To preserve the native conformation of
the proteins and to prevent breakdown of potential higher protein
assemblies, the lysis buffer used to homogenize the tissues was free of
detergents and denaturing agents. Total lysate (TL) was then separated
by centrifugation into detergent-insoluble pellet (P) and supernatantnical α2β2 tetramer in dopaminergic neurons, Biochim. Biophys. Acta
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Fig. 2. In-cell cross-linking analysis of Hb structure. A) iMN9D cells overexpressing tagged α and β chains or empty control cells were treated with chemical cross-linker DSS while
in culture. Equal amounts of total proteins were loaded on SDS–PAGE and analyzed by Western blotting using anti-Hb antibody. Hb staining is visible in empty cells, indicating the
endogenous protein. Asterisks indicate non-speciﬁc bands. Images are representative of three independent experiments. B) iMN9D cells stably expressing α and β chains were in-
cubated with chemical cross-linker DSS for the indicated time. After cell lysis, equal amounts of proteins were processed as in A. Puriﬁed HbA was included as control. Molecular
weight markers are indicated for each gel (kDa). Monomeric, dimeric, trimeric and tetrameric species are indicated by arrows.
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along with protein standards. Puriﬁed recombinant HbA was also in-
cluded as control. Immunoblotting with Hb-speciﬁc antibody revealed
that in vivo endogenous Hb from mouse ventral midbrain migrates
with an apparent molecular weight of 64 kDa similarly to the puriﬁed
recombinant protein (Fig. 4). Tetrameric Hb could be observed at simi-
lar levels in TL and S fractions. Interestingly, a smaller but detectable
amount of Hb was associated to soluble HMW aggregates. Competition
experiment veriﬁed that bands corresponding to tetrameric and
HMW-associated Hb were indeed speciﬁc. Surprisingly, fraction P did
not contain any Hb neither as tetramer or HMW aggregate (data notPCAanti-Hb 
Soluble fractionsA
MW
Tetramer
HMW
aggregates
64 
Fig. 3. Biochemical analysis of native endogenous hemoglobin in neuronal cell lines. A)
non-dopaminergic (Neuro2a) neuronal cells were lysed and detergent-soluble proteins w
Bio-Rad protein assay kit. Equal quantities were loaded on native PAGE and endogenous Hb
was used for protein competition assay (PCA). Relative molecular weight (MW) is indicated
by arrows. Images are representative of three independent experiments. B) HMW aggregat
iMN9D and Neuro2a cells were lysated as in A. After centrifugation, pellet was recovered and
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denaturing conditions (data not shown).
To our knowledge this is the ﬁrst time that native Hb from mouse
brain is shown to exist as a tetramer in vivo. Recent studies indicate
that upon aging, Hb levels are increased in neurons and the protein
co-localizes with proteinaceous aggregates [16,24]. We could not
ﬁnd HMW insoluble aggregates of Hb in vivo, albeit these forms
could be easily detectable in soluble fraction in the brain as well as
in the insoluble fractions in neuronal cell lines. It remains to be
assessed whether Hb retains its tetrameric structure and/or form in-
tracellular insoluble aggregates when pathological conditions occur.anti-Hb 
Insoluble fractionsB
64 KDa
HMW
KDa
Endogenous Hb is a tetramer in neuroblastoma cells. Dopaminergic (iMN9D) and
ere recovered after centrifugation. Total protein content was determined with the
was visualized by Western blot with anti-Hb antibody. Puriﬁed recombinant human Hb
on the right (kDa). Tetramers and high molecular weight (HMW) aggregates are shown
es containing Hb are present in the detergent-insoluble fraction of neuronal cells lines.
analyzed by native PAGE. Endogenous Hb was detected using anti-Hb antibody.
nical α2β2 tetramer in dopaminergic neurons, Biochim. Biophys. Acta
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Fig. 4. Endogenous Hb is a tetramer in vivo in the mouse brain. Native Hb was extracted
from the ventral midbrain of 12-months old C57BL6 mice. Tissue homogenization was
performed under non-reducing and non-denaturing conditions. Total lysate (TL),
detergent soluble (S) and insoluble (P) fractions were separated. Equal quantities of pro-
teins were loaded on native PAGE. Puriﬁed recombinant HbA was included as control.
Speciﬁcity of bands was assessed by competition assay (PCA). Relative molecular weight
(MW) is indicated on the right (kDa). Hb tetramer is indicated by an arrow. The image
is representative of two independent tissue preparations from four C57BL6 mice.
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Hb is the main component of erythrocytes in the blood, where it
serves as a molecular cargo of oxygen and carbon dioxide to and
from tissues. The assembly of α2β2 tetramer is essential for Hb to
function as oxygen carrier in the blood. In recent years, expression
of Hb has been observed in cell types other than erythrocytes, includ-
ing dopaminergic neurons in the mouse [6] and human brain [16].
The exact function and structure of Hb in neurons is presently
unknown.
Using native PAGE and in-cell cross-linking, we demonstrate that
Hb is present as α2β2 tetramer when overexpressed in dopaminergic
iMN9D cell line. The canonical α2β2 structure can also be observed for
endogenous Hb expressed by dopaminergic and non-dopaminergic
neuronal cell lines. Importantly, native Hb exists as a 64 kDa tetramer
in mouse ventral midbrain in vivo.
This work suggests that neuronal Hb may retain some of the bio-
chemical activities and biological functions of Hb of erythroid lineage
laying down the foundation for a better understanding of its role in
brain physiology and in neurodegenerative diseases.
Abbreviations
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